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Estrogen receptors (ERs), are members of the super family of ligand-regulated nuclear 
transcription factors, mediate the action of estrogens, including its primary endogenous 
ligand 17b-estradiol (E2). ERs have two isoforms, namely estrogen receptor α (ERα) and 
estrogen receptor β (ERβ). One of the functional domains of ER—ligand binding domain 
(LBD) has two binding sites; the ligand binding cleft (LBC) directly interacts with the 
ligands, and the second binding cleft—action function 2 (AF-2) hosts a coactivator or 
corepressor protein, which up- or down-regulate ER-mediated transcription. ERs are 
promiscuous, this allows many xenobiotic compounds that have structural similarities with 
E2 can bind at the LBC. These compounds are xenoestrogens (e.g., genistein in soy foods, 
bisphenol-A in plastics). Despite the crucial role of ERs in human health, little is known 
about the details of the communication between their two binding sites and the precision of 
interactions between the LBC with enormous number of xenoestrogens presenting in 
environment and foods. These complex interactions were studied in the research described in 
this thesis using molecular modelling system (Schrödinger). 
The first part of this thesis investigates the architectural communication between the two 
binding sites (LBC and AF-2); this provides a basis for understanding the different levels of 
ER’s biological activities. In this work, Schrödinger (a molecule computational platform) is 
used to study the interactions between ligands (i.e., in this thesis, flavonoids) and the LBC; 
this indicates the potential effects of structural features of ligands on their binding energies 
and binding affinities with ERs, thus differentiating ligands’ ERs-driven bioactivities. The 
iv 
second part of this thesis describes studies on structure-activity relationships for dietary 
xenoestrogens-isoflavones with ERa using a gene reporter bioassay (MELN assay). The third 
part of the thesis uses a cell proliferation study (Caco-2 cell line) to study the structure-
activity relationships of selected isoflavones with ERβ. In this part, gallic acid, an inhibitor of 
UDP-glucose dehydrogenase, is used to interfere with the conjugation of isoflavones; this 
investigates the effect of intestinal phase II metabolism on isoflavone’s bioactivity (i.e., ER-
driven activity). The last part of the thesis uses an in vitro gut fermentation system to 
investigate the effects of selected isoflavones gut bacterial populations, and uses a Caco-2 
monolayer system to study the absorption and metabolism of the isoflavones. 
The studies show that, the communication between the two binding sites (LBC and AF-2) via 
sharing helix components is triggered by ligands docked at the LBC. Ligands with different 
structural properties can initiate different degrees of conformational changes in the LBC, 
resulting in different knock-on effects on AF-2, this facilities different amino acid residue 
orientations change in AF-2, which would form correspondingly different noncovalent 
interactions with the regulatory protein. This, in turn, likely determines the bioactivity of 
ERs. In addition, the precision of interactions between ligands (i.e., flavonoids) and LBC 
indicates the polar substitution arrangements (i.e., hydroxyl groups) might affect the binding 
energy and binding affinity, and thus, likely results in different ER-mediated bioactivities. 
This finding is supported by increased ligand output from isoflavones-exposed MELN cells 
and increase proliferation of ERβ-expressing Caco-2 cells exposed to isoflavones. In 
addition, the UDP-glucose 6-dehydrogenase inhibitor, gallic acid increases the proliferative 
ERβ-driven effect of isoflavones on Caco-2 cells, because it prevented phase II metabolism 
of isoflavones. In the in vitro gut fermentation experiments, isoflavones change gut bacterial 
v 
populations, and these changes are likely positive in a human health setting. Finally, in vivo 
cell culture experiment shows isoflavones are taken up by a Caco-2 cell monolayer model 
system which mimics the gut mucosa; this indicates that isoflavones might be absorbed and 
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1 Chapter 1 – Introduction 
1.1 Food functionality 
Food is any substance consumed to provide nutritional support for an organism. It is of plant 
or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, 
vitamins, and minerals.1 Originally, food functionality was regarded as the ability of such 
substrates to be ingested and assimilated by an organism’s cells to provide energy, maintain 
life, or stimulate growth.2 Food functionality is gaining significant importance with more in-
depth understanding of the risks and benefits associated with foods-health promotion and 
disease prevention.1 An understanding of the possible mechanisms of biological activity of 
functional food components is important if they are to be developed in a health promotion 
setting. Interestingly, flavonoids have been extensively studied as a key functional 
component that is linked to health promotion. China has been regarded as the origin of 
“medicinal and edible plants”.3 Ginger is a traditional Chinese medicine which has been used 
to help prevent the common cold; this is likely due to ginger containing low-melt fatty acids, 
this fatty acid may release energy during evaporation in vivo, but more importantly, ginger is 
rich in curcumin (a flavonoid), which can inhibit the rhinovirus (the most common family of 
cold viruses).4 Another example is goji berry, which is recommended for its benefits for 
eyesight. The key compounds found in goji berry, are lutein and zeaxanthin, both of which 
have been reported to prevent cataracts and macular degeneration. These compounds may act 
to protect the eyesight from ultraviolet phototoxicity via quenching reactive oxygen species.5, 
6 In Tunisia, T. gallica has been used as a traditional treatment for liver disorder, because 
Tamarix gallica contains the flavonoids, 5-hydroxy-3,7, 4'-trimethoxyflavone and 3,5,7-
trihydroxy-4'-methoxyflavone, which are known for their heptatonic and stimulant 
properties.7 
In addition, some flavonoid-containing foods have been linked to sexual development and 
reproduction.8 In ancient China, people fed rams with dry leaves of epicedium during the 
breeding season.8, 9 This ancient tradition is in fact supported by a study that showed that 
icariin, a functional component of epicedium, has testosterone-mimicking properties.10  On 
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the other hand, in the United Kingdom, red clover is used to increase the milk yielding 
capacity of goats, this is due to the high concentration of formononetin (FOR) which is an 
estrogen mimic can occupy and activate ERs. In addition, tofu (a soybean-based food) is used 
to increase breast-milk production, and the higher soy consumption in Japan compared with 
the United States (US) is linked to a lower incident rate for breast cancer in Japan (more than 
80% of breast cancer is estrogen positive).11  Soy isoflavones are estrogen mimics because of 
their similarity in structure to the natural estrogen 17b-estradiol (E2) which activates estrogen 
receptors (ERs) and initials estrogenic responses.12  Indeed, these isoflavones (e.g., genistein 
(GEN), daidzein (DAID) have been proved to occupy and activate ERs.13 
1.2 Estrogen receptors and estrogens 
1.2.1 Overview 
Steroid hormone estrogens influence the growth, differentiation, and functioning of many 
higher target tissues and cell types, and ERs have two isoforms, namely estrogen receptor α 
(ERα) and estrogen receptor β (ERβ).14, 15 These two isoforms of ER have highly similar 
protein architecture but with different amino acid orientations.16 The bio-action of ERs is 
triggered via ligand binding at a ligand binding cleft (LBC), and its consequential knock-on 
effects for facilitating the second binding cleft—activation function 2 (AF-2) to host 
coactivator or corepressors protein, which up- or down-regulate ER-mediated transcription.13, 
17 ERs’ promiscuity allows many xenobiotic compounds that have structural similarity to E2 
to bind at the LBC; these xenobiotics are termed xenoestrogens.13,18 
1.2.2 ERs 
ERs, members of the super family of ligand-regulated nuclear transcription factors, mediate 
the action of estrogens, including the primary endogenous ligand E2. As outlined before 
(Section 1.2.1), ERs have two isoforms, namely ERα and ERβ. ERs have six domains (A–F) 
including three major functional domains comprising a hypervariable N-terminal domain 
(containing activation function 1 (AF-1) that contributes to the transactivation function in the 
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absence of a bound ligand (e.g., E2);13 a highly conserved central domain responsible for 
specific DNA binding, dimerization, and nuclear localization; and a C-terminal domain 
involved in ligand binding and ligand-dependent transactivation function, which is the ligand 
binding domain (LBD).13, 19, 20  In addition, the LBD comprises two separate but interacting 
binding clefts—the LBC and AF-2.13, 21 The LBC binds a ligand (either agonist or 
antagonist), which initiates a conformational change that exposes AF-2 to allow its 
interaction with regulatory proteins (Fig. 1.1).22 The conformational change initiated by 
ligand binding activates ERs’ dissociation from a heat shock protein (usually Hsp90).13 
Phosphorylation then occurs, which aids receptor dimerization. The dimer then moves into 
the nucleus and binds to DNA via the estrogen response element (ERE) or via a protein DNA 
binding intermediate.23  Coregulatory protein recruitment then occurs.13,24  The coregulatory 
proteins comprise coactivators (promotors of ER activity) and corepressors (suppressors of 
ER activity). The bound regulatory protein establishes a “triangular relationship” with the ER 
and the bound ligand that facilitates fine tuning of the estrogenic response.13, 25 
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Figure 1.1: Schematic representation of the mechanism of action of estrogens. The estrogen (e.g., E2) 
binds to the LBC of ER; this initiates a conformational change of ER and facilitating ER dimerization. 
The ER dimer binds to DNA at a specific binding site and up-regulates specific genes associated with 
cellular feminisation. Figure from I.C. Shaw Food Safety—The Science of Keeping Food Safe, 
Wiley-Blackwell. Reproduced with permission of the author. 
In the LBD of ERs, helix (H) 3 to H12 (Fig. 1.2) are important in the functional architecture 
of the LBD; they are folded into three layers—H5/6, H9 and H10—sandwiched between two 
additional layers comprising H1–4 and H7, H8, H11.13, 21  The LBC is completely partitioned 
from the external environment and occupies a relatively large portion of the LBD’s 
hydrophobic core (Fig. 1.2). The LBC comprises segments from H3, H6, H8 and a preceding 
loop, H11, H12 and the S1/S2 hairpin (Fig. 1.2).13, 21  The arrangement of these helices 










ERs form a dimer






hydrophobic cleft formed by the remaining segment of H3 and part of H5, H4 and H12 (Fig. 
1.2).13   
 
Figure 1.2: Protein structure alignment of ERα (Protein Date Bank (PDB) entry code: 1ERE (grey), 
ligand: E2 ) and ERβ (PDB entry code: 3OLS (red), ligand: E2) in agonist conformation. The LBC is 
shown in an orange ellipse, the AF-2 is shown in a blue ellipse. The ligand is shown in green. 
However, the antagonist conformations of ERs are distinctly different from the agonist 
conformations (Fig. 1.3).20 Figure 1.3 shows the protein structure alignment of agonist 
conformation of ERα (PDB entry code: 1ERE, ligand: E2) and antagonist conformation of 
ERα (PDB entry code:1ERR, ligand: raloxifene); which illustrates H12 was physically 
obstructed by an antagonist ligand (raloxifene) with a bulky side chain;  In addition, the 
protein structure alignment of agonist conformation of ERb (PDB entry code:3OLS, ligand: 
E2) and antagonist conformation of ERb (PDB entry code: 1QKN, ligand: raloxifene) also 
shows H12 was pushed away by the antagonist ligand (raloxifene). Both conformational 
changes of individual ER isomers caused the displacement and dysfunction of AF-2.20  
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Figure 1.3: a: protein structure alignment of agonist conformation of ERα (Grey, PDB entry code: 
1ERE, ligand: E2) and antagonist conformation of ERα (Blue, PDB entry code:1ERR, ligand: 
raloxifene); b: protein structure alignment of agonist conformation of ERb (Red, PDB entry 
code:3OLS, ligand: E2) and antagonist conformation of ERb (Purple, PDB entry code: 1QKN, ligand: 
raloxifene). H12s of both agonist and antagonist conformation of ERs are shown in red ellipses. This 
shows the different orientations of H12 in the agonist and antagonist conformation of ERs. Ligands 
are shown in green. 
1.2.3 Estrogens 
Estrogens are important in both female and male.26 In females, estrogens are responsible for 
the development of female secondary sex characteristics (e.g. breasts, wider hips, fat 
distribution) and for regulation of the menstrual cycle (Fig. 1.4).27 The major sites for the 
biosynthesis of estrogens are the ovaries and placenta, and to a lesser extent the liver, adrenal 
cortex, fat cells and mammary glands.28 The levels of estrogens are increased during 
pregnancy; this increase is caused by the relative higher production of estrogens in the 
placenta.29 In males, estrogens modulate libido, spermatogenesis, and erectile function.28 The 
major site of production of estrogens in men is in the testis by the Leydig cells and germ cells 
affecting normal male gonadal development and spermatogenesis.30 In addition, estrogens are 
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produced in the brain which has been linked to energy homeostasis via an ER neuronal 
cluster.31, 32  
There are three natural estrogens; namely, estrone (E1), E2, and estriol (E3) (Fig. 1.5).33 E2 is 
responsible for secondary sex characteristics, puberty onset, and the control of the menstrual 
and reproductive cycle in women.34, 35 The level of E2 depends on the age, sex, and stage of 
the menstrual cycle of an individual.36-38 The serum E2 concentration in women fluctuates 
with progression of the menstrual cycle (Fig. 1.4).36-38 During the follicular phase of the 
menstrual cycle, E2 increases and peaks as high as 9 × 10−4 mg/L, signalling ovulation (Fig. 
1.4).39 After the release of egg in the ovulation phase, this is the luteal phase with a decrease 
of E2 and following a plateau phase (Fig. 1.4).39 However, the concentrations of E2 will 
fluctuate between the plateau ranges during the luteal phase (Fig. 1.4).39 The length of the 
follicular, ovulation, and luteal phase are individually different.40 Women’s serum E2 levels 
ranges from 3.1 × 10−5 to 4 × 10−4 mg/L; whereas the serum levels of E2 in males pre-
pubescent children, and post-menopausal women ranging from 5 × 10−6 to 4.6 × 10−5 mg/L 
because of the reduction of estrogens.38  
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Figure 1.4: Serum levels of circulating E2 in women during the menstrual cycle showing the large 
fluctuations. Ovulation usually occurs on day 13 or 14. The figure adapted from Shaw IC (2018) Food 
Safety—The Science of Keeping Food Safe, Wiley-Blackwell, p251, Fig. 9.7. Reproduced with 



















Day of menstrual cycle
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Estrogenicity describes the physiological activity of a compound compared to E2. E3 has  
weaker estrogenicity compared with E2, and ‘free’ E3 (non-protein bound) is almost 
undetectable in women who are not pregnant;41 this is due the rapid metabolism of E3 and 
excretion in urine.42 However, during pregnancy, E3 is the most biosynthesised estrogen and  
being increased in the placenta during this time.43 E3 is also present in high concentrations in 
bile, meconium, and the corpus luteum.44 Unlike E1 and E2, E3 is not biosynthesised in the 
ovaries, instead it is biosynthesised in the liver.45 This is achieved through the hydroxylation 
of E1 and E2 by cytochrome P450 (CYP450) 3A4 (Fig. 1.5).43 In addition, E3 is used as a 
medication in menopausal hormone therapy to treat menopausal symptoms, such as hot 
flashes and dyspareunia, but treatment with E3 has been reported to exhibit some side effects 
including breast tenderness, and endometrial hyperplasia.44 
Figure 1.5: Biosynthesis of E3 from E2 via E1 and 16α-hydroxyestrone.  17β-HSD: 17β-
hydroxysteroid dehydrogenase. 
E1 was the first pure steroid hormone isolated by Adolf Butenandt in 1929 from the urine of 
pregnant women.46 Similar to E2, E1 is biosynthesised from cholesterol in the gonads and 
adipose tissue.46 Additionally, E1 can be biosynthesised from E2, and E2 can also be 



















(Fig. 1.5), which mainly occur in liver.15 This reversible conversion allows E1 to be used as 
clinical treatment for postmenopausal symptoms (e.g., hot flashes, night sweats).15 However, 
E1 is now mostly no longer marketed for postmenopausal treatment; this is due to the use of 
synthetic estrogens (e.g., 17α-Ethinylestradiol (EE2) with better properties including longer 
activity, higher oral bioavailability, and greater estrogenicity compared with E1.47  
1.2.4 The metabolism of estrogens 
Estrogens circulate in the blood in free or protein-bound forms and would undergo Phase I 
hepatic metabolism; their irreversible hydroxylation can produce estrogen metabolites at C-2, 
C-4, or C-16 positions of the steroid ring (e.g., 2-OH-estradiol (Table 5.2), and resulting in 
different estrogenicities and half-life.48 In the liver, estrogens are conjugated through 
glucuronidation or also through sulfonation to allow for biliary excretion.48 Conjugated 
estrogens are excreted in bile, urine, and faeces; this has been proved by the injection of 
radioactively labelled estrogens in women and suggesting biologically significant proportion 
of estrogens are reabsorbed in the circulation (Fig. 1.6).48 Hepatically conjugated estrogens 
excreted in the bile can be deconjugated by bacterial species (e.g., phyla Bacteroidetes and 
Firmicutes) with b-glucuronidase activity in the gut, leading to the reabsorption into the 
enterohepatic circulation (Fig. 1.6).48 
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Figure 1.6: The metabolic pathway of estrogens showing that estrogens are biosynthesised in the 
ovary, estrogens circulate into bloodstream in free or protein-bound forms, then undergo hepatic 
phase II metabolism. The conjugates are excreted in urine or in bile into the feces. Afterwards, the 
conjugated estrogens excreted in the bile can be deconjugated by  β-glucuronidase from gut bacteria 
and reabsorbed.  
1.2.5 The LBC of ERs 
Estrogens mediate their actions through ERs.49 ERs have specific binding sites for estrogens, 
the binding sites have conformational binding specificity and binding requirements for 
ligands (e.g., E2).50 Figures 1.7 and 1.8 show the LBC of ERa and ERb, respectively; the 
overall homology of the LBD between ERa and ERβ is less than 55%, but these two ER 
isoforms have great homology in their overall architecture (Fig. 1.2). In addition, the LBC, 
where interacts directly with ligands, of these two isoforms of ERs are remarkable highly 
homologous and providing similar binding environment and for ligands.51  
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Figure 1.7: X-ray crystal structure of E2 in the binding pocket of ERα showing the H-bonds 
(---, point out with a red arrow) between the ligand and LBC. Regions of the protein are 
represented as red for negative, blue for positive, green for nonpolar, cyan for polar, grey for 
neutral. Amino acid residues interacting with the ligand via H-bonds are shown. All amino 





Figure 1.8: X-ray crystal structure of E2 in the binding pocket of ERβ showing the H-bonds 
(---, point out with a red arrow) between the ligand and LBC. Regions of the protein are 
represented as red for negative, blue for positive, green for nonpolar, cyan for polar, grey for 
neutral. Amino acid residues interacting with the ligand via H-bonds are shown. All amino 
acids residues within 3 Å of the ligand are also shown to indicate the chemical nature of the 
binding pocket. 
1.2.6 The distribution of ERs 
Estrogens mediate the growth, bio-functions of many target tissues by activating an 
intranuclear binding protein (i.e., ERs).52 The most common target tissues are in the male and 
female reproductive systems, such as the mammary gland, uterus, ovary, testis, and prostate 
(Fig. 1.9).52 Estrogens are mainly produced in the ovaries and testes.53 They diffuse in and 
out of all cells, but are retained with high affinity and specificity in target cells by ERs.53 
Once bound by estrogens, the ERs undergo a conformational change, allowing the receptor to 
bind with high affinity to chromatin and to modulate transcription of target genes.14 In 
addition, estrogens also play an important role in bone maintenance and in the cardiovascular 
system, where estrogens have certain cardio protective effects.12  
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The biological significance of the existence of two ER isoforms is unclear. Perhaps the 
existence of two ER isoforms provides, at least in part, an explanation for the selective 
actions of estrogens in different target tissues which contains different expression levels of 
different ER isoforms (Fig. 1.9).51  In fact, the high degree of interspecies conservation of the 
individual ER isoforms throughout vertebrate evolution could suggest that the basis for the 
selective effects of estrogens resides in the control of different subsets of estrogen-responsive 
promoters by the two ER isoforms.51 This would indicate different expression of the ER 
isoforms in target tissues.51  
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Figure 1.9: The distributions of ERs in the human body. 
18 
1.2.7 Evolution of ER: birth of the estrogen mimic 
ER evolved in a pristine environment, in which it developed an intimate and highly specific 
relationship with estrogens, particularly E2.54, 55 The specificity of this relationship was key 
to female sex hormone function.54, 56 In time, the earth became polluted with chemicals, some 
of which have molecular analogues with E2.54, 17 These estrogen analogues can occupy the 
previously estrogen-specific LBC and thus set the receptor off on its gene regulatory path.54, 
20 These estrogen analogues are termed estrogen mimics or xenoestrogens (from the Greek 
ξένος, meaning foreign) and are now thought to be responsible for human and ecosystem 
effects such as reduced human sperm count, precocious puberty,54, 57 decreased alligator penis 
length, and imposex in dog whelks (Nucella lapillus)58— and all because of some man-made 
pollutants (e.g., the antifungal methylparaben used in some cosmetics; Fig. 1.10).54,59 The 
first synthetic estrogen was produced in 1938, when Dodds’s research group synthesised 
diethylstilbestrol (DES) (Fig. 1.10), a chemical compound with significant estrogenic 
properties.54,60 In the study by McLachlan et al., DES was used to animal husbandry with 
effects such as increased weight gain in cattle, and caponisation of roosters.61 Furthermore, 
DES has been used in medicine; for example, as a treatment for prostate cancer and for 
lactation suppression, and to reduce miscarriage rates.62 In addition, some molecules derived 
from food plants (e.g., GEN from soybeans) are estrogen mimics;54,17 because of this, soy 
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phytoestrogens have been applied in food supplements to alleviate menopause symptoms 
(e.g., hot flushes and loss of bone).13 
Figure 1.10: Schematic representation of ERα with E2 showing the ideal molecular requirements for 
binding. A selection of estrogen mimics is also shown, orientated to highlight their structural 
analogies to E2 and their potential interactions with the LBC. 
1.3 Phytoestrogens and their implications for human health 
1.3.1 Overview 
Xenoestrogens have been separated as phytoestrogens and synthesised xenoestrogens, 
depending on their sources.63 Synthesised xenoestrogens come mainly from pharmacological 


























Phytoestrogens, however, are from plants, and have been found widely in dietary produce 
including fruit and vegetables.65 Previous research shows that phytoestrogens possess many 
positive effects on human health; for example, they have anti-cancer and anti-oxidative 
properties in cell and animal model studies, and play an important role in the nervous 
system.8, 66 However, some negative effects of phytoestrogens have been reported—chiefly 
but not limited to male feminization cryptorchidism, and precocious puberty in females.67 
1.3.2 What are phytoestrogens? 
The word “phytoestrogen” is derived from the Greek φυτόν meaning plant and estrogen, this 
means estrogen mimics from plant.68 The major classes of phytoestrogens of current interest 
from a nutritional and health perspective are the flavonoids, coumestans, and lignans (Table 
1.1), which are ubiquitous within the plant kingdom. They are biosynthesised in plants from 
phenylpropanoids and simple phenols. A conspicuous feature of the chemical structure of 
phytoestrogens is the presence of a phenol group, which is a prerequisite for binding to the 
ERs;69, 70 The relative estrogenicity of these phytoestrogens (where E2 equals 1) is at least 
104 times less than E2 (Table 1.1).71, 72 Indeed, phytoestrogens can interact with ERs and 
trigger estrogen bio-actions; their actions at the cellular and molecular level are influenced by 
many factors, including but not limited to concentration dependency, receptor status, 






Table 1.1: Examples of phytoestrogens from three main classes and their estrogenic potencies,72 
where E2 equals 1. 
Basic structure  Compounds 








































1.3.3 Some examples of phytoestrogens 
Coumestrol is a natural compound in the class of coumestans, and was first identified and 
reported as a phytoestrogen in ladino clover in 1957.74 In addition, coumestrol has been 
detected in some foods, including soybeans, brussels sprouts, and spinach.73 The highest 
concentrations of coumestrol were found in clover, kala chana (a type of chick pea), and 
alfalfa sprouts.75 Coumestrol has been reported to increase the expression mRNA in the 
hypothalamus in brain which links the nervous system to the endocrine system via 
the pituitary gland; this indicates the potential role of coumestrol in modulating of 
endocrine.76 Enterolactone and enterodiol are mammalian lignans formed by the action of 
intestinal bacteria from plant lignan precursors (e.g., matairesino and sesamin) present in the 
diet (e.g., whole grains and oil seeds).77 Previous investigations indicated enterolactone and 
enterodiol may protect against breast cancer and prostate cancer;95, 65, 78 besides the 
estrogenic-related health effect, the two phytoestrogens have been shown to be effective 
antioxidants against DNA damage and lipid peroxidation.79 A good example of a flavonoid 
phytoestrogen is GEN from soy (Fig. 1.10).80 GEN has a significant structural analogy with 
E2 (Fig. 1.10),72  which allow this compound to bind with key amino acid residues in the 
LBC of ERs, via noncovalent interactions (e.g., hydrogen bonds (H-bonds), thus initiating the 
estrogenic response.81 However, the phytoestrogens from different chemical classes show 
different estrogenicities because of their varying structures (Table 1.1).72 
There are many health effects of phytoestrogens have been reported both in a positive and 
negative sense.82 Positive effects include their use in post-menopausal women as a “partial 
hormone replacement” that could alleviates symptoms of the menopause when plasma E2 
levels decline rapidly.83 This rapid decline of E2 has been linked to a reduction in the 
incidence of post-menopausal disorders such as osteoporosis.84 On the other hand, their 
negative health effects have also been reviewed extensively,85-87 and are chiefly, but not 
limited to, male feminization (e.g., reduced sperm count,88, 89 increased incidence of 
hypospadias 47 and cryptorchidism, precocious puberty in females,90 as well as myriad effects 
in the environment, such as reduced penis length in alligators).91 
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1.3.4 The effects of phytoestrogens on health 
1.3.4.1 Phytoestrogens and cancer  
Traditional consumption of soy products has been linked to the lower incidence of breast and 
prostate cancers in Asian countries such as China and Japan compared with Western 
countries.92 The potential association between dietary phytoestrogens and breast cancer has 
been studied frequently.66, 93-95 At a cellular level, phytoestrogens including a total of 13 
compounds from isoflavones, flavonoids, and lignans have been studied in previous research, 
and the results showed a biphasic effect of phytoestrogen on the DNA synthesis in human 
breast cancer cell (MCF-7 cells), which was inhibited at high concentration when the cells 
cultured with the selected phytoestrogens, but DNA synthesis in MCF-7 cells was induced 
exposure to low concentrations of the tested phytoestrogens.96 Importantly, the induction 
effects of phytoestrogen on DNA synthesis is close to the probable level in humans.97 
Interestingly, in an in vitro study, the low concentration of GEN and DAID also showed 
antagonist inhibition of an anti-breast cancer medicine—tamoxifen (Fig. 1.11).98 In addition, 
an in vivo experiment reports that rat were treated neonatally with GEN; and the results show 
that GEN treatment reduced the cell proliferation in the mammary gland.98 In an 
epidemiological study of colorectal cancer (in 1997–2000), dietary phytoestrogens have been 
shown to be associated with colon cancer by reducing the risk of this cancer; this could be 
linked to the ERb-mediated activity of such phytoestrogens in the colon which might 
influence the proliferation of colon cells.66, 99 100  




ERs exist in the human GI tract (Fig. 1.9) and human colon cancer cell lines (e.g., Caco-2, 
T84, SW1116).51 Some other epidemiological studies and trials consistently report that 
hormone replacement therapy (HRT) could cause a significant reduction in colorectal cancer 
risk among women.101 A previous study suggested that estrogens could modify lipids and bile 
acid or decrease the estrogenic regulation, which might be associated with carcinogenesis; in 
turn, these estrogens may affect colorectal cancer risk.51 Interestingly, a previous study 
indicated the estrogen inactivation in colonic cancer; the research indicated that E1 inhibited 
colonic cell proliferation, whereas E2 did not.102 This means that the protective effect of HRT 
on colonic cancer might be due to estrone.102 Several epidemiological studies indicated 
lowered colorectal cancer risk associated with the consumption of soy foods, although 
findings are varied by types of soy foods, colorectal cancer sub-site, and sex.100 A case-
control study evaluated the association between phytoestrogen (including lignan and 
isoflavone) intake and colorectal cancer risk.99 The results showed that both dietary lignan 
and isoflavones intake was associated with a significant reduction in colorectal cancer risk.99 
In addition, the research also reported that encode enzymes (e.g., CYP450s, catechol O-
methyl transferase) could be involved in the metabolism of phytoestrogens;103 this suggests 
that dietary intake of phytoestrogens is potentially modifiable.103  
1.3.4.2 Phytoestrogens and reproduction  
Phytoestrogens can both promote and inhibit reproductive processes.104 A previous research 
shows, phytoestrogens extracted from green tea, are able to inhibit cell proliferation, increase 
the rate of apoptosis, and influence the release of steroid hormones in porcine ovarian cells.78 
In addition, the development of precocious puberty and ovarian function might be altered by 
consumption of soybean-based foods; this is likely due to the high levels of phytoestrogen 
isoflavones in soy foods.78 Another investigation in rats showed that, after 10 d of a soy-
based diet in the postnatal period, offspring rats suffered from a high rate of 
demasculinization in adulthood.105 Nevertheless, there are some studies showing adverse 
influences of xenoestrogens on sperm parameters; for example, previous research in the 
United States60, 106 suggested that phytoestrogens could affect sperm quality.60, 106 In addition, 
Shaw suggested that the food-derived xenoestrogen cocktail would have a greater effect on 
males because it adds a larger proportion to the total estrogenicity load.107  
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1.3.4.3 Phytoestrogens and cardiovascular disease  
Coronary heart disease (CHD) is the leading cause of death in humans.66 It has been 
suggested that a major factor for the increase of the incidence of CHD is the loss of E2 after 
menopause.108 The abundance of certain phytoestrogens (e.g., soy isoflavones) in Asian diets 
and the lower rates of “Western diseases” such as CHD in such a population have suggested a 
protective role for these mostly soy-derived substances.66 Phytoestrogens may also have 
effects on pathophysiologic vascular processes such as lipid profile (reduction of low-density 
lipoprotein, cholesterol, and these effects could delay the progression of atherosclerosis.65 In 
addition, an animal model study reported that dietary soy isoflavones (i.e., GEN and DAID) 
improved coronary vascular function, by enhancing the dilator response to acetylcholine of 
atherosclerotic arteries in female monkeys, and the incidence of coronary artery disease has 
been reported to increase after menopause.109, 110 This suggests the dietary supplement of 
food phytoestrogen may apply as a viable alternative to traditional HRT (e.g., E2).109  
1.3.4.4 Phytoestrogens and the immune system 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), is a 
transcription factor that can initiate inflammation and immune responses.111 This intracellular 
signalling pathway can be suppressed by soy phytoestrogens (e.g., GEN), which suggested 
the soy phytoestrogen might affect the immune system.112 Indeed, there are several in vivo 
and in vitro studies supported that phytoestrogens have the potential to affect the immune 
system.113 For example, GEN inhibits antigen-specific immune response in an in vivo study 
in mice and suppresses lymphocyte proliferation in vitro, which is a fundamental 
characteristic of the response of lymphocytes to antigenic stimulation.114, 115 Based on this, 
GEN has been used as a treatment for immune diseases in animal mode system studies, and 
exhibited inhibitory effect on allergic inflammatory responses.113  
1.3.4.5 Phytoestrogens and the nervous system  
In 1971, Gorsk suggested that the central nervous system (CNS) is a target for sex 
hormones.116 Previous studies using light microscopic immunocytochemical and 
26 
hybridization observed the cells with ERα, ERβ, and guanine nucleotide-binding protein (G- 
protein) coupled with estrogen receptor 1(ER1), which is the gene coding ERα, throughout 
the brain, from the most rostral regions of the forebrain to the cerebellum.117  
In the learning and memory region of the brain, including the prefrontal cortex, nucleus 
acumens, and dorsal striatum, membrane-associated ERs are observed, and this finding could 
underline a mechanism for the rapid effects of estrogens on these regions.118 The effects of 
estrogens on dopamine-dependent cognition likely result from binding at both nuclear and 
membrane-associated ERs, so elucidating the localization of membrane-associated ERs helps 
provide a more complete understanding of the cognitive effects of these hormones.117 119 
Since phytoestrogen can mimic E2 and activate ERs, emerging experimental and clinical 
evidence shows that phytoestrogens could influence memory mechanisms, cognition, postural 
stability, fine-motor skills, mood, and affectivity.120 In addition, phytoestrogens may exert a 
protective action against neurodegeneration and brain injury.120 Hajiranhimkhan et al. 
showed soy isoflavones may affect neurons via both steroid receptor and 5-
hydroxytryptamine receptor (i.e., through both estrogenic and serotonergic activities).95 ,121 In 
addition, phytoestrogen flavonoids have been reported to express various pharmacological 
potentials and mechanisms of action on the catecholamine (e.g., dopamine and epinephrine) 
system in adrenal medullary cells and sympathetic neurons; this suggests that these 
flavonoids might influence neuronal responses, by affecting catecholamine synthesis and 
uptake.78, 122 Interestingly, GEN (but not DAID) can enhance noradrenaline uptake by 
noradrenergic neuroblastoma cells.95, 120 In contrast, DAID was shown to inhibit 
catecholamine synthesis and secretion induced by a physiological secretagogue, namely, 
acetylcholine.95, 120  
1.4 Phytoestrogens in food – risks versus benefits  
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1.4.1 Overview 
Phytoestrogens mainly come from flavonoids, which include a six main subclasses; flavone, 
isoflavone, isoflavane, flavanone, coumestan, dihydrochalcone. The dietary source of 
phytoestrogen flavonoids are fruits and vegetables, and soy isoflavones could constitute the 
majority, partly because of the huge consumption of soy and soy-based foods, and another 
reason is the relatively high concentration of isoflavones in soy (> 1%, dry weight) compared 
with other food sources of phytoestrogen flavonoids.122 Soy-based foods are classified 
according to their food manufacturing process, namely, unfermented soy foods and fermented 
soy foods. The diverse food manufacturing processes; (soaking, grinding, filtration, and 
fermentation) could change the composition of isoflavones.109 
1.4.2 Sources of phytoestrogens 
As outline before, many phytoestrogens are flavonoids including six subclasses based on 
chemical structures (Table 1.2),123 Isoflavones are the most common group of flavonoid 
phytoestrogens, and they are often found in legumes, such as soy beans.123 There are two 
main compositions of isoflavones found in soybeans, daidzin and genistin, and their 
corresponding aglycones: DAID and GEN respectively (Table 1.3). They comprise more than 
1% of the dry weight of soybeans, depending on the species;124 for example, compared with 
American varieties of soybeans, Japanese varieties have greater amounts of isoflavones.125  
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Table 1.1: Examples of phytoestrogens from different subclasses of flavonoids, and their major food 
sources. 
Subclass Name Substitution 
position 
Food source 
Flavone & Flavonol 
 
Apigenin 5,7,4´ (-OH) Celery, parsley 
Acacetin 
5,7, (-OH);  
4´ (-OCH3) 
Black locust tree 




Soy-based foods (e.g., 
soy milk, tofu) Glycitein 
7,4´(-OH); 
 6 (-OCH3) 
DAID 7,4´(-OH) 
Isoflavane 














































Naringenin 5,7,4´(-OH) Grapefruit, coconut 
Coumestan 
Coumestrol 3,2´ (-OH) Soy sprouts, lima beans 
Dihydrochalcone
 






































Table 1.2: The main isoflavones in soy, and their structures. 
Molecular forms Substances Substitutions 
Glucosides 
 












DAID H H 
GEN OH H 
Glycitein H OCH3 
1.4.3 Worldwide cultivation and consumption of soybean 
Soybeans, indigenous to China, are one of the top five plant foods in China along with rice, 
millet, wheat, barley and have been cultivated for about 5000 years.122, 126 Initially, soybeans 
were introduced to Southeast Asia, before being cultivated in Europe in the eighteenth 
century and America in the nineteenth century.126 Since 1940, soybeans have been became 





















soybeans worldwide.122 In addition, approximately 102.77 million hectares are used for 
soybean cultivation worldwide, with a total harvest of approximately 239.26 million tons in 
the 2011/2012 season.122  
The nutritional value of soybeans has been documented widely.127 Firstly, according to 
Zambiazi’s research, soybeans contain significantly high levels of unsaturated fatty acids, 
particularly omega-3 fatty acids, which are well known to be an important member of the 
healthy fatty acids, and associated with cancer prevention, brain development and visual 
function.128, 129 In addition, previous study concluded that soy-derived products are more 
beneficial than animal products, due to the lowering of serum triglycerides, low-density 
lipoprotein (LDL) and cholesterol of soy protein.130 With a better understanding of soybean-
related health benefits and consumer acceptance, soy products now account for a much larger 
share of the food market than ever before.131 For instance, between 2000 and 2007, there 
were more than 2700 kinds of soy-based food product introduced into the US market.131 
1.4.4 Unfermented soybean foods 
Generally, soybeans foods are classified as one of two types, depending on the food 
manufacturing process: unfermented or fermented.132 In Western countries, soybean foods, 
normally unfermented soybean foods, are an important component added in food 
manufacturing processes; for example, bread manufacturing.132 There are various traditional 
soybean foods that have been widely accepted for a long time, for example, soybean flour 
and soy nuts.132 Soybean flour is made from roasted soybeans that have been ground into fine 
flour; they are characterised by their fat content: either full fat or defatted.122, 132 To increase 
the total protein percentage of foods, soybean flour is widely used as a basic ingredient in 
food production, especially in bakery goods and pasta; this is due to the significant amount of 
soy protein in soybean (soy protein constitutes about 50% of the dry weight of soybean).133 
Owing to major changes in food process technology, soy protein, either alone or in 
combination with some other vegetable proteins122 is included in the production of various 
kinds of texturized meat substitute products, cheeses, and dairy substitute products.133 These 
foods can enrich the diversity of vegetarian and medically necessary diets; for example, in the 
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management of hyperlipidaemia, which requires patient to decrease their intake of 
cholesterol.133  
In the Eastern world, unfermented soybean foods have accounted for a large percentage of 
the diet since ancient times.132 For example, soymilk is produced by soaking dried soybeans 
and grinding them in water, this food is in a written record in China from AD 82.132 The 
aqueous extract of soy protein contains similar concentrations of protein and fat as 
unpasteurized cow’s milk, but soymilk does not contain any lactose or cholesterol and is used 
as an alternative to dairy milk for lactose-intolerant people.122, 134 Tofu is another popular 
unfermented soy food, also invented in China and introduced into Japan in the Tang Dynasty 
(around AD 618), and was introduced to Western countries only approximately 200 years 
ago.135 Tofu is made by coagulating soymilk and then pressing the resulting curds into 
blocks.24, 136 During the coagulating step, a coagulant (such as a calcium or magnesium salt or 
glucono delta-lactone) is used to precipitate soy protein from soymilk to form a jelly-like 
curd.122, 137 Following the downstream processes, curds are converted into diversified 
intermediate products in different shapes.137 Furthermore, to create diverse kinds of textures 
in terms of hardness, moisture, the jelly-like curds are further pressed and treated with food 
additives (e.g., soy sauce, chilli sauce).138 
1.4.5 Fermented soybean foods  
There are a variety of fermented soybean foods with a long production history and significant 
popularity in Eastern countries.139 Miso is a very popular and widely used cooking condiment 
in Japan.139 This soy-based food is prepared from soybeans, wheat, rice, and barley, alone or 
mixed with sea salt, and then fermented in a sealed container.140 Generally, Aspergillus 
oryzae, yeast, and lactic acid-producing bacteria are required for the fermentation process.140 
Soy sauce or Jiang You is one of the most commonly used seasonings in Eastern countries 
and has become popular in the Western world in recent year.141 Soy sauce production has a 
similar ingredients and process to miso,142 and soy sauce is made by mixing soybeans and 
roasted grain with mould cultures, such as A. oryzae and other microorganisms and yeasts.143 
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Soy sauces are classified according to their uses, such as laochou used for colouring, and 
shengchou used for seasoning with a shorter fermentation compared with laochou.143  
Tempeh is a traditional Indonesian food produced by growing Rhizopus on peeled and 
partially cooked soybeans.141 Typically, banana leaves are used as the fermenting cover. 141 
Tempeh provides high levels of protein, and has been suggested as an important source of 
vitamin B13 and is used as a meat replacement in vegetarian diets in South Asia.141  
Douchi (Natto in Japanese) is the first fermented soy food on record.144 It originated in China 
(around 165 BC) and has been used as a food seasoning.144 There are two types of douchi 
owing to the different strains of microorganism used in their fermentation, namely, Mucor 
sp., and Aspergillus sp., which is the most popular type of microorganism for soy 
fermentation.144 
Sufu, also called Fu-ru or Dou-fu-ru, is a cheese-like soybean food with a soft texture and 
pronounced flavour.145 Sufu is a side dish consumed normally with rice porridge in the south 
of China; in north China, people prefer to eat sufu with steamed buns.146 Sufu is produced by 
fungal or bacterial fermentation of tofu.147 The primary steps are the preparation of pehtze 
(tofu with culture mould), salting and ripening.147 The various types of sufu are determined 
by their processing methods, colours and flavours.146 For example, according to which 
fermentation method is used, there are naturally fermented sufu, bacterial fermented, and 
enzymatically ripened sufu147 and the naturally fermented sufu is fermented slowly with 
naturally-occurring bacterial and fungal spores in the air.146 
Doenjang is a popular fermented soybean paste from Korea, and can be used as a dipping 
agent for vegetables or barbecued meats.148 This soybean paste is traditionally produced from 
meju, a fermented block made from crushed cooked soybeans.149 The bacterium used in meju 
fermentation is Bacillus subtilis, and moulds such as Mucor sp, and Aspergillus sp. After the 
fermentation (1-3 months), depending on the block size, meju is set aside for further 
fermentation under brine in pottery jars.149 The liquid and solid are separated after 
fermentation, with the solid residue being doenjiang.150 
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1.4.6 Effects of food manufacturing processes on the composition of 
isoflavones 
Isoflavones exist as aglycones, including DAID and GEN, and as their corresponding 
glucoside conjugates in soybean and soybean-based foods (Table 1.3).124 Many studied show 
that the compositions of isoflavones in soybean products would be changed during the 
manufacturing processes.151 A good example is the production of tofu, the raw soybeans 
being soaked, ground with a certain proportion of water, then filtered, after which the 
supernatant was boiled and coagulated.152 Previous research indicated that different ratios 
between water and soybeans during grinding varied the compositions of isoflavones.152 
Results showed the optimum water to bean ratio during grinding, in terms of estimating the 
loss of isoflavones, was 10:1.152 It has been reported that heat treatment during the boiling 
could convert some malonyl isoflavones to their corresponding acetyl form, and a proportion 
of isoflavones were removed during defoaming in tofu production.153 Another research 
studied the effects of coagulants on the isoflavone levels during tofu production. This study 
shows calcium sulphate is the best coagulant for tofu manufacture in terms of its high yield 
and preservation of isoflavones.154 
Interestingly, fermentation has been reported to have a significant influence on compositions 
of isoflavones in soy foods.147 The study of Yin et al. shows that most glucoside isoflavones 




Table 1.3: Isoflavone compositions of sufu processing on its catalysis isoflavones content.147 
Sample Glucoside form (%, w/w)                    Aglycone form (%, w/w) 
 
Daidzin Glycitin Genistin Total 
isoflavone 




53.1 3.8 41.8 98.7 0.4 0.2 0.7 1.3 
Tofu 20.1 2.7 59.2 82.0 13.6 3.6 0.8 18.0 
Pehtze 2.5 1.2 15.5 19.2 28.7 5.6 46.5 80.8 
Salted 
pehtze 
2.5 0.8 12 15.3 30.8 6.1 47.9 84.7 
Sufu ND 0.3 NDa 0.3 33.5 7.8 58.4 99.7 
ND, not detected 
What is more, the activity of β-glucosidase, which catalyses the cleavage of the glucoside 
moiety to release the aglycone, was very low in tofu, but quickly increased during the 
fermentation; as a result, studies have shown highly significant increases in aglycones during 
fermentation.11, 144, 147 
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1.5 Metabolites of DAID and GEN during fermentation, and their 
biological activities 
1.5.1 Overview 
The fermentation of soy-based foods involves fungi, bacteria and yeast, which might cause 
biotransformation of isoflavones because of the enzymes released by these organisms, such 
as CYP450 and b-glucosidase.155 A few hydroxylated metabolites have been found in 
fermented soy foods, and these compounds have been reported to have anti-cancer and higher 
anti-oxidative properties than their parent compounds.156 
1.5.2 Hydroxylated compounds of GEN and DAID 
An interesting point that should be appreciated from the research by Yin et al. is that the 
decrease of glucoside isoflavones (e.g., daidzin and genistin) was larger than the increase of 
their corresponding aglycones (e.g., DAID and GEN, respectively). 147 This suggests the 
aglycones might be further converted into other metabolites. Besides the conversion between 
glucoside isoflavones and aglycone isoflavones, two types of biotransformation products of 
DAID and GEN, namely ortho-hydroxydaidzein (OHD) and ortho-hydroxygenistein (OHG) 
have been isolated and identified from fermented soybean foods.157 Only 3ʹ-ortho-
hydroxylated compounds are found naturally in plants as well as in fermented soy foods, such 
as Orobus tuberosus, Machaerium villosum.157 These metabolites have the same structural 
skeleton but extra hydroxyl groups compared with their parent compounds.157 The isoflavone 
metabolites are characterised by the position of the extra hydroxyl groups compared with 
their precursor compounds: OH-DAIDs and OH-GENs are named as 6-hydroxydaidzein (6-
OH-DAID), 8-hydroxydaidzein (8-OH-DAID), 3ʹ-OH-DAID (3¢-hydroxydaidzein), 6-
hydroxygenistein (6-OH-GEN), 8-OH-GEN (8-hydroxygenistein), and 3¢-hydroxygenistein 
37 
(3ʹ-OH-GEN) (Fig. 1.12). Meanwhile, their biological potencies have been determined by in 
vivo and in vitro experiments.157  
 
Figure 1.12: Structures of the hydroxylated derivatives of DAID and GEN produced during soy 
fermentation. 
1.5.3 The sources of hydroxylated compounds of isoflavones and their 
bioactivity potency 
6-OH-DAID was isolated from the Japanese soybean food koji, which is fermented with A. 
oryzae.156 After soaking and steaming, soybeans were formed into cylindrical balls, and 
incubated at 30℃ for 4 d. In an in vitro experiment, 6-OH-DAID showed greater anti-oxidant 



































been reported to induce cell cycle arrest at the S and G2/M phases and suppress the 
proliferation of HCT-116 (a human colon cancer cell line). This DAID metabolite also 
exhibited a strong competitive activity in tyrosinase inhibition in both in vitro and in vivo 
experiments, this suggests the potential utilisation of 6-OH-DAID for skin disorder.158, 159 
8-OH-DAID and 8-OH-GEN were isolated from miso fermented with Aspergillus saitoi and 
purified by silica gel column chromatography.160 Previous study shows these two 
hydroxylated metabolites of isoflavones have significantly greater anti-oxidative activity in 
both oil-based and aqueous systems compared with GEN and DAID.159 In addition, both of 
the metabolites showed tyrosine kinase inhibitory activity, and also exhibited anti-
proliferative activity in cancer cell culture experiments: for example, HL-60 cell (human 
leukemic cell line) and HCT-116 cell (human colon cancer cell line).139, 161, 162 
3ʹ-OH-DAID was also isolated from miso and douchi, which are fermented with Aspergillus 
oryzae and Salmonella. typhimurium TA 98 at room temperature.163 Both in vitro and in vivo 
experiments indicated that endothelial growth factor receptor-positive skin cancer cells can 
be suppressed effectively by 3-OH-DAID.164, 165 In addition, the 3-OH-DAID showed 
relatively higher anti-oxidant potency by the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical-
scavenging assay compared to its parent compound (i.e., DAID).  
3ʹ-OH-GEN was the first hydroxylated metabolite of isoflavones to be isolated from 
fermented soybean-based food (i.e., tempeh).166 In bioactivity assays, 3ʹ-OH-GEN induced 
G2-M cell cycle arrest and inhibited the proliferation of T47D breast cancer cells.166 In 
addition, 3ʹ-OH-GEN has been reported to against human immunodeficiency virus-1 (HIV-1) 
integrase and suggesting this compound may be used as a potential treatment for HIV1 
infection (Acquired Immune Deficiency Syndrome (AIDS).149 Moreover, 3ʹ-OH-GEN shows 
extremely potent of hepatoprotective activity on D-galactosamine-induced cytotoxicity in 
primary cultured mouse hepatocytes.167-169 
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1.6 Aim and objectives of this thesis 
The overall aim of this thesis is study the complex interrelationships between ERs, their 
ligands, and bioactivities, focusing on isoflavones in a functional food setting. This will be 
achieved by the following research objectives: 
• Use a computational bio-molecule platform (Schrödinger) to investigate the 
communication between the LBC and AF-2 of ERa via the conformation changes 
caused by docked ligands. 
• Use Schrödinger to study the effects of structural properties of ligands (i.e., in this 
thesis flavonoids) on their theoretical ERα binding energy, and potential implication 
for estrogenicity. 
• Use Schrödinger to investigate the theoretical binding energy/affinity of isoflavones 
with ERa. 
• Use the MELN assay to study the structure ERa-driven bioactivity relationship of 
isoflavones. 
• Use Schrödinger to study the theoretical binding energy and binding affinity of 
isoflavones with ERb. 
• Study the effects of isoflavones on the proliferation of Caco-2 cells, and investigate 
the potential structure-activity relationships of isoflavones. 
• Investigate the potential influence of the intestinal phase II metabolism on the ERb-
driven bioactivity of isoflavones. 
• Use an in vitro gut fermentation model to investigate the effects of isoflavones on 
human gut bacterial populations. 
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• Use a Caco-2 monolayer transportation system to study the absorption and 
metabolism of isoflavones.  
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1.7 Thesis map 
The interrelationships between the chapters in this thesis are shown in Figure 1.13. 













2 Chapter 2 –Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
2.1.1.1 General Chemicals and Solvents 
All general chemicals were purchased from ECP Ltd, New Zealand, unless listed below.  
Dimethyl sulfoxide (DMSO; Scharlau Chemie, SA, Spain). 
Gallic acid (GA) (Sigma-Aldrich, New Zealand Ltd.). 
High Performance Liquid Chromatography (HPLC) grade methanol, acetonitrile (Sigma-
Aldrich, New Zealand Ltd.). 
Milli-Q water (purified using the Milli-Q system, 18.2 MΩ/cm, Merck Millipore Merck Ltd., 
Auckland, New Zealand).  
2.1.1.2 Authentic standards 
6-hydroxydaidzein (6-OH-DAID), 8-hydroxydaidzein (8-OH-DAID), 3ʹ-OH-DAID (3¢-
hydroxydaidzein), 8-OH-GEN (8-hydroxygenistein), and 3¢-hydroxygenistein (3ʹ-OH-GEN) 
(Indofine Chemical Company, Hillsborough, NJ, US). 
17β-Estradiol (E2), genistein (GEN), daidzein (DAID), formononetin (FOR) (Sigma-Aldrich, 
St. Louis, US). 
Fulvestrant (ICI 182,780, Sigma-Aldrich, St. Louis, US). 
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All the authentic standards were dissolved in DMSO to make 1 mM stock solutions. 
2.1.1.3 Lab wares 
Centrifuge tubes (15 mL, 50 mL; LabServ®, Thermo Fisher Scientific, New Zealand Ltd., 
Auckland, New Zealand). 
Eppendorf tubes (100 μL, 600 μL, 1.6 mL; Thermo Fisher Scientific, Melbourne, Australia). 
Glass HPLC vial (2 mL, SUN SRi, Thermo Fisher Scientific, Auckland, New Zealand). 
Hamilton Syringe (10 μL, Sigma-Aldrich, New Zealand Ltd.).  
Non sterile syringe filters (7.5mm non-sterile PTFE hydrophobic filter, Thermo Fisher 
Scientific, Melbourne, Australia). 
Micro well white tissue culture plates, sterile (Nunc™ F96 MicroWell™ White Polystyrene 
Plate 24, 96 wells, Thermo Fisher Scientific, New Zealand Ltd., Auckland, New Zealand). 
Periplast plastic counting chamber (Thermo Fisher Scientific, Melbourne, Australia). 
T-75 sterile culture flask (Sigma-Aldrich, New Zealand Ltd.).  
Sterile culture flasks (Nunc™ EasYFlask™ Cell Culture Flasks, 75 cm2, filter, Thermo 
Fisher Scientific, New Zealand Ltd., Auckland, New Zealand). 
Sterile filters (Steritop-GP, 0.22 μm, polyethersulfone, 500 mL 45 mm, Merck Millipore). 
Varioskan Flash (Thermo Fisher Scientific, New Zealand Ltd., Auckland, New Zealand). 
2.1.1.4 Biologicals 
Benzyl penicillin (Sigma-Aldrich, New Zealand Ltd). 
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Bovine Serum Albumin (BSA; Sigma-Aldrich Ltd., New Zealand). 
D-Luciferin (Sigma-Aldrich Ltd., New Zealand) 
Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich Ltd., New Zealand). 
Fetal bovine serum (FBS; Life Technologies, Auckland, New Zealand). 
Inulin power (Sigma-Aldrich Ltd., New Zealand). 
L-Cysteine HCl (Sigma-Aldrich Ltd., New Zealand). 
LightCycler® 480 SYBR Green Ⅰ Master mix (Roche Diagnostics, Germany). 
Minimal Essential Medium (MEM) with Earle’s Salts and 20 mM L-glutamine (Sigma-
Aldrich New Zealand Ltd). 
Phenol red-free MEM powder (Sigma-Aldrich, New Zealand Ltd). 
Radioimmunoprecipition (RIPA) buffer (Sigma-Aldrich Ltd., New Zealand). 
Resazurin sodium salt (Sigma-Aldrich Ltd., New Zealand). 
Streptomycin sulfate (Sigma-Aldrich, New Zealand Ltd). 
Sulfatase/b-glucuronidase from Helix pomatia (≥10,000 units/g solid) (Sigma-Aldrich, St. 
Louis, US). 
Trypan blue (Sigma-Aldrich, New Zealand Ltd). 
Type-I collagen (Sigma-Aldrich, New Zealand Ltd). 
TrpLE® express (Thermo Fisher Scientific, Auckland, New Zealand). 
Trypsin powder (Becton Dickinson, Auckland, New Zealand). 
Wilkins Chalgren anaerobic (WCA) broth (Thermo Fisher Scientific, Melbourne, Australia). 
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Anaerobic chamber (Coy Laboratory Products Inc., Michigan US). 
Octadecylsilane (ODS) SPE bulk sorbent (Agilent, US). 
C18 SecurityGuad column (Phenomex, North Shore City, New Zealand). 
Centrifuge (multifuge 1 S-R, Heraeus, Hanau, Germany). 
HPLC System (Dionex, US). 
Incubator shaker (Thermo Fisher Scientific, Melbourne, Australia). 
Inverted microscope (CKX41, Olympus, Melbourne, Australia).  
Laminar flow cabinet (Cytoguard CG2000 series, model CGA-180, Clyde Apac, Sydney, 
Australia).  
Microscope camera (Toup Ltd.).  
Millipore sterile filter (0.45 μM, Merk Millipore, US). 
Millicell voltohmmeters (Merck, Germany). 
Phenomenex C18 Prodigy 5µm ODS3 100 A 250 × 4.60 mm column (Phenomenex, North 
Shore City, New Zealand (S/No 584453-48). 
Rotor-Gene 6000 machine (Bio-strategy, New Zealand). 
Transwell Insert (Life Sciences, MA, US). 
Techne Sample Concentrator (Total Lab System Ltd, Auckland, New Zealand). Preparation of 
cell culture media, bacteria culture media and related reagents 




Benzyl penicillin (3.0 g) and streptomycin sulfate (2.8 g) were added to 100 mL sterile Milli-
Q water; this mixture was stirred using a magnetic stirrer for 24 h. The final solution was 
stored at 4°C for up to six months.  
2.2.1.2 PBS buffer 
A packet of PBS powder was added to a 1 L Schott bottle. Milli-Q water (900 mL) was added 
and the PBS dissolved via vigorous shaking. The pH was adjusted to 7.4 using 1M or 0.1M 
HCL or 1M or 0.1M NaOH as appropriate. The pH adjusted solution was topped up to 1 L 
with Milli-Q water. The solution was autoclaved (120°C, 15 psi for 80 min) and then stored 
at 4°C.  
2.2.1.3 Trypsin proteinase 
NaCl (8.5 g) was dissolved in Milli-Q water (1 L). Trypsin powder (25 g) was added to the 
0.85% w/v (aq) NaCl (1 L) and stirred (using a magnetic stirrer) at room temperature for 1 h. 
The trypsin solution was sterilised by filtration and dispensed into 10-20 mL aliquots and 
stored at -20°C. EDTA (3.72 g) was dissolved in PBS (1 L) and sterilised by autoclaving. 
This PBS/EDTA (PE) solution was diluted 10-fold with PBS and 90 mL of the diluted PE 
was mixed trypsin solution (10 mL) to produce the final trypsin solution (2.5% w/v, (aq). 
This solution was stored at 4°C for up to 3 weeks.  
2.2.1.4 Heat inactivation of fetal bovine serum  
Fetal bovine serum (FBS, 500 mL) was thawed at 4°C overnight. The thawed serum was 
gently warmed in a 37°C incubator for 30 min with gentle inversion every 10 min to ensure 
even temperature distribution. After the serum reached 37°C it was placed in a 56°C water 
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bath for 60 min with gentle inversion every 10 min. The serum was left to rest at room 
temperature for 30 min. Aliquots (100 mL) were transferred to Schott bottles and stored at 
−20°C.  
2.2.1.5 Charcoal-dextran Stripped FBS 
MgCl2 (H2O)6, sucrose (85.6 g), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES, 2.4 g) was added to a 1 L Schott bottle. Milli-Q water (1 L) was added to the bottle 
and shaken vigorously. The solution was divided into 50 mL aliquots. Two aliquots were 
added to two 50 mL plastic centrifuge tubes each containing dextran coated charcoal (0.137 
g). The centrifuge tubes were inverted 10 times to ensure even distribution of charcoal-
dextran. The tubes were incubated for 24 h at 4°C.  
Following incubation, the charcoal-dextran solution was centrifuged at 500 × g for 10 min 
and the supernatant was discarded. Inactivated FBS (50 mL) was added to each pellet. The 
tubes were inverted 10 times and incubated for a further 24 h. The FBS-charcoal mixture was 
then centrifuged at 1700 × g for 10 min and the stripped FBS decanted into a 100 mL Schott 
bottle and stored at −20°C.  
2.2.1.6 Phenol Red RPMI-1640 Medium Containing 10% v/v Inactivated FBS 
Heat inactivated FBS (100 mL) was thawed at 4°C overnight. Phenol red RPMI-1640 powder 
(9.6 g) and NaHCO3 (2.0 g) were added to a 1 L Schott bottle. Milli-Q water water (900 mL) 
was added and the powder dissolved by vigorous shaking. The pH was adjusted to 7.4 (see 
Section 2.1.3.2) and Milli-Q water (100 mL) was added. Sodium pyruvate solution (1 mL) 
was added to the RPMI-1640 solution and 900 mL was sterilised via ultra-filtration through a 
0.22 µM filter. The antibiotics (5 mL) and FBS (100 mL) were sterilised via ultra-filtration 
through the same 0.22 µM filter, respectively. The complete RPMI-1640 culture medium 
solution (1 L) was stored at 4°C.  
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2.2.1.7 Phenol Red Free RPMI-1640 Medium Containing 10% v/v Stripped FBS 
Charcoal-dextran-stripped FBS (100 mL) was thawed at 4°C overnight. Pre-bought phenol 
red free RPMI-1640 culture medium solution (900 mL) was sterilized via ultra-filtration 
using a 0.22 µM filter, followed by adding antibiotics (5 mL) and FBS (100 mL). The 
complete phenol red free RPMI-1640 culture medium solutions (1 L) was stored at 4°C.  
2.2.1.8 Minimal Essential Medium (MEM) containing 10% v/v heat-inactivated FBS 
Heat inactivated FBS (100 mL) was thawed at 4°C overnight. MEM (900 mL) was sterilized 
via ultra-filtration using a 0.22 µM filter, followed by antibiotics (5 mL) and FBS (100 mL), 
respectively. The complete phenol red free MEM culture medium solution (1 L) was stored at 
4°C. 
2.2.1.9 Trypan blue solution (0.4% w/v in PBS)  
Trypan blue power (0.4 g) was dissolved in 100 mL PBS. 
2.2.1.10 Luciferin stock solution  
A stock solution of luciferin was prepared in DMSO (25 mg/mL). Aliquots (200 µL) were 
stored in amber vials at −80°C. 
2.2.1.11 Inulin solution 
Inulin powder (500 mg) was added to a 1 L Schott bottle. Milli-Q water (500 mL) was added 
and the powder dissolved by vigorous shaking. Then, the inulin solution was stored at 4°C.  
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2.2.1.12 Wilkins Chalgren anaerobic (WCA) broth 
Wilkins Chalgren anaerobic (WCA) broth powder (33 g), L-cysteine HCl (0.5 g), resazurin 
sodium salt (0.5 mg) were added to a 1 L Schott bottle,170 Milli-Q water (900 mL) was added. 
The pH was adjusted to 6.8 using 1 M and 0.1 M HCL or NaOH as appropriate. The pH 
adjusted solution was made up to 1 L with Milli-Q water. The solution was autoclaved 
(120°C, 15 psi for 80 min) and then stored at 4°C.  
2.3 Autoclaving 
All glassware and consumables including Schott bottles, glass pipettes, sample vials, 
micropipette tips and Eppendorf tubes were autoclaved at 120°C, 15 psi for 80 min. All 
autoclaved equipment was then dried at 75°C for 1 h prior to use.  
2.4 Caco-2 cell maintenance and passage 
Caco-2 cells were routinely passaged when the cultures has reached confluence (approx. 107 
cells). Used MEM was vacuum aspirated using a flame sterilised Pasteur pipette. PBS (4 mL) 
was added to inactivate the any residual MEM. TrpLE® express (3 mL) was added to detach 
the cellular monolayer. The culture flasks were incubated at 37°C with 5% v/v CO2 in air 
until cells were seen to be fully detached under an inverted microscope (approx. 10 min) 
MEM (10 mL) was added to inactivate the TrpLE® express and the cell suspension was 
transferred to a 50 mL centrifuge tube. The suspension was centrifuged at 4000 × g for 5 min 
and the supernatant was vacuum aspirated. The pellet was suspended in fresh MEM (10 mL 
for each new culture) and vortex mixed for 10 s to produce a homogenous suspension. Cell 
suspension (10 mL) was added to a 75 cm2 culture flask containing 10 mL fresh MEM to 




2.5 Cell counting 
Vertiplast Plastic Counting Chambers were used to count large volumes of cells samples at any 
given time. An aliquot of cell sample suspension was collected at known volume (20 µL) and 
mixed in 1:1 ratio with trypan blue. A 9 µL aliquot of each sample was added to 9 × 9 grids 
(triplicate). The same 5 squares were counted for each sample under an inverted microscope at 
100 × magnification.  
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2.6 Experimental Procedures 




Chapter 3: In silico studies of ERα and its 






3 Chapter 3 – In silico studies on ERα and its intimate 
interactions with ligands  
The content of this chapter is the subject of the following publication: Ye H, Dudley SZ & 
Shaw IC (2018) Intimate estrogen receptor-α/ligand relationships signal biological activity. 
Toxicology. 408, 80-87  
3.1 Introduction  
3.1.1 Overview 
ERs, including ERα and ERβ, are  nuclear receptors (NRs) which control the development, 
homeostasis and metabolism of the organism.14 The LBD, which is one of the six functional 
domains on ERs; has two interacting binding sites LBC and AF-2. The LBC directly interacts 
with ligands can cause knock−on effects to facilitate the AF-2 to accommodate regulatory 
proteins.  
3.1.2 Estrogen receptors and their mechanism of estrogenic activity. 
NRs are transcription factors that control essential developmental and physiological 
activities.171 Many NRs, such as ERα and ERβ respond to a hormonal and metabolic milieu 
that includes high affinity natural ligands such as E2 and an ensemble of lower affinity 
ligands such as environmental xenoestrogens (e.g., BPA).172, 173 This can lead to diverse 
endocrine−disrupting health effects, including cancer, infertility, and development mental 
abnormalities.174, 175 Both of ERα and ERβ are E2−activated nuclear receptors (NR3A1–
nuclear receptor subfamily 3, group A, member 1 & 2).54 As outlined above, the LBD is one 
of the functional domain of ERs, it comprises two separates, but connecting binding clefts: 
LBC and AF-2.20 Under normal circumstances, E2 binds to the LBC and initiates a protein 
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conformational changes, exposing AF-2 to interaction with regulatory proteins.54, 3 
Phosphorylation of serine then occurs which aids the targeted receptor (e.g., ERα) 
dimerization.21, 176 The dimer then moves into the nucleus and binds to DNA via a DNA 
binding domain (ERE) or via a protein DNA binding intermediate.54, 177 Recruitment of 
regulatory protein then occur.54, 178 Furthermore, regulatory protein recruitment controls the 
degradation of ERs via tyrosine phosphorylation.54, 179 This phosphorylation signals initiation 
of the proteasome ubiquitination pathway, leading to polyubiquitinated ERs which are 
transported to the proteasome for degradation.54, 180 The regulatory protein recruitment 
influences the ubiquitination process, leading to differential downstream bioactivity effects; 
for example, cell proliferation and cell migration.54, 179 An amino acid core region in the ERs 
binding domains contain two zinc finger motifs that cooperate to stabilize a rigid 
DNA−binding recognition helix and a flexible helix supported dimerization loop which 
docks onto DNA’s ERE.19 This results in gene expression modulation181 and ultimately 
cellular feminization (Fig. 3.1). In this chapter, the intimate “triangular relationship” between 




Figure 3.1: The process of E2 docking at the LBC of an ER resulting in a knock-on effect on AF-2 to 
accommodate regulatory proteins. E2 passes through the biological membrane then is docked in the 
LBC of the ER resulting in a conformational change; this interaction between the docked ligand and 
LBC trigger the knock-on effect on AF-2, and generates the binding interface for regulatory proteins. 
After the dimerization of ERα, the dimer bonds to ERE (Diagram by author). 
3.1.3 The requirements for binding at the LBC 
Highly efficient and specific binding of ligands to the LBC are prerequisites for the 
biological activity of estrogen action.54 A decade ago, Müller et al., illustrated the structural 
homology between different ligands bonded with the LBC, and suggesting the potential 
importance of hydroxyls of ligands in the their interactions with LBC (Fig. 3.2).54, 182 In 
addition, the X-ray crystal structures of complexes of ERs with different ligands (e.g., E2 
(PDB entry code: 1ERE), and GEN (PDB entry code: 1X7R) indicate the specificity of the 
interactions could be mediated by hydrogen bonds (H-bonds) between key functional groups 
on the ligands (e.g., E2’s 17β-hydroxyl; Fig. 1.7) and specific LBC amino acid residues (e.g., 
His 524).54, 20 This 3-dimensional lock and key approach exploits the unique spatial 
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arrangement of the ligand’s functional groups and relevant amino acid residues in the LBC.54, 
20 Once a ligand is docked, it appears that hydrophobic interactions are created between the 
ligand and the LBC.54, 20 This pulls ER’s helices towards the ligand, initiating the 
all−important conformational change which facilitates receptor dimerization and consequent 
bioactivity.54, 20, 183 
Figure 3.2: Superposed xenoestrogens and E2 in the LBC showing the structural similarity between 
xenoestrogens and E2. Figure from an early paper describing estrogen mimic interactions with ERs—
a concept was born. Figure adapted from Müller et al., (1995) Toxicological aspects of oestrogen-
mimetic xenobiotics present in the environment, Toxicol. Ecotoxicol. News, p 69 Fig. 1. Reproduced 
with permission of the publisher: Taylor & Francis. 
The binding kinetics and Gibbs free energy of the noncovalent interactions at the interface 
between a ligand or a regulatory protein and its targeted binding site (i.e., LBC or AF-2), 
balanced by dissociation /ligand kinetics determine the lifetime of the binary complex and 
thus overall biological activity.54, 184 The presence and strength of noncovalent interactions 
rely on the relative locations and spatial arrangements of specific amino acid residues which 
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facilitate the interactions with a ligand or a regulatory protein.54, 64 Thus, the different ligands 
could have different binding energies and binding affinities with ERs,54, 184 which differential 
their estrogenicities; and in turn, this might affect food functionality of phytoestrogen–
containing foods (e.g., isoflavones in soy)—this is a focus of the research presented in this 
thesis. 
3.1.4 Food phytoestrogens and their gut-mediated metabolites 
Food functionality is gaining significant importance in a marketing context and is being 
advocated for the management and prevention of some disorders and diseases.185 For 
example, isothiocyanate–rich foods (e.g., broccoli) have been promoted for the prevention of 
colorectal cancer, and resveratrol in red wine has been associated with life-prolonging, anti-
cancer and cardio-protective properties.186 Flavonoids are important food components, 
theoretically, they fit the binding characteristics of ERs (i.e. two aromatic hydroxyls 
separated by approximately the right length of hydrophobicity) (Table 1.1 & 1.2).187 In 
addition, many flavonoids have been proved to be estrogen mimics and utilised in a 
functional food context; for example, isoflavones−rich breads are used as partial ‘hormone’ 
replacements for postmenopausal woman.188 Chemically, flavonoids have the general 
structure of a 15–carbon skeleton, which consists of two phenyl rings (A and B) and 
heterocyclic ring (C) with various substitutes patterns in the different subclasses including 
isoflavone, isoflavane and flavone.187 For example, isoflavone is ketone containing 
compounds, but isoflavane is not (Table 1.2). In addition, within the same subclass, the 
individual compounds have different hydroxyls arrangements (Table 1.2).187 Both of these 
structural characteristics might affect bioactivity of flavonoids; for example, estrogenicity. 
In addition, gut microbiome comprise tens of trillions of bacterial cells.189 A major function 
of the bacteria is to process the metabolism of food functional compounds (e.g., flavonoids) 
and producing metabolites which can be utilised in beneficial ways to support host 
biology.170 Two examples of the metabolites of food phytoestrogens are: DAID is 
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metabolised to the more estrogenic S-equol (Table 3.3, Fig. 3.3),190 and GEN is converted to 
less estrogenic dihydrogenistein (Fig. 3.3).191 However, the molecular basis of the different 
estrogenicities of metabolites compared to their parent phytoestrogens is still unknow. 
  
Figure 3.3: Top: gut microbiome−mediated biotransformation of GEN (left) to dihydrogenistein 
(right). Bottom: gut microbiome−mediated biotransformation of DAID (left) to S-equol (right).  
A better understanding of the mechanisms underlying the bioactivity of chemicals is crucial 
for any health claims to be made. However, such studies are time consuming and expensive.  
Therefore, the application of in silico modelling studies to investigate possible 
receptor−mediated mechanisms might be useful in exploring food component functionality. 
The incorporation of enhanced levels and extracts of active principles from functional foods 
in food supplements further illustrates the economic importance of food functionality in a 
health setting.192 For example, resveratrol dietary supplements are marketed as preventing 
heart disease and cancer despite their being no clinical trials to support their efficacy.192 An 
understanding of the possible mechanisms of biological activity of functional food 
components is important if they are to be developed in a health promotion setting. Some 
bioactive food components have been studied by the pharmaceuticals industry as potential 
drugs;193 for example, resveratrol underwent clinical trials in 2010, but was withdrawn 


















3.1.5 The advantages of in silico study 
In the context of receptor—mediated biological activity, structure affinity relationship is the 
interdependency between compound structures and their binding affinity.173 This is a good 
predictor of biological activity and toxicity, and is useful as a preliminary to deciding (in a 
drug development context) whether a new compound has pharmaceutical potential.194 For 
example, results of a molecular modelling studies show gossypol (a natural polyphenol 
compound extracted from cotton seeds) can bind B-cell lymphocyte/leukemia-2 (Bcl-2) 
family proteins, such as B-cell lymphomaextra-large (Bcl-xL), which is critical component of 
the intrinsic apoptotic pathway.195 This suggested that gossypol is a potent inhibitor of Bcl-2 
proteins, and thus gossypol was regarded as a potential chemotherapeutic agent.196 Indeed, 
gossypol has been reported to target Bcl-2 family protein and inhibit a wide range of human 
carcinoma cell lines derived from breast (T47D), prostate (Du-145), cervix (HeLa).196 This 
clearly showed the predictive power of molecular modelling in the context of receptor/ligand 
binding. In addition, E2 and its interaction with ERs have been studied in silico which gives a 
clear understanding of the molecular attributes necessary for estrogenic activity.20, 197, 198 For 
example, comparing the structures of E2, dichlorodiphenyltrichloroethane (DDT) and BPA 
and their estrogenicities, which were determined by MCF-7 cell proliferation experiment, 
demonstrate this well (Table 3.1). 190, 202 The requirements for occupancy of ERs are an 
aliphatic hydroxyl group and an aromatic hydroxyl group (i.e., the potential form H-bonds) 
separated by 9.6 Å of hydrophobicity; E2 fulfils these requirements exactly because it is ER’s 
natural ligand.20 BPA partially fulfils the ideal binding requirements—it has two aromatic 
hydroxyl groups separated by 9.3 Å by a region of hydrophobicity;199 however, DDT has 
chlorine atoms which do not form H-bonds but form “halogen bonds” due to their 
electronegativity which interact electrostatically with key amino acid residues in the LBC of 
ERs.200 Nevertheless, this interaction partly fulfils ERs ligand requirements and so DDT is a 
weak estrogen mimic.201 Indeed, the order of relative estrogenicity to E2, i.e., E2 ® BPA ® 
DDT, reflects their structure affinity relationships (Table 3.1).190, 202-204  
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Table 3.1: Five molecules that fit ERa’s LBC showing their molecular structures aligned to 
emphasise their molecular analogies, and their relative estrogenicities to E2 (based on MCF-7 cell 
proliferation studies). 190, 202   





























Molecular modelling studies of the ligand candidates clearly show their different affinities 
with ERa based on their predicted binding orientation and structural characterises, in 
particular the spatial arrangements of the key binding groups (e.g., -OH).205 These complex 
structure affinity relationships support structure activity relationships leading to different 
estrogenicities. In addition, the binding between the natural ligand (E2) and ERs (Fig. in1.7) 
indicate the binding requirements are very similar between ERa and ERb; however, the 
biological tests based on ERb are rare (e.g., the most commonly used test estrogenicity screen 
(E-Screen) assay, chemical activated luciferase gene expression (CAULX) assay are both 
ERa-based). In this chapter, an in silico system Schrödinger platform to predict flavonoids’ 
binding energies with ERa, and investigate the potential structural effects of flavonoids on 
their binding affinity and estrogenicity (data from published data).  
3.1.6 Overview of docking using the Schrödinger platform and its potential 
limitations 
The docking project describes the use a software package named Glide in Schrödinger 
platform, this aims to dock molecules from a physical or virtual database (PDB X-ray crystal 










(PDB entry code) of ERα).206 Glide has been designed to perform as close to an exhaustive 
search of the positional, orientational and conformational space available to the ligand as is 
feasible, while retaining sufficient computational speed to screen large libraries.186, 206 In 
addition, Glide has been reported to have following performance characteristics: less docking 
time compared with other docking programs, robustness in binding mode prediction, 
reasonable binding affinity prediction compared with experimental data for crystallised 
complexes.186, 206 Importantly, the scoring functions in Schrödinger have been reported to 
have great dock accuracy with ERs.207 However, in the Schrödinger docking studies, because 
of the utilisation of a rigid receptor (ER) situation, the orientation of amino acid residues are 
restricted, resulting in limited possibilities of interaction with the docked ligand.208 This 
suggests the potential conformational changes caused by different ligands with the LBC 
cannot be predicated and presented by the docking study, in turn, which may influence the 
accuracy of the results yielded by docking study. This is the key potential limitation of the 




3.2 Research objectives 
The objectives of the research described in this chapter are: 
•  Use a computational bio−molecule platform (Schrödinger) to investigate the 
communication between the LBC and AF-2 of ERa via the conformation changes 
caused by the docked ligand. 
• Study the effects of structure properties of ligands (i.e. flavonoids) on their theoretical 




3.3.1 Protein preparation for flavonoids docking studies.  
The X−ray crystallographic coordinate of ERα were taken from the PDB 
(http://www.rcsb.org), the X-ray crystal structures of ERα complexed with ligands (e.g., 
GEN in PDB entry 1X7R) were used. This crystal structure of ERα has common polypeptide 
chains. Protein fragment crystals are derived from different polypeptides of the ERα protein 
according to the particular preparative methodologies. This means that they might have 
different polypeptide chains and each chain has a docked ligand (e.g. GEN). One of these 
chains was arbitrarily used as the ligand–receptor subunit for these docking studies, others 
were deleted. Missing amino acid residues (Ser 305, Tyr 331, Asp 332, Pro 333, Thr 334, 
Arg 335, Pro 336, Phe 337, Arg 548, Leu 549) based on the ERa’s primary sequence were 
added to complete the protein structure using the Schrödinger ‘Prime’ command. Besides the 
ligand, a water molecule was kept if it was known to be important for ligand−receptor 
interaction, 209 others (solvent water) were removed.209 Restrained Minimization was run to 
provide controls for optimizing the corrected structure, relieving any strain and fine−tuning 
the placement of specific groups (e.g., hydroxyls). Hydrogen atoms are always optimized 
fully, which allows relaxation of the H-bond network and alleviates potential steric clashes 
by user–selected root–mean–square deviations (RMSD) with a tolerance of 0.3 Å.186  
3.3.2 Receptor Grid generation 
The receptor grid for docking studies was set up and generated from the Receptor Grid 
Generation panel of Glide (Schrödinger Release 2017-1: Glide, Schrödinger LLC, New York, 
NY, 2017). The natural LBC was used for these docking studies, but the original bound 
ligand (e.g., GEN) was excluded; this determines the position and size of the active site (i.e., 
the LBC) for ligands docking. 
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3.3.3 Preparation of potential ligands  
In this study, 20 flavonoids from different subclasses were select as potential ligands for 
ERa. They are primuletin, primetin, chrysin, apigenin, norwogonin, acacetin, scutellarein, 
diosmetin, artocarpetin, 6-Hydroxyluteolin, kaempferol, GEN, glycitein, DAID, FOR, 
biochaini A, naringenin coumestrol, phloretin. These ligands for the docking studies were 
built and prepared using LigPrep (Schrödinger Release 2017-1: LigPrep, Schrödinger LLC, 
New York, NY, 2017); was at most 32 ligand poses were generated. 
3.3.4 Ligand docking and calculations of DockingScores 
Rigid-receptor-flexible-ligand docking calculations were performed using Glide in extra 
precision (XP) mode. Each ligand was conformationally sampled in the LBC, and each pose 
was scored in terms of its Emodel, which is used for selecting the “best” pose (with lowest-
Emodel) of a ligand. Glide uses a scoring function–DockingScore to predict the binding 
energy then evaluates and semiquantitatively ranks the binding affinity of potential ligands 
with their target receptors in a specified conformation (e.g., 1ERE of ERα).208, 206 
DockingScore is an empirical scoring function; it is used to predict the ligand binding free 
energy and rank different candidate ligands in order of their binding affinities.206 
DockingScore has many components, including H-bond value, hydrophobic enclosure reward 
(HER), low molecular weight reward, rotatable bond penalty. In the Glide scoring function of 
docking study, the optimum distance between two hydrophobic molecules for facilitating 
hydrophobic interaction is 0.5 Å, but if the distance between ligands atoms and the target 
atom of an amino acid residues over 3 Å, their hydrophobic interaction will not be 
accounted.208 The DockingScores of ligands were used to predict the order of binding 
affinities of the docked ligands with the receptor. The H-bonds and p−p interaction were 
shown using a Ligand Interaction Diagram. The hydrophobic enclosure was shown using 
Corey-Pauling-Koltun (CPK) model. The topographic view of AF-2 was shown in Figure 
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3.12 using residue property representation: red = negative, blue = positive, green = nonpolar, 
cyan = polar, grey= neutral. 
3.3.5 Protein structure alignment. 
Protein structure alignment (Schrödinger Release 2017-1: Protein Structure Alignment, 
Schrödinger LLC, New York, NY, 2017) was used to investigate the conformational changes 
triggered by the binding of different ligands at the LBC of ERα. The X-ray crystallographic 
coordinate of ERα were taken from the PDB, and the protein preparation process is same as 
descried before (Section 3.3.1). Missing amino acid residues (see Table S1, Appendix A) of 
all the studied complex of ERα with different ligands based on the protein’s primary 
sequence were added to complete the protein structure using the Schrödinger ‘Prime’ 
command. The complexes of ERα with ligands were selected and aligned. The alignment 
score, which describes the structural analogy between any two selected complexes of ERα, 
was determined. A lower value means the selected two X-ray crystal structures have a greater 
degree of structural homology. 
3.4 Results and Discussion 
3.4.1 LBD architecture 
As discussed before (Section 1.2.2, Chapter 1), in ERα, H3–H12 (Fig. 3.4 (a) are important 
in the functional architecture of the LBD, which comprises the two binding clefts (i.e. LBC 
and AF-2). These helices are folded into three−layers, and H5/6, H9 and H10 sandwiched 
between two additional layers comprising H 1–4 and H7, H8, H11.54, 20 The LBC comprises 
segments from H3, H6, H8 and a preceding loop, H11, H12 and the S1/S2 hairpin (Fig. 3.4 
(a).54, 3 This binding site is partitioned from the external environment and occupies a 
relatively large portion of the LBD’s hydrophobic core (Fig. 3.4 (b).54 The arrangement of 
these helices creates a 3-dimensional LBC at the narrow end of the LBD with adjacent AF-
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2.54 AF-2 is the hydrophobic cleft formed by the remaining segment of H3 and part of H5, H4 
and H12.54 The sharing of H3 and interlinking of other helices in both clefts suggests the 
LBC and AF-2 may have architectural contact (Fig. 3.4 (a) facilitating communication 
between these two binding clefts.  
Figure 3.4: Arrangement of helices in the LBD of ERα to create LBC (blue; E2 in situ) and 
H11−linked AF-2 (red−orange) (a). E2 docked in the LBC showing the H-bonds (---, point out with a 
red arrow) between E2’s 3-hydroxy and His-524, and E2’s 17β-hydroxyl and the Glu-353, Arg-394 
and H2O triumvirate.54 Regions of the protein are represented as red for negative, blue for positive, 
green for nonpolar, cyan for polar, grey for neutral. Amino acid residues interacting with the ligand 
via H-bonds are shown. All amino acids residues within 3 Å of the ligand are also shown to indicate 
the chemical nature of the binding pocket. Diagram generated in Schrödinger using the  Ligand 
Interaction Program (See Section 3.3.4). 
The arrangement of amino acid resides in ERα’s LBC points to ligand specificity; however, 
the LBC is surprisingly promiscuous being able to accommodate a broad array of ligands 
providing they have particular molecular attributes.54 The interaction of the natural estrogen–





separated. These binding requirements can be achieved by various compounds (e.g., 
flavonoids).210  
3.4.2 ERα promiscuity and consequences of promiscuity 
Interestingly, the total volume of the LBC (450 Å3) is greater than E2’s volume (245 Å3)20 
which allows for a degree of ligand promiscuity providing the basic tenets of docking are 
obeyed. 54 These docking requirements are dictated by the spatial arrangement of the key 
binding amino acid residues (Fig. 3.4 (b);54 they are ideally an aromatic hydroxyl and an 
aliphatic hydroxyl with a 9.66 Å separation and a region of hydrophobicity between the 
docking centres according to E2’s structure.54, 199 However, surprisingly, there is a degree of 
flexibility about the docking requirements such that electron withdrawing groups (e.g., -Cl) 
can substitute for hydroxyls, and the strangely large LBC volume means that it can 
accommodate larger, bulky unnatural ligands (e.g., DDT).54, 211 More efficient filling of the 
LBC with a ligand, which has a larger hydrophobic region, might lead to greater engagement 
between the adjacent hydrophobic amino acid residues and the docked ligand.54  
The receptor’s promiscuity means that a large number of endogenous estrogens (e.g., E3) and 
exogenous xenoestrogen (e.g., GEN) have been shown to stimulate the proliferation of MCF-
7 (ERα–mediated cell line), this suggests these compounds could be recognised and accepted 
by ERα. 54, 190, 204, 210 Other estrogen mimics could also elicit cellular estrogen responses by 
the same mechanism. Interestingly, the intimate relationship between ligands and the LBC 
could be varied because of the different molecular attributes of ligands (e.g., hydroxyl 
patterns, molecular hydrophobicity), and, this their interactions (i.e., H-bonds and van der 
Waal’s forces) with amino acids residues in the LBC will vary considerably. Alignment of 
the crystal structures of ERα/ligand complexes shows the comparison of the conformational 
response by binding with different ligands. For example, aligning the ERα/E2 (PDB entry 
code: 1ERE) conformation with ERα/methylparaben (PDB entry code: 4TV1) 54, 23 shows a 
remarkably similar receptor conformational response (Fig. 3.5), even though methylparaben 
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is significantly smaller than E2 and only interacts with the Glu-353, Arg-394, H2O 
triumvirate (Fig. 3.5), which suggests methylparaben has less binding energy and binding 
affinity than E2 with ERα. 54 This explains methylparaben’s estrogenicity (Table 3.1). In 
addition, an isoflavone, GEN has significant structural similarity to E2 forming H-bonds with 
same specific amino acids (e.g., His 524); this explains why GEN is accepted as a ligand by 
the ERα (Fig. 3.6).209  
Figure 3.5: Alignment of the crystal structures of ERα complexes with methylparaben (PDB entry 
code: 4TV1-green) and E2 (1ERE-grey) showing the H-bonds between methylparaben or E2 with 
LBC. Amino acid residues interacting with the ligand via H-bonds are shown. All amino acids 
residues within 3 Å of the ligand are also shown to indicate the chemical nature of the binding pocket. 
Diagram generated in Schrödinger using the Ligand Interaction Program (See Section 3.3.4). 
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Figure 3.6: Alignment of the crystal structures of ERα complexes with E2 (PDB entry code:1ERE–
grey) and GEN (PDB entry code:1X7R–cyan) showing key amino acid residues’ orientation and helix 
positions. The different orientations of His 524 in the both conformations of ERα are shown in a red 
ellipse. H-bonds are shown as yellow dashed lines. Amino acid residues interacting with the ligand 
via H-bonds are shown. All amino acids residues within 3 Å of the ligand are also shown to indicate 
the chemical nature of the binding pocket. Diagram generated in Schrödinger using the Ligand 
Interaction Program (See Section 3.3.4). 
Many flavonoids are phytoestrogens, this means that these compounds likely fit the structural 
requirements for binding to the LBC of ERα.8, 92 However, flavonoids have many subfamilies 
with different molecular skeletons, which lead to different structural features.212 In addition, 
within the same flavonoid subfamily; they are different with spatial arrangement of hydroxyl 
groups. for examples, the isoflavones DAID and GEN have different hydroxyl pattern, which 
might form different interactions with the LBC resulting in different binding affinities with 
ERα. This structure diversity will likely influence ligands’ bio-potency (i.e., estrogenicity). 
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3.4.3 Estrogenic activity of food flavonoids and their DockingScores. 
Flavonoids are present in many foods (e.g., GEN and DAID in soy) and dietary supplements 
(e.g., isoflavone supplements for menopausal women); many are estrogen mimics—they 
comprise part of the complex dietary cocktail that humans are exposed to daily and are 
possibly responsible for the functionality of these foods.213 And some flavonoids (e.g., soy 
isoflavones) are thought to have significant biological effects at the population level (e.g., 
reduced sperm quality59). 20 flavonoids from different subclasses (Table 3.2), representing 
various structural features, were selected for docking studies in ERα in this chapter.   
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Table 3.2: Twenty compounds from different subclasses of flavonoids showing different substitution 
arrangement, DockingScore (kcal/mol), HB value (kcal/mol), and HER (kcal/mol) with the LBC of 
ERα.  
















Primuletin 5 (-OH) −8.13 −1.1 −2.93 
Primetin 5, 8 (-OH) −8.47 −1.44 −2.82 
Chrysin 5, 7 (-OH) −8.5 −1.50 −2.7 
Apigenin 5, 7, 4´        
(-OH) 
−8.64 −1.6 −2.7 
Norwogonin 5, 7, 8 (-OH) −8.37 −1.44 −2.62 
Acacetin 5, 7, (-OH);      
4´ (-OCH3) 
−8.58 −1.1 −2.5 
Scutellarein 5, 6, 7, 4´    
(-OH) 


















Diosmetin 5, 7, 3´         
(-OH);         
4´ (-OCH3) 
−8.47 −1.5 −2.4 
Artocarpetin 5, 3´, 4       
´(-OH);        
7 (-OCH3) 
−7.56 −2.01 −2.3 
6−Hydroxyl
uteolin 
5, 6, 7, 3´, 
4´(-OH) 
−9.37 −3.36 −2.2 
Kaempferol 5, 2, 7, 4´ (-
OH) 





GEN 5, 7, 4´(-OH) −9.3 −1.69 −2.7 
Glycitein 7,4´(-OH);    
6 (-OCH3) 
−9.09 −1.6 −2.7 
DAID 7, 4´(-OH) −9.0 −1.3 −2.8 
FOR 7(-OH);   
4´(-OCH3) 

















Biochanin A 5, 7, (-OH); 
4´ (-OCH3) 
−8.9 −1.1 −2.7 
Isoflavondiol
 
S-equol 7, 4´ (-OH) −10.44 −1.3 −2.93 
Flavanone
 
Naringenin 5, 7, 4´(-OH) −10.2 −1.44 −2.3 
Coumestans
 
Coumestrol 3, 2´ (-OH) −10.4 −1.04 −2.7 
Dihydrochalcone
 
Phloretin 2, 4, 6´, 4´         
(-OH) 



















































Table 3.2 Subclasses of flavonoids - the different subclasses have different molecular 
skeletons which maybe the hydrophobic cores of ligands for ERs, and might form important 
hydrophobic interactions with ERa. Within each subclass, compounds have different 
substitution arrangement (i.e., hydroxyl groups and methoxyl groups). These structural 
characteristics contribute to different H-bond values, HERs, thus give different 
DockingScores shown in Table 3.2. 
Over 5,000 naturally occurring flavonoids have been identified in plants;214 however, 
surprisingly few of them have been studied using functional assays to determine, for 
example, their estrogenicity.215 Table 3.3 shows published relative estrogenicity (determined 
by yeast estrogen screen assay (YES assay), 190 for the flavonoids studied in this chapter 
(estrogenicity values are not available for all the flavonoids studied), where E2’s value equals 
1, the DockingScores of selected flavonoids obtained from the Docking study in this chapter. 
The molecular structures show that these flavonoids have the key common structural 
features: namely, hydroxyl groups and a hydrophobic backbone, this means they have similar 
structural and spatial arrangements of the key functional groups (i.e., hydroxyl) to E2’s key 
moieties. These two important structural features might facilitate interactions between these 
candidate ligands and the LBC of ERα by H-bond formation and hydrophobic interactions. 
Interestingly, the order of estrogenicities of the compounds studied is the same as the order of 
their DockingScores (Table 3.3). This trend indicates a potential association between the 
ligand/receptor docking energy (i.e., DockingScore) and estrogenicity.190, 216  
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Table 3.3: Food sources, structure, estrogenicity and DockingScores with ERα of selected flavonoids. 
Compound Examples of 
food source 





































































 2.3 ×10−2 −10.44 
3.4.4 Does the H-bond value determine a ligand’s binding affinity to ERα? 
The H-bond value is the sum of the individual H-bond energies based on both the angles and 
distance between the donor and acceptor atoms in the bond. It is determined by the relative 
orientation and distribution of the bound atoms of ligands and the corresponding interacted 
receptor atoms.217 This means that the H-bond value could be affected by both distribution 
and orientation of the ligand’s hydroxyls which might form H-bond with amino acid residues 
in the LBC.217 There are two interesting trends in the data shown in Table 3.2. Firstly, the 
ligands, which have more phenolic hydroxyls, have larger H-bond values. This is likely due 
to the increased number of H-bonds formed between the ligand’s -OH groups and the amino 
acid residues at the LBC. In addition, this trend is exemplified by the following flavones 
which have different numbers of hydroxyls and different H-bond values—primuletin 
(monohydroxy, −1.1 kcal/mol), primetin (dihydroxy, −1.4 kcal/mol), apigenin (trihydroxy, 
−1.6 kcal/mol) and two isoflavones, DAID (dihydroxy, −1.3 kcal/mol) and GEN (trihydroxy, 
−1.69 kcal/mol). In addition, GEN has higher estrogenic activity than DAID (Table 3.3), this 
suggests H-bond might influence the ligand’s estrogenicity. This is logical since the more 
hydroxyl–mediated H-bonds between the ligand and its receptor, the stronger the interaction 
resulting in higher binding energy and binding affinity, and thus resulting in the greater the 









The understanding of H-bond interaction in the ligand–receptor binary system has been 
supported by the previous study of pyrazole ligands interacted with ERα.197 This study shows 
triphenol pyrazole ligands have greater ERα relative binding affinity (RBA) than 
monohydroxy and dihydroxyhenols (where the binding affinity E2 equals 1) (Table 3.4).197 
This might be due to the additional hydroxyls of triphenol ligands can form more H-bond 
resulting in higher binding energy, and thus lead to higher RBA compared with 
monohydroxyl- and dihydroxyl-phenol pyrazole.197 The effect of H-bond interaction has been 
also proved by the previous research of an enzyme/inhibitor system (i.e., xanthine oxidase 
(XO)/flavonoid).218  The research shows that, apigenin has one more hydroxyl group than 
chrysin (Table 3.2), the additional hydroxyl of apigenin might form additional H-bond with 
XO, which would increase the binding energy of apigenin and binding affinity with XO. In 
addition, the published date shows apigenin has a greater binding affinity and stronger 
inhibitory activity than chrysin with XO.218  
Table 3.4: RBA of 4-ethylpyrazole tri-, di-, and monophenol, where the binding affinity of E2 equals 
100%*.197 Et = ethyl; X, Y, Z are three substituent positions. 
 
      X                 Y                Z RBA with ERα 
      -OH            H                 H 3.1 
      -OH           -OH              H 8.9 
      -OH           -OH              -OH 36 
Six of these flavonoids with different polar substitution arrangement (i.e. hydroxy and 
methoxy) were selected to investigate more details of the H-bond interactions with the LBC 
of ERα. Figure 3.7 illustrates a trend that the amount hydroxyls of ligand influence the 













(monohydroxyl) forms one hydrogen (Fig. 3.7 (a), norwogonin (trihydroxyl) forms two 
hydrogen bonds (Fig. 3.7 (b), scutellarein (tetrahydroxyl) forms three (Fig. 3.7 (c),  and 6-
hydroxy luteolind forms four hydrogen bonds with the LBC (Fig. 3.7 (d). In addition, Figure 
3.7 also shows that methylation of vicinal dihydroxy flavonoids (e.g., Biochanin A) changes 
ligand interactions with ERα; this likely results from that methylation sterically hinders the 
ligands interaction with the receptor, forcing the unmethylated hydroxyl to interact with a 
different amino acid residue (Fig. 3.7 (e) and (f), and resulting in a lower binding affinity 
with ERα.219 This finding may explain why GEN is more estrogenic than Biochanin A (Table 
3.3).220 An extra polar substituent might interfere with ligand ERα hydrophobic 
interactions;221 this likely results from the extra polar substituent causing unfavourable 
interactions at the hydrophobic region of the LBC and influencing the binding energy and 
binding affinity of the ligand; for example, kaempferol has one more hydroxyl than GEN and 
showed lower estrogenicity in the previous research of YES assay (Table 3.3). In summary, 
the potential effects of polar substitutions on ligand binding affinity and estrogenicity 
depends on their substituents positions and orientations.  
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Figure 3.7: Ligand interactions with amino acid residues in ERα visualised in Schrödinger. Purple 
arrows represent H-bonds, direction of arrow denotes donor to acceptor in the H-bond. Different 
coloured residues represent amino acid charge properties: blue = positive charge, red = negative 
charge, cyan = polar, green = nonpolar.  
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3.4.5 Does the HER determine a ligand’s binding affinity with ERα? 
The HER is the term used to differentiate the relationship between the hydrophobicity of 
ligands with the geometric receptor environment.208 This describes the spatial arrangement of 
hydrophobic amino acid residues (e.g., Leu) in a ligand binding cleft of 217 for example, a 
receptor (e.g., ERα) which supports hydrophobic interactions between a ligand and the 
receptor;217 I term this a parallel arrangement. For the perfect interaction, a hydrophobic 
ligand should be enclosed in a hydrophobic microenvironment in the LBC to give the 
maximum potential for hydrophobic interactions—ideally this would involve the ligand 
sandwiched between two hydrophobic regions of the LBC.208 Previous research indicates 
that, thermodynamically a hydrophobic ligand ‘prefers’ to sit in a hydrophobic binding cleft 
comprising hydrophobic amino acid residues (e.g., Leu and Val);206, 222 conversely, increased 
hydrophilic character reduces ideal thermodynamic fit to a hydrophobic cleft.217 The balance 
between hydrophobicity of a ligand to hydrophilic character of the accommodated ligand 
determines its binding energy and binding affinity with the receptor.217 
Six compounds from different subclasses of flavonoids were selected for study the 
contribution of molecular skeletons to the ligands’ theoretical binding energy (i.e., 
DockingScore) of the selected ligands with ERα. As can be seen from Table 3.5 and Figure 
3.8, coumestrol has the highest HER, this is likely due to coumestrol binds to the LBC and 
sits ‘parallel’ to the binding cleft’s hydrophobic region. Phloretin has more (i.e., 2) rotatable 
bonds (Fig. 3.9) than apigenin, kaempferol and naringenin (i.e., 1), while coumestrol has no 
rotatable bonds (Fig. 3.9) resulting in the lowest HER (Table 3.5). This trend indicates, in the 
same binding environment particularly having a same hydrophobic region, that a ligand sits 
parallelly could bind more strongly than a ligand with a non−parallel molecular arrangement 
(i.e., with polar substitution outside the parallel plane; for example, kaempferol (Table 3.5).  
The impact of rotatable skeleton of ligands on their binding affinity and bioactivity is also 
supported by a previous study of an enzyme/inhibitor system (i.e., XO/flavonoid), which 
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requires structural requirements of ligands for their inhibitory activity.218 The previous study 
suggests that, the flavonoid’s planar structure and the presence of a non-rotatable C2=C3 
(Table 3.2) bond could lead the ligand to sit parallel in the binding domain of XO and this 
contribute to this ligand’s binding affinity, thus promoting its inhibition of the enzyme; for 
example, the comparative between naringenin and apigenin (Molecular structures are shown 















Table 3.5: Examples of flavonoid subclasses and their hydrophobic enclosure reward. 











































Figure 3.8: Selected flavonoids and their hydrophobic enclosures in the ERα LBC; the ligand (green) 
is shown by ball and stick representation. Hydrophobic amino acid resides are labelled within 3 Å of 
the ligand are also shown as CPK representation. 
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Figure 3.9: Molecular structures of phloretin and coumestrol showing rotatable bonds in phloretin, but 
there are no rotatable bonds in coumestrol 
3.4.6 Gut biotransformation of flavonoids might produce metabolites with 
different estrogenicities than their parent flavonoids. 
Interestingly, gut microbiome−mediated biotransformation of some flavonoids results in the 
formation of metabolites with different estrogenicities to their parent compounds; for 
example, DAID is metabolised to the more estrogenic S-equol (Table 3.3, Fig. 3.3),190 and 
dihydrogenistein, which is a gut−mediated metabolite of GEN, is less estrogenic than its 
parent compound (Fig. 3.10).223 The different estrogenicities of metabolites compared with 
their parent compounds likely result from their different structural features. For example, 
S−equol does not have a keto group (Fig. 3.3), which was predicted to have a greater HER 
than DAID and thus resulting in higher binding affinity (Table 3.3). This keto group might be 
the key factor that differentiates the estrogenicities of S−equol and DAID. In addition, 
dihydrogenistein does not have a double bond on the pyran ring whereas GEN does, this 
means that the molecular structure of dihydrogenistein is more rotatable than GEN (Fig. 
3.10), this could result in dihydrogenistein having a lower hydrophobicity and thus a lower 
binding affinity with ERa than GEN. The change of estrogenicity during flavonoid’s 
metabolism might result in changes in bioactivity which, in turn, could lead to both health 
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benefits and risks. For example, increasing estrogenic load could be beneficial in 
peri−menopausal women who are responding physiologically to the natural reduction in their 
estrogen levels as the menopause progresses. Dietary flavonoids, or flavonoid dietary 
supplements, might ameliorate symptoms of menopause,224 especially if 
microbiome−mediated biotransformation of the flavonoids leads to increased estrogenicity. 
However, on the risk side, men exposed to dietary flavonoids might develop ERα−mediated 
adverse effects at a population level, including reduced sperm count225 and gynecomastia.63 
Similarly, pre-pubertal girls (they have low estrogen levels226) might be triggered to enter 
puberty earlier by dietary flavonoid exposure because female puberty requires an estrogen 
stimulus.227 This will likely be exacerbated if microbiome-mediated biotransformation 
increases the dietary flavonoids’ estrogenicities. Indeed, it is thought that increased exposure 
to environmental estrogen mimics is related to an increased incidence of precocious puberty 
in girls worldwide.227 
The quantitative production of S-equol from DAID differs between individuals, this possibly 
reflects their gut microbiome composition because it is likely that not all bacterial species 
convert DAID to S-equol.228 This points to the possibility that inter-individual variation in gut 




Figure 3.10: Three-dimensional representation of the structures of GEN and dihydrogenistein showing 
the absence of a carbon double bond in dihydrogenistein allowing distortion of the ring resulting in a 
more rotatable structure compared with GEN. 
The in silico study of flavonoids reported here indicates these ERα ligands could have 
different interactions with the LBC because of their structural differences. Interestingly, in 
the protein alignment study, the X-ray crystal structure of ERα complexed with GEN (PDB 
entry code: 1X7R) shows a slight shift at His-524 on H11 compared with E2’s (PDB entry 
code: 1ERE) (Fig. 3.6), which implies a difference in the conformational response of ERα to 
these ligands. In addition, as discussed above (Section 3.4.1), the LBC and AF-2 shares H12, 
and H12 is linked to H11 via a polypeptide loop. This means, a ligand might affect the 
conformation of AF-2 by interacting with H11 (Fig. 3.2), or, of course, direct interaction with 
H12 may lead to the AF-2’s reconformation. 230 
3.4.7 The LBC’s plasticity 
Protein alignment of different complexes of ERα/ligand in this study shows that he docked 
ligands with bulky side substitutions have greater effects on the conformation of the LBC 
with concomitantly greater communication effects on AF-2 compared with the natural ligand, 
E2. This can be visualised by aligning structures derived from X-ray crystallography of the 
ERα’s LBC with E2 (PDB entry code: 1ERE) and an agonist model compound, oxabicyclic 
heptene sulfonate (OBHS) (PDB entry code: 5U2D54, 176), the alignment score is 0.016   
 
92 
(Table 3.6). This protein alignment shows that H11 responds explosively to OBHS and 
moves some 90° compared to H11 with E2 docked; this is illustrated by the relative positions 
of the Lys-531 residue (Fig. 3.11). The knock-on effect on AF-2 caused by the docked OBHS 
is mediated by the polypeptide loop connecting H11 and H12, this results in a significant 
change in the conformation of AF-2. For example, Lys-531 on the H11 and Glu-542 on the 
H12 significantly change their relative spatial arrangements (Fig. 3.11). Indeed, raloxifene 
caused greater knock-on effect on the AF-2 facilitating antagonist conformation of the LBC, 
and resulting in higher alignment score (0.044) compared to other ligand/ER⍺ complexes 




Figure 3.11: Crystal structures of the complexes of ERα with E2 in situ (1ERE–grey) aligned with 
ERα with OBHS in situ (5U2D–black) showing spatial arrangements of key helices—the position of 
H11 differs greatly between the two crystals which would have significant knock-on effects to AF-2. 





Table 3.6: Alignment scores between different ligand/ERα complexes. 




































3.4.8 ERα LBC/AF-2 topography. 
A topographic view of the outer surface of the LBD reveals the binding environment 
presented to the regulatory protein.54, 23 The amino acid residue properties presented to 
approaching prospective ligands are very different with E2 docked compared to the docked 
bulky OBHS (Fig. 3.12). For example, with E2 docked (PDB entry code: 1ERE), the surface 
of AF-2 shows Glu-542 exposed whereas OBHS-bound ERα shows both Glu-542 and Glu-











environment to an approaching regulatory protein and likely influences the interaction 
between the regulatory protein and AF-2. Further to this, the topographical charge 
distribution is quite different between these two ligand/ERα complexes (Fig. 3.12) which 
again alters the interaction potential between regulatory proteins and the AF-2 binding cleft.  
Figure 3.12: Topographic views of the AF-2 of ERα bound with E2 (a) and OBHS (b). Regions of the 
protein are represented as red for negative, blue for positive, green for nonpolar, cyan for polar, grey 
for neutral. Orange dashed lines show the shape of AF-2.  
Aligning published ERα crystal structures with different ligands in situ gives an invaluable 
insight into the effects of ligand structures on the different conformations of LDB. The 
implications of these conformational changes for cellular outcomes are at present very 
difficult to determine, but it is clear that the molecular structures of ERα’s ligands have an 
enormous effect on the helix pattern of the LBC and AF-2 knock-on conformational changes. 
The bulkiness of ligand side substitutions is perhaps the best determinant of conformational 
change and thus is a key factor in designing both agonists and antagonists for the LBC which 
likely have flow-on effects to AF-2; such agonists might be useful in the treatment of 
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menopausal symptoms, and antagonists might be apply for the treatment ERα positive breast 
cancer. 
In addition, the alignment of the LBD’s crystal structure with E2 docked ERα complex and 
bulky alien ligands (e.g., OBHS) in situ shows a significant bulkiness effect in initiating 
receptor conformational changes. This conformational change facilitates different spatial 
arrangements of amino acid residue in the AF-2; which might lead to might form different 
interactions with the regulatory protein. For example, an ERα/E2 LBD crystal (PDB entry 
code: 1ERE) aligned with ERα LBD crystals with the following docked ligands in situ: the 
breast cancer drug, raloxifene (PDB entry code: 1ERR20), ETP (5T1Z 54, 231) (Table 3.6) or 
GEN (PDB entry code: 1X7R) provides insight into intimate and subtle ligand/receptor 
communications.  
The effect of raloxifene on the position of H12 (purple in Fig. 3.13) is profound when 
compared to ETP’s (orange in Fig. 3.13) and GEN’s (cyan in Fig. 3.13) effects; this is 
probably due to raloxifene’s ethylpyridine side group which literally pushes H12 away and 
cause the rearrangement of AF-2.54,178 E2, GEN and ETP do not have correspondingly bulky 
groups like raloxifene (Table 3.6). Indeed, H12 is affected similarly by E2, GEN and ETP, 
which is very different to the H12’s explosive effect caused by the docked raloxifene (Fig. 
3.13). These more ‘conventional’ facilitate the formation by conformational changes of the 
AF-2 which can accommodate the regulatory protein. These differences distinguish agonists 
from antagonists.54, 20 
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Figure 3.13: ERα with Raloxifene in situ (1ERR–purple) aligned with ETP (5T1Z–orange), and GEN 
(1X7R–cyan) in situ showing the spatial arrangement difference of key helices − the position of H12 
differs greatly in the Raloxifene crystal compared to the others. Minor orientation differences in H12 
for ETP (5T1Z–orange) and GEN (1X7R–cyan) in situ in ERα are illustrated by the differences in the 
spatial arrangements of Asp-538 and Glu-542. AF-2 is shown in a blue ellipse. Helices are 
represented by ribbons. 
A comparison between ETP and GEN in situ in the LBC illustrates that GEN results in a 
conformational change which facilitates H-bonding of the GRIP-peptide (a fragment of a 
regulatory protein) via Glu-542 in AF-2; whereas, ETP bound to the LBC causes a different 
conformational change which does not favour H-bond formation (Fig. 3.14). This is likely 
because Glu-542 on H12 is re-orientated when ETP is bound compared GEN is bound, and 
might resulting in different binding affinities. Occupancy of AF-2 by a regulatory protein is 
important in modulating ERα’s biological activity and so the conformational differences 
resulting from GEN’s or ETP’s occupancy could alter ERα’s response—this might explain 




Figure 3.14: AF-2 of ERα with ETP in situ (orange–5T1Z) aligned with AF-2 of ERα with GEN in 
situ (cyan–1X7R) with regulatory protein fragment (GRIP-peptide) bound to AF-2 (orange or cyan 
according to the crystal structure from which it was derived). This shows that the regulatory protein 
fragment bound to ERα/GEN H-bonds to Glu-542; whereas, the regulatory protein bound to ERα/ETP 
has no corresponding H-bond. H-bonds are shown as yellow dashed lines. Helices are represented by 
ribbons. 
3.4.9 Regulatory proteins 
Regulatory proteins are DNA-binding transcriptional regulators, which are recruited to the 
AF-2 when the ERα /ligand dimer binds to the ERE.54, 232 There are two types of regulators, 
coactivators and corepressors, which up- or down-regulate, respectively, ERα-mediated 
transcription.54, 16 Coactivators are histone acetyltransferases-acetylation loosens the 
chromatin structure, exposing the target genes to the transcriptional machinery.54, 16 
Recruitment of coactivators influences this process, leading to gene transcriptional changes 
which might underlie differential estrogenicity.54, 16  
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Previous study shows a fragment (SRC-1a) of a regulatory protein has clear differences in 
affinity for AF-2 depending on the ligand bound to the LBC of ERα (Table 3.7).54, 233 In 
Table 3.7, Relative Recruitment Ability (RRA) of AF-2 for SRC-1a with GEN docked in the 
LBC is 0.06, and for BPA is 0.0003 (assigning 100 to E2).54, 233 This is likely due to the 
different binding affinities of the regulatory protein with AF-2. When different ligands bind 
to ERα they result in different conformational changes in the LBC causing various knock-on 
effects on the conformation of AF-2. These modified conformations and binding potentials of 
AF-2 present a different amino acid residue orientation which leads to diverse binding 
environments for regulatory proteins. This means that the binding affinities of regulatory 
proteins to different ligand/ERα complexes are likely to lead to differential bioactivities. In 
vivo, this might be extrapolated when a complete regulatory protein is involved, the LBC 
ligand might alter the nature of regulatory protein binding to AF-2 which would have 











Table 3.7: Relative recruitment ability (RRA) of different ligand/ER complexes with fragments (TIF2 
and SRC−1a) from different regulatory proteins. 
Ligand RRA TIF2                              RRA SRC−1a 
 
E2 100 100 
DES  11 5.0 
GEN 0.005 0.06 
BPA < 0.0001 0.0003 
In summary, a ligand that binds to the LBC could determine bioactivity via the 
conformational change induced in the AF-2, which, in turn, modulates regulatory protein 
recruitment. The strength of interaction between regulatory proteins and AF-2 is likely to be 





This chapter has three major outcomes. Firstly, it shows the LBD’s architecture of ERa and 
the potential communication between the LBC and AF-2 via the sharing of H3 and H12. In 
addition, the knock-on effects of LBC docked ligands on H11 in the LBC could trigger a 
further conformational change to H12 resulting in reorientation of exposed amino acid 
residues, facilitating in a topographic change which exposed AF-2.  
Secondly, with a good understanding of the ligand binding environment of the LBC and 
ligand binding requirements, the in silico modelling study of flavonoids with ERa (PDB 
entry code: 1X7R) demonstrated that, theoretically, the structural features of different ligands 
(e.g., hydroxyl groups, degree of hydrophobicity) can affect noncovalent interactions (e.g., 
H-bond interaction and van der Waals’ interaction) between ligands and the amino acid 
residues in the LBC; this results in different binding affinities, which could, in turn determine 
the estrogenicity of ligands and the functionality of, for example, phytoestrogen-containing 
foods. A detailed understanding of the interaction of ligands with ERα gives insight into their 
potential biological activity; this could be in a pharmacological or a functional food setting, 
and so might play a role in designing pharmacologically active ligands (e.g., in the treatment 
of ER positive breast cancer). In addition, the understanding of the functionality of 
flavonoid−containing foods might be important in a human health context. In silico 
modelling studies might help to predict functionality and potential bioactivity of food 




Thirdly, this chapter shows that an investigation of the chemical biology of the intimate 
interactions between the LBC and its ligands; this provides a molecular basis for 
understanding different levels of ERα’s biological activities. Individual ligands result in 
varying conformational changes in the LBC, which, in turn, lead to different knock-on effects 
on AF-2 via the sharing architectural components (e.g., H12) with the LBC. The different 
knock-on effects determine orientations of amino acid residues presenting different charge 
environments for hosting regulatory proteins as they approach the AF-2. This means the time 
of bindings between a regulatory protein and the ligand/ ERα complexes might be different. 
The length of time that regulatory protein−bound ERα sits on the ERE determines the gene 
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4 Chapter 4 – Studies on structure interaction relationship of 
isoflavones with ERa: In silico and in a gene reporter 
bioassay (MELN) 
4.1 Introduction 
4.1.1 The interactions between the LBC and their ligands 
As discussed before (Section 3.4.1, Chapter 3), the structure of the natural ligand, E2 and its 
interactions with the LBC indicates that the ideal binding characteristics for ERa are two 
hydroxyl groups in the separated by a hydrophobic skeleton. The in silico study in Chapter 3 
indicates that both amount and orientation of hydroxyl groups are important in the 
interactions between the ligand and the LBC, this may determine the binding energy, thus 
influence receptor-driven activity (i.e., estrogenicity). The importance of the different 
orientations of hydroxyl group can be also proved by the overlay of 17a-estradiol and E2 
(Fig. 4.1); this influences the presence of H-bond between the ligand and the LBC, which, in 
turn, results in different estrogenicities: 17a-estradiol is less estrogenic than E2.64,234  
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Figure 4.1: Overlay of 17a-estradiol and E2. E2 and 17a-estradiol bind at the LBC of ERa via H-
bonds ( ,Indicated by red arrows). Helices are represented by ribbons. 
In addition, Chapter 3 introduced the potential structure-binding affinity/activity relationships 
of ligands with ERa; ligands with different structural features have different binding energies 
and binding affinities resulting in correspondingly different levels of estrogenicities. This is 
due to the presence and strength of the noncovalent interactions which are determined by the 
relative locations and spatial arrangements of a ligand with specific amino acid residues in 
the LBC.20 This, in turn, influence ligands estrogenicities. For example, published data show 
that whiles E2 and E3 have great structural similarities yet a different arrangements of 
hydroxyls; this results in different binding affinities and estrogenicities, and suggests that the 
structures of ligands could determine their estrogenicities (Table 4.1).235 In addition, GEN 
and BPA present different molecular skeletons which are likely to be the hydrophobic core of 
the ligand that interacts with the hydrophobic region of the LBC (Section 1.2.2, Chapter 1), 




Table 4.1: Examples of exogenous estrogenic compounds and xenoestrogens.235 








BPA  0.66 0.018 
4.1.2 Soy isoflavones 
A recent World Health Organisation report assessed the state of the science of endocrine 
disrupting chemicals (EDCs) and reported that there are over 8000 known EDCs and 
potentially many more.236 A large proportions of these EDCs are estrogen mimics; they can 















product (e.g., EE2 and methylparaben).237 Xenoestrogens are classified as synthetic estrogens 
(e.g., BPA in polycarbonate plastic) or phytoestrogens (e.g., GEN in soy beans).17, 209 Soy 
isoflavones are the main dietary phytoestrogens, and have been used medicinally in hormone 
replacement therapy to alleviate menopause symptoms.13, 124, 189 However, as mentioned 
before (Section 1.2.3, Chapter 1), the environmental exposure to these compounds may 
cause ERα-mediated adverse effects at a population level, such as reduced sperm count,225 
and might lead to precocious puberty in girls,226 because female puberty requires an estrogen 
stimulus.227 Interestingly, GEN and DAID can be biotransformed to hydroxylated 
metabolites, which have been widely detected in fermented soy foods (Fig. 1.12).157 These 
metabolites have the same hydrophobic molecular skeletons as their parent compounds 
(estrogen mimics) but with different substituent arrangements (i.e. hydroxyls; Fig. 1.12), 
which might facilitate H-bond interactions with amino acid residues. This indicates the 
metabolites of isoflavones fit the binding requirements for interacting with ERa, but might 
facilitate different noncovalent interactions with the LBC resulting in different ERa-driven 
effects. This hypothesis will be studied in this chapter. 
4.1.3 Bio-assays for estrogenicity  
To determine the estrogenicity of environmental chemicals and dietary components, bio-
assays have been used.238 Receptor-gene assays use transgenic human cell lines or yeast 
cells;239 that have been co-transfected with complementary DNA (cDNA) and a reporter gene 
containing an ERE.240 In addition, in these type of assays, yeast or a mammalian cell line 
lacking endogenous ER is transfected with an expression plasmid carrying the ERα, ERβ 
cDNA or any desired receptor variant together with an ER-inducible promoter or the ERE 
linked to a chloramphenicol acetyl transferase (CAT) or luciferase reporter cDNA. Addition 
of ER ligands induces dose-dependent transcription of the reporter protein CAT or luciferase 
and can easily be monitored and quantified.241, 242 Another type of induced proliferation test 
employing estrogen-responsive target cells (e.g., breast cancer cells) is a common method to 
assess the estrogenicity of compounds.243 For example, the E-Screen uses breast cancer cells 
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(MCF-7) which are exposed to a range of concentration of the test compound and cell 
proliferation monitored. In each E-Screen test, a dilution series of E2 (0.1 pM–1000 pM) is 
set up as a positive control, and the cells  treated only with phenol red (an estrogen mimic, 
Fig. 4.2) free medium (e.g., phenol red-free RPMI-1640 medium) as a negative control.202 
Following the incubation period, cells are treated with trichloroacetic acid to precipitate 
proteins which is then stained with sulforhodamine B. The absorbance (492 nm) of protein 
bound with dye is measured; this quantitatively corresponds to the cell number.202 Either by 
counting cells or determining protein levels as a surrogate for cell number. However, the 
limitation is mitogens other than estrogens also can influence the cell proliferation thus 
rendering non-specific responses by estrogens.244  
Figure 4.2: Molecular structure of E2 and phenol red 
In addition, the binding affinity determines the strength of the interaction between a ligand 
and its receptor (e.g., estrogens and ERa), which, in turn, determines the receptor-driven 
effect of candidate ligands.217 Measurement of the binding of a ligand (e.g., a xenoestrogen) 
to ERα or ERβ is usually done by competitive binding assays with radioactively or 
fluorescently labelled E2.245, 246 Competitive binding assays determine RBAs compared to a 
positive control (E2), and therefore enable a ranking and prioritization of several 
compounds.246 However, competitive binding assays do not measure physiological responses 













Perhaps the ultimate bioassay is one that involves ligand interaction in cells expressing ERs. 
A good example of such an assay is the MELN (MCF-7 cells are transfected with ERE-Glob-
Luc-SVNeo plasmid) assay. The MELN assay is a sensitive recombinant cell receptor gene 
assay designed to determine the estrogenic potency of test chemicals.55 The MELN assay 
uses MCF-7 cells which express endogenous ERa that are stably transfected with only an 
estrogen-regulated luciferase gene driven by an ERE in front of the bGlobin promoter (ERE-
bGlob-Luc) which modulates luciferase expression (Fig. 4.3). This, in turn, activates the 
production of bioluminescence from the luciferase reaction following the addition of luciferin 
(Fig. 4.4).55 These MELN cells enable the detection of compounds that bind to ERa or 








Figure 4.3: Schematic representation of the interaction between an estrogen (e.g., E2) and ERa 
resulting in induction of luciferase activity; this shows the working mechanism of MELAN assay. E2 
binds to the LBC of ERa facilitating AF-2’s hosting of a regulatory protein. After the dimerization of 
ERα, the dimer binds to ERE, which activates the b-Globin promoter resulting in expression of 
luciferase. Luciferase catalyses the luciferin reaction which produces bioluminescence. 




Figure 4.4: Bioluminescence reaction. 
4.1.4 In silico study of the interaction between isoflavones and ERa  
Chapter 3 introduced that in silico studies for understanding the possible receptor-mediated 
mechanisms that might be useful in drug discovery or exploring food component 
functionality in a receptor–ligand setting.199 For example, in silico studies have been widely 
applied to the prediction of estrogenicity.198, 247 Previous research reported a molecular 
docking system is used to model the interactions between anthraquinone derivatives (AQs, 
from plants, e.g., senna and rhabarb) and ERa (PDB ID:1X7R), and theoretical binding 
energy and estrogenicity have been successfully predicted.198 Importantly, the predicted 
estrogenicity of AQs did not show a significant difference, compared with YES assay 
results.198 In this chapter, the Schrödinger platform is used to investigate ERa interaction at a 
molecular level with selected ligands (i.e., isoflavones) and to study the theoretical binding 
energy of isoflavones with ERa. In addition, the MELN assay is used to measure the 


































4.2 Research objectives  
The objectives of the research described in this chapter are: 
•  Use a computational bio−molecule platform (Schrödinger) to investigate the potential 
binding energy/affinity of selected isoflavones with ERa. 
• Use the MELN assay to study the structure ERa-driven bioactivity relationship of 
selected isoflavones. 




4.3.1 In silico modelling studies 
The molecular docking studies were carried out as described before (Section 3.3.1, Chapter 
3). The protein preparation and the receptor grid was prepared as described before (Section 
3.3.1, Chapter 3). A single water molecule was also included in the protein-ligand complex 
as the triumvirate of the Leu-387, Arg-394 and H2O interacts by H-bond with the 3¢hydroxyl 
of GEN (Fig. 4.5). This water molecule is important for ligand–receptor interactions, but 
other water molecules were removed.209  
Figure 4.5: X-ray crystal structure of GEN in the binding pocket of ERα showing the triumvirate of 
the Leu-387, Arg-394 and H2O interacting via a H-bond with the 3¢-hydroxyl of GEN (shown in a red 





4.3.2 Preparation of ligands 
Ligands (isoflavones shown in Table 4.2) were built and prepared using LigPrep 
(Schrödinger Release 2017-1: LigPrep, Schrödinger LLC, New York, NY, 2017).  
4.3.3 Ligand docking and calculations. 
Rigid receptor–flexible ligand docking calculations were performed using Glide in Extra 
Precision (XP) mode, and the process is same as descried in Section 3.3.4 Chapter 3.  
4.3.4 The MELN assay of isoflavones 
These studies were carried out in collaboration with Katherine Trought, and carried out in her 
laboratory (Landcare Research, Lincoln). 
4.3.4.1 MELN cell culture 
All culture media, experimental reagents, and isoflavones stock solutions were prepared as 
described in Chapter 2. MELN cells were obtained from INSERM, Montpellier France. They 
were routinely cultured in phenol red free RPMI-1640 medium containing 10% v/v stripped 
FBS, at 37 °C, 95% relative humidity and a CO2 concentration of 5% v/v in air.  
MELN cells were seeded into 96-well tissue culture plates (2.5 × 105 cells/mL) with 200 μL 
phenol red free RPMI-1640 medium containing 10% v/v stripped FBS. After 24 hours, the 
medium was replaced by fresh phenol red-free RPMI-1640 medium. A dilution series of the 
individual isoflavones was made in DMSO and 1 µL added per well (final concentrations are: 
5 × 10−6 M, 1.25 × 10−6 M, 3.13 × 10−7 M, 7.81 × 10−8 M, 1.95 × 10−8 M, 4.88 × 10−9 M, 1.22 
× 10−9 M, 3.05 × 10−10 M). E2 was used as the standard, the final concentrations are: 7.60 × 
10−14 M, 3.05 × 10−13 M, 1.22 × 10−12 M, 4.88 × 10−12 M, 1.95 × 10−11 M, 7.81 × 10−11 M, 3.13 
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× 10−9 M, 1.25 × 10−9 M, 5.0 × 10−9 M in the well. Blanks were created by adding 1 μL 
DMSO per well. After 24 h incubation, the exposure medium was discarded, and replaced 
with 100 µL of media containing luciferin (25 mg/mL in DMSO). The plate was incubated 
for 5 min at 37°C and the luminescence was measured at 1 second intervals per well, with 7 
readings per plate using a Varioskan Flash plate reader. Data were expressed in relative light 
units (RLU). The data was normalized by dividing the RLU response of experimental wells 
by the mean RLU of the corresponding blanks. Standards, positive controls (E2 at 1.9 × 10−11 
M) and blanks were run on all plates. All the experimental compound responses were 
determined from three independent experiments.  
The protein content of the MELN cells was measured by using a fluorescence assay, in which 
fluorescein was added to MELN cells in 96 wells cell culture plate, plated using the method 
described by Lorenzen and Kennedy,248 to determine cytotoxic responses caused by the 
studied isoflavones. BSA was used to create a calibration graph (see Fig. S1, Appendix B). 
The detection limit was determined using three times the standard deviation (SD) of the 
solvent control, yielding detection limits of 1.1 × 10−12 M E2. 
4.3.4.2 Data analyses 
Raw data from MELN assays were analysed using Microsoft Excel® (Microsoft Corporation, 
Redmond, WA). Mean values ± SD were calculated. The average of the “no cell control” was 
subtracted from all mean values and supramaximal responses were removed. The data were 
evaluated by a nonlinear four-parameter logistic model to estimate the EC50 (concentration 
for 50% of maximal effect) using GraphPad Prism (Version 7). The RAA of each compound 
was calculated as the ratio of the EC50 value of each compound and the EC50 value of E2.   
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4.4 Results and Discussion 
4.4.1 In silico study of the interactions between isoflavones and ERa 
The in silico study predicts that all studied isoflavones can bind to the LBC of ERa. Table 
4.3 shows that the individual isoflavones have the same molecular skeleton (Table 4.2) but 
with different hydroxyl substitution patterns, thus facilitating different noncovalent 
interactions with the LBC; this likely result in different H-bond values, HER, and thus 
different DockingScores which might influence the binding affinity of the ligands (Table 
4.2). This indicates the potential contribution of structural features (e.g., hydroxyls 




Table 4.2. Substitution positions, HB value, HER, and DockingScore of the studied isoflavones (in 
order of DockingScore). 






 6-OH-DAID 4¢, 6, 7 (-OH) −2.42 −4.99 −11.99 
3¢-OH-GEN 3¢, 4¢, 5, 7 (-OH) −2.59 −4.71 −11.8 
 8-OH-GEN 4¢, 5, 7, 8 (-OH) −2.5 −4.6 −11.68 
 8-OH-DAID 4¢, 7, 8 (-OH) −2.27 −4.97 −11.62 
3¢-OH-DAID 3¢, 4¢, 7 (-OH) −2.13 −5.01 −11.5 
 GEN 4¢, 5, 7 (-OH) −1.7 −4.8 −10.79 
 DAID 4¢, 7 (-OH) −1.26 −4.90 −10.49 
FOR 4¢ (-OH); 7 (-OCH3) −0.64 −5.23 −9.78 
As described before (Section 3.4.4, Chapter 3), H-bond value is the sum of the individual H-
bond energies between a ligand and the receptor which is determined by both distribution and 
orientation of the ligand’s hydroxyls that might form H-bonds with amino acid residues in the 
LBC under a ligand–receptor situation.217 Table 4.2 shows that the studied isoflavones have 
different arrangements (i.e., number and positions) of hydroxyls on their molecular skeletons, 
and have different H-bond values. This suggests the H-bond value could be affected by the 
number of hydroxyls on the ligand; for example, the H-bond value of DAID 
(dihydroxyisoflavone; −1.26 kcal/mol) < GEN (trihydroxyisoflavone; −1.7 kcal/mol) (Table 
4.2). However, some isoflavones with the same number of hydroxyls have different H-bond 
values; for example, both 6-OH-DAID and 3¢-OH-DAID are tri-hydroxy isoflavones, but the 
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H-bond value of 6-OH-DAID is −2.42 kcal/mol and 3¢-OH-DAID is −2.59 kcal/mol. This 
could be due to their different hydroxyl orientations resulting in different H-bond interactions 


























































































































































































































































In addition, the methoxy group of FOR leads to steric hindrance that also affects the ligand 
binding energy to ERα. This hindrance was predicted to force the methoxy hydroxyl groups 
to interact with different amino acid residues, which is shown in Figure 4.6, thus resulting in 
a lower DockingScore for FOR (−9.78 kcal/mol) compared with DAID (−10.49 kcal/mol), 
and thus a lower binding affinity. Interestingly, published results of a competitive radiometric 
binding assay with [3H]-E2 shows 2,3-bis (4-hydroxyphenyl) propionitrile (DPN) has a 
higher RBA compared with its methylated derivate (Table 4.3);173 this is likely due to the 
stearic hindrance caused by the methylated hydroxyl group, forcing the methylated derivate 
to interact with ERs at a unfavourable orientation, resulting in lower RBA with ERs. 
Table 4.3. RBA of DPN and its methylated derivate with ERa and ERb 
 
Ligand R1 R2 ERa ERb 
DPN p-OH p-OH 0.25 18 
Methoxy-DPN p-H, o-Me p-OH 0.87 60 
As discussed before in Chapter 3, HER is the term used to differentiate the relationship 
between the hydrophobicity of ligands and the 3 dimensional receptor environment.208 This 
describes the spatial arrangement of hydrophobic amino acid residues (e.g., Leu) in a LBC of; 
for example, a receptor (in this case ERa) that supports hydrophobic interactions between a 
ligand and the receptor.208, 206 Table 4.2 shows that the isoflavones studied have similar HER 
(range from −4.6 to −5.23 kcal/mol); this could be due to the same hydrophobic region (Fig. 
4.6). However, the different arrangements of hydroxyls appear to affect the HER. For 
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example, the HER of DAID (−4.9 kcal/mol) is less than the corresponding values for FOR 
(−5.23 kcal/mol), because the hydroxyl is more polar than the methoxyl, resulting in less 
hydrophobicity of DAID. In addition, the HER of 8-OH-GEN (−4.6 kcal/mol) is less than 
that for 3¢-OH-GEN (−4.71 kcal/mol) as 8-OH-GEN has more free hydroxyls, which cannot 
form H-bonds with amino acid residues in the LBC. These s− free hydroxyls are not 
favourable in the hydrophobic binding region of the LBC and resulting in a reduction in 
8- OH-GEN’s hydrophobicity (Fig. 4.6). Likewise, Table 4.1 shows E3 has an extra hydroxyl 
compared with E2 and resulting in a lower RBA (9.41) and correspondingly lower RAA 
(17.6);235 this also suggests the extra hydroxyl could cause unfavourable interaction with the 
LBC of ERα, and, thus decrease the RBA of the ligand with ERs. This might result in a 
corresponding decrease in estrogenicity.235 The docking study of isoflavones described here 
provides important information about how non-steroidal estrogenic compounds are oriented 
in the LBC, and shows that the potential effects of polar groups on ligand binding depend on 
both the relative position on the skeletal ring structure and their spatial orientations thus 
facilitating with the specific interactions with amino acid residues in the LBC.  
4.4.2 Estrogenicity of isoflavones 
The results of fluorescence assay show there is not cytotoxic responses caused by the studied 
isoflavones on MELN cells. The estrogenicities of the selected eight isoflavones were 
determined using the MELN assay. Figure 4.7 shows that the isoflavones cause different 
estrogenic responses in the MELN assay and that the responses are dose-dependent. The EC50 
and RAA of the selected isoflavones are shown in Table 4.4, all the isoflavones studied are 
weakly estrogenic (the RRAs of isoflavones are at least 104 times less than E2, where E2 = 
1). Hydroxylated metabolites of GEN and DAID showed greater RAA in the MELN assay 
compared with their less hydroxyl parent compounds (Table 4.4). For example, the RAA of 
GEN is 1.1 × 10−5, which is less than 3¢-OH-GEN, its RAA is 1.7 × 10−5 ; the RAA of DAID 
is 1.5 × 10−6 , which is less than 3¢-OH-DAID, its RAA is 2.3 × 10−5 (Table 4.4). 
 
126 
However, the exception to this trend is 8-OH-GEN, which has a significant lower RAA than 
GEN. This might be due to 8-OH-GEN’s additional hydroxyl groups of (Fig. 4.6) which 
means that there are no free potential H-bonding amino acid residues in the vicinity of the 
docked ligand, the additional hydroxyl cannot form H-bonds with the LBC (Fig. 4.6). In 
addition, the extra hydroxyl groups would have unfavorable interactions with the 
hydrophobic region of the binding cleft. 
 




Table 4.4. Comparison of EC50 and RAA (determined by MELN assay) of isoflavones. 
Compound EC50 (M) RAA 
E2 1.5 × 10−13 1.0 
6-OH-DAID 3.8× 10−9 4.0 × 10−5 
8-OH-DAID 4.8 × 10−9 3.2 × 10−5 
3¢-OH-DAID 6.8 × 10−9 2.3 × 10−5 
3¢-OH-GEN 9.1 × 10−9 1.7 × 10−5 
GEN 1.4 × 10−8 1.1 × 10−5 
DAID 1.0× 10−7 1.5 × 10−6 
8-OH-GEN 5.1 × 10−8 3.0 × 10−6 
FOR 4.2 × 10−7 3.6 × 10−7 
4.4.3 Structure activity relationship of isoflavones  
Structure activity relationship links structural features of molecules to their biological 
activities.249 The interaction between ligands and ERa, and the corresponding receptor-driven 
activity is a good example;72 this ligand–receptor system requires specific binding 
characteristics (e.g., binding affinity and binding energy), which are determined by the 
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relative spatial arrangement of a ligand’s functional groups (e.g., hydroxyl, keto) and the 
docked ligand would be predictable in an in silico molecular modelling system (e.g., 
Schrödinger).250 In silico study is a crucial facet of drug design, used by the pharmaceuticals 
industry today.250 Even without sophisticated molecular modelling software, it is possible to 
predict pharmacological properties related to key functional groups on a molecule by 
comparing activities of closely related structures (i.e., structure–activity relationships).218  
In this study, the estrogenicity of eight isoflavones was studied. Most of the hydroxyl-
metabolites have higher DockingScores than their corresponding parent compounds; this 
predicts the increase in estrogenic potency seen in the MELN assay (Table 4.4). The 
additional hydroxyls are likely to mean that form more H-bonds are found with specific 
adjacent amino acid residue in the LBC of ERa (e.g., His 524, Fig. 4.6). In turn, this may 
increase the binding energy and binding affinity of the hydroxylated metabolites to ERa. 
Indeed, the positive association between amount of hydroxyl groups of ligands and receptor-
driven activity (i.e., estrogenicity) is supported by published work that show that based on the 
same ligand-receptor system; previous research showed biochanin A (having an extra 
hydroxyl than FOR, Fig. 4.8) is more estrogenic than FOR.223  
Figure 4.8: Structural comparison between biochanin A and FOR showing biochanin A has an extra 













Intriguingly, 8-OH-GEN does not fit the positive correlation trend between DockingScore 
and estrogenicity discussed above. The Schrödinger modelling system predicts that 
8-OH-GEN would have a higher binding energy than GEN; the DockingScore of 8-OH-GEN 
(−11.68 kcal/mol) is higher than GEN (−10.79 kcal/mol). This implies 8-OH-GEN would be 
more estrogenic than GEN. However, the MELN assay shows 8-OH-GEN (RRA: 3.01 × 
10−6) has weaker estrogenicity than GEN (RRA: 1.70 × 10−5). This is likely due to the two 
free hydroxyls on 8-OH-GEN (Table 4.2) which are unable to form H-bonds with amino acid 
residues in the LBC (Fig. 4.6) and reducing the hydrophobicity of 8-OH-GEN, and thus 
influencing its estrogenicity. Previous research shows, this is similar to the weaker 
estrogenicity of morin (EC50 = 2.4 × 10−7 M) compared to apigenin (EC50 = 2.4 × 10−6 M).190 
Again, the extra hydroxyl of morin might be not favourable in the hydrophobic region of the 
LBC of ERa, thus resulting in lower estrogenicity compared to the less hydroxylated 
compound apigenin (Fig. 4.9). 
Figure 4.9: Structural comparison between morin and apigenin showing morin has two additional 


















In this chapter, the Schrödinger platform is used to predict the binding energy and order of 
binding affinity of GEN, DAID and their hydroxylated metabolites with ERa. This in silico 
study indicates that the number and orientation of hydroxyls on ligands could affect the 
binding energies and resulting in different binding affinities. Results of the in silico study 
presents a trend: more hydroxyls might form more H-bonds resulting in a higher binding 
energy with the receptor. However, the free hydroxyl groups of ligands, which cannot form 
any polar interactions (e.g., H-bonds) with amino acid residues in the hydrophobic region of 
the LBC; this might decrease the hydrophobicity of the ligand resulting in unfavourable 
contact with the LBC of ERa, thus reducing binding energy and influencing estrogenicity. 
These results are backed up by the MELN assay: hydroxylated metabolites of GEN and 
DAID exhibit greater estrogenicity than their corresponding precursors. However, 8-OH-
GEN is an exception which does not follow this trend; this compound is predicted to have a 
greater binding affinity than the parent compound GEN, but surprisedly showed a weaker 
RRA in the MELN assay compared to GEN. This likely results from the unfavorable 
interactions of the free hydroxyls of 8-OH-GEN with the hydrophobic region of the LBC. 
Hydroxylated metabolites of DAID and GEN are produced from food fermentation and have 
different estrogenicities compared with their parent compounds. The type of metabolite 
depends on the specific microorganism used in the fermentation;157, 251, 252 which is due to 
specific CYP450 expressed by the microorganism.253, 254 In short, this suggests a potential 
link between food science technology (e.g., food fermentation) and functional components 
(e.g., isoflavones and their fermentation metabolites) of foods. The raw materials used in the 
fermentation process can be converted into different metabolites (e.g., hydroxylated 
isoflavones); these metabolites have different levels bio-activities (e.g., estrogenicities), and 
this determines food functionality.  
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Chapter 5: The ERβ-mediated effects of 







5 Chapter 5 – The ERβ-mediated effects of isoflavones on the 
proliferation of Caco-2 cells 
5.1 Introduction 
5.1.1 Distributions and functionalities of ERs 
Steroid hormones are important in control mechanisms for many different biological 
functions depending on the distributions of individual isoforms of steroid hormone receptor, 
including, but not limited to, metabolism, inflammation, proliferation and development, 
immune function, and reproduction.51, 255, 173 As previously discussed in Chapter 1, ERα is 
mainly found in the central nervous system, liver, breast and ovary; and plays an important 
role in maintaining the cell proliferation in these organs or tissues.12, 52 For example, the 
regulation of ERα in the central nervous system has been linked with energy homeostasis, 
which is associated with obesity.256 Obesity has been increasing sharply in industrialized 
countries since the last century and is now recognized as a global epidemic; Over one-third of 
Americans are obese, and the population of obesity in developing countries (e.g., China and 
Thailand) is increasing quickly.257 A decrease in estrogen signalling caused by ageing or 
gonadectomies increases body weight and central (abdominal cavity) adiposity,256 and mice 
with the ERα gene knockout from the brain (by gene-targeting techniques) showed central 
adiposity.258  
ERβ has little importance in reproductive processes, particularly the proliferation of the cell 
of mammary glands or endometrium, and ERβ is not expressed in the pituitary which 
controls the development and growth of germ cells.52 However, ERβ has been found in the 
cardiovascular system, urogenital tract, and GI tract.52, 259 Interestingly, the incidence of 
cardiovascular disease differs significantly between men and women,260 this suggests that, in 
part, estrogen levels might influence the risk factor of cardiovascular disease. In addition, the 
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incidence of atherosclerotic diseases is low in premenopausal women (higher average 
estrogen level), rises in postmenopausal women (lower estrogen level), and is reduced to 
premenopausal levels in postmenopausal women who receive estrogen therapy.261 This could 
be explained by a previous research, which shows estrogen increases vasodilatation and 
inhibits the response of blood vessels to injury and the development of atherosclerosis.261 
Wild-type ovariectomized female mice and mice lacking ERβ were treated with E2, which 
showed that a lowering of hypertrophy in females is associated with ERβ.259, 262 In addition, 
the fact that ERβ is the predominant ER isoform in the GI tract (e.g., epithelium, vascular 
smooth muscle, and endothelium) draws more attention to the potential interaction between 
ERβ and GI physiology.64, 259, 263 Evidences of the impact of female hormones on GI 
physiology from observation of several functional GI disorders suggested considerable 
gender-specific epidemiological differences.259, 264 For example, the female/male ratio for 
slow-transit constipation is approximately 9:1; which suggests this might be linked to the 
higher prevalence of irritable bowel syndrome in women than in men because of the 
important role of the estrogen regulation in the GI tract.265 This ‘gender bias’ suggests the 
involvement of female hormones in the regulation of GI motility, which has been supported 
by the delayed GI transit time during pregnancy (high E2 and progesterone) compared with 
women during the menstrual cycle (corresponding low E2 and progesterone, except the 
follicular phase).266  
Importantly, ERβ-mediated effects in the colon can extend to pathological conditions; for 
example, results of the rodent models of chronic intestinal inflammation show that an 
increase in colonic permeability is associated with a decrease in ERβ mRNA,259, 267, 268 this 
may lead directly to gut diseases (e.g., colon cancer, inflammatory bowel disease).64, 263  
5.1.2 The potential selective-tissue bioactivities of isoflavones via binding ERs 
Section 1.2.5 Chapter 1 introduced the overall homology of the LBD between ERa and ERβ 
is surprisedly less than 55%; however, the LBC, which interacts directly with ligands, these 
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two isoforms of ER are remarkable homologous. This indicates that the two isoforms of ER 
might provide similar binding environment for ligands (Figs. 1.7 & 1.8).54 173 Intriguingly, 
previous research shows that the binding affinities of ligands with the two isoforms of ER are 
different, and soy isoflavones (a main source of phytoestrogens) have a higher binding 
affinity to ERβ compared with ERα.64 For example, the RBA of GEN and DAID interacting 
with ERα are 4 and 0.1, but with ERβ are 87, and 0.5 respectively, where E2’s binding 
affinity is 100.64 This suggests the relative ERβ-mediated bioactivity of GEN and DAID in 
ERβ-predominated organs (e.g., gut cells) would be greater than the relative bioactivity in 
ERα-predominated organs (e.g., human breast); where E2 is set up as a standard compound.12  
The Caco-2 cell line is a continuous cell line of heterogeneous human epithelial colorectal 
adenocarcinoma cells from the GI tract.269 Published research shows that the proliferation of 
Caco-2 cell cultures were stimulated with either E2 or GEN alone, but was inhibited by either 
E2 or GEN in the presence of ICI 182,780 (Fig. 5.1), which is a pure antagonist  of ERs.270 In 
addition, ERb is the predominated isoform of ER in Caco-2 cells.52, 270, 271 Bring the 
statements in this section together, the proliferative effects of E2 and GEN on Caco-2 cell 
line is ERb mediated.52, 270, 271 














The hydroxylation in food fermentation processes converts two estrogen mimics—GEN and 
DAID into their hydroxylated metabolites, this potentially increases the number of H-bonds 
of ligands with the LBC and resulting in greater binding affinity (Section 1.5.2, Chapter 1).. 
In addition, the MELN assay in Chapter 4 shows these hydroxylated metabolites have 
different ERa-driven activity. 
5.2 Research Objectives 
The objectives of the research described in this chapter are: 
•  Use a computational bio−molecule platform (Schrödinger) to study the theoretical 
binding energy and binding affinity of selected isoflavones (including GEN, DAID 
and their hydroxylated metabolites) with ERb. 
• Study the effects of selected isoflavones on the proliferation of Caco-2 cells, and 
investigate their potential structure-activity relationships. 
• Investigate the potential influence of the intestinal phase II metabolism on the ERb-




5.3.1 In silico modelling studies 
The molecular docking studies were carried out as described before (Section 3.3.1, Chapter 
3). The protein preparation and the receptor grid was adapted from Section 3.3.1, Chapter 3). 
The X-ray crystallographic coordinate of ERβ was taken from the PDB , and the X-ray 
crystal structure of ERβ complexed with GEN (PDB entry 1X7J) was used (Fig. 5.1).209 This 
crystallize structure of ERβ has two identical chains (Chain A and Chain B), with each chain 
having a docked ligand (i.e., GEN). Chain A was arbitrarily used as the ligand–receptor 
subunit for this docking study, and chain B was deleted. Missing amino acid residues (Ala 
262, Tyr 411, Pro 412, Leu 413, Val 414, Thr 415, Ala 416, Thr 417, Gln 418, Asp 419, Ala 
420, His 498, Val 499, Leu 500) were added to complete the protein structure using the 
Schrödinger ‘Prime’ command. Ligands (isoflavones) were built and prepared as described 
before (Section 3.3.3, Chapter 3). Rigid-receptor-flexible-ligand docking calculations were 
performed using XP mode and the process was same as the Section 3.3.4 Chapter 3. 
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Figure 5.2: X-ray crystal structure of GEN in the binding pocket of ERb (PBD entry code: 
1X7J) visualised in Schrödinger showing the H-bonds (---, pointed out with a red arrow) 
between the ligand and LBC. Amino acid residues interacting with the ligand via H-bonds are 
shown. All amino acids residues within 3 Å of the ligand are also shown to indicate the 
chemical nature of the binding pocket.  
5.3.2 Caco-2 cell proliferation studies 
The Caco-2 (ATCC HTB-37) cell were a gift from Associate Professor Jacqui Keenan 
(Christchurch School of Medicine, University of Otago). The preparation of culture media, 
experimental reagents, and stock solutions of isoflavones are described in Chapter 2.  
5.3.2.1 Caco-2 cell culture  
The cell culture method was adapted from Budd et al.272 Caco-2 cells were cultured at 37ºC 
in a humidified atmosphere of 5% CO2 v/v in air atmosphere in MEM with Earle’s Salt and 
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L-glutamine, supplemented with 10% (v/v) heat-inactivated FBS, 0.1 mM MEM non-
essential amino acids and 1% (w/w) penicillin/streptomycin.272  
5.3.2.2 Isoflavone exposure experiments 
The exposure concentrations (range from 5 × 10−8 M  to 6.4 × 10−5 M) of isoflavones were 
prepared from the stock solutions in DMSO.270, 273 The blank was set up with the same 
volume of chemical solvent in the absence of isoflavones and a positive control group 
consisted of E2 at concentrations ranging from 1.92 × 10−12 to 1 × 10−8 M. ICI 182,780 (1 
µM) (Fig. 5.2),274 an antagonist compound for ERs, was used as a negative control.271 
Briefly, the cell cultures were incubated with individual isoflavones. After 3 d, the culture 
medium was aspirated, and the cells were washed with 5 mL PBS followed by addition of 3 
mL 2.5 % trypsin (w/v), and the culture plate was incubated for 15 min at 37ºC. 
Subsequently, 12 mL MEM containing 3 mL trypsin was added to the cell cultures and was 
thoroughly mixed to suspend the cells then the mixture was transferred to a 50 mL sterile 
centrifuge tube. The cell counting process is described as Section 2.5. 
5.3.2.3 GA treatment 
Caco-2 cells were pre-treated with GA at 37.5 µM (GA’s IC50–half maximal inhibitory 
concentration  value of Caco-2 cell is 68.7 µM) for 24 h, then cultured with selected 
isoflavones (GEN and 8-OH-GEN) at 0.5 µM for another 72 h.275 Afterwards, the cells were 
treated with trypsin and counted as described above (Section 5.3.2.2). 
5.4 Results and Discussion 
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5.4.1 In silico study of the interactions between isoflavones and ERb 
In the in silico study, seven isoflavones were docked at the LBC of ERb. Table 5.1 shows 
that these isoflavones have different H-bond values, HERs, and thus different 
DockingScores. GEN and DAID, which are estrogen mimics,210 were predicted to have lower 
binding energy and lower binding affinity than their hydroxylated metabolites (Table 5.1); 
this suggests these that the hydroxylated metabolites might interact with LBC and be 
estrogenic. In addition, the different H-bond values and HERs indicate the potential 
contribution of structural features (i.e., the distributions of hydroxyls) to the interaction of 
isoflavones with the LBC thus resulting in different DockingScores and binding affinities 










Table 5.1: Substitution positions, H-bond value, HER, DockingScore of the studied isoflavones (in 
order of DockingScore). 




HER       
kcal/mol 
DAID 7, 4' −11.03 −1.21 −5.68 
GEN 5, 7, 4' −11.45 −1.67 −5.52 
3'-OH-DAID 7, 3', 4' −11.56 −1.72 −5.64 
8-OH-GEN 5, 7, 8, 4' −11.64 −1.66 −5.38 
3'-OH-GEN 5, 7, 3', 4' −11.72 −2.18 −5.47 
8-OH-DAID 7, 8, 4' −11.85 −1.92 −5.64 
6-OH-DAID 6, 7, 4' −11.88 −2.18 −5.57 
As discussed in Section 3.4.4 Chapter 3 H-bond value is determined by the orientation of 
individual H-bonds, which is based on both the angles and distance between the donor and 
acceptor atoms in the bond.217 This means that H-bond values could be affected by both 
distribution and orientation of the ligand’s (e.g., selected isoflavones) hydroxyls which might 
form H-bonds with amino acid residues in the LBC under a ligand/receptor docking situation. 
Table 5.1 shows these isoflavones have various arrangements of hydroxyls and different H-
bond values; this indicates that an increasing trend in the H-bond values could be due to 
additional hydroxyls. For example, the H-bond value of DAID (−1.21 kcal/mol) < the H-
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bond value of GEN (−1.67 kcal/mol) < the H-bond value of 3¢-OH-GEN (−2.18 kcal/mol) 
(Table 5.1). Interestingly, some isoflavones have the same number of hydroxyls but show 
different H-bond values; for example, 6-OH-DAID (−1.72 kcal/mol) and 3¢-OH-DAID 
(−2.18 kcal/mol). This likely result from the different hydroxyl arrangements between 6-OH-
DAID and 3¢-OH-DAID and the formation of different H-bond interactions with ERb (Fig. 
5.3). In addition, Figure 5. 3 shows a specific hydroxyl arrangement (i.e., 8-OH-DAID, Table 
5.1) changes the ligand’s relative orientation with ERb, thus leading the hydroxyls (i.e., the 
hydroxyl at positions 7 and 8; Table 5.1) to interact with different amino acid residues in the 
LBC compared with DAID. An understanding of the importance of H-bond interactions in a 
ligand–receptor binary system might be supported by the higher RBA of triphenol pyrazole 
(Table 3.4) with ERa compared with monohydroxy- and dihydroxy-phenols,197 which was 























































































































































































































































Section 3.4.5, Chapter 3 introduced that, a hydrophobic ligand ‘prefers' to sit amongst 
hydrophobic residues in a hydrophobic binding cleft; conversely, the increased hydrophilic 
character could cause unfavourable interactions to a hydrophobic cleft and likely reduces 
ideal thermodynamic fit.206 Table 5.1 shows that GEN, DAID, and their hydroxylated 
metabolites do not have remarkable different HER (rang from −5.38 to −5.68 kcal/mol), this 
likely result from the same hydrophobic regions (isoflavone’s molecule skeleton, Fig. 5.3) of 
these ligands of ERb. However, the different arrangements hydroxyls still affect the HER. 
For example, compared with DAID, 8-OH-GEN has additional hydroxyls that cannot form 
any H-bonds with amino acid residues at the LBC because of their orientation (Fig. 5.3). The 
free hydroxyls of 8-OH-GEN (5, 8 -OH) are unfavorable to the hydrophobic binding pocket 
of ERb, reducing 8-OH-GEN’s hydrophobicity and decreasing its binding energy (Table 5.1). 
This also could explain the similar HER of DAID (−5.68 kcal/mol) and 3¢-OH-DAID (−5.64 
kcal/mol), because the additional hydroxyl of 3¢-OH-DAID forms a H-bond with LBC, which 
does not have unfavourable interaction with the LBC (Fig. 5.3). In addition, the extra polar 
substituent might influence the hydrophobicity of a ligand and interfere with ligand’s ERα 
hydrophobic interactions. This can be supported by previous study showing that both 4-OH-
estradiol and 2-OH-estradiol have weaker RBA than E2 (Table 5.2).52   
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Table 5.2: The RBA of 4-hydroxyestradiol and 2-hydroxyestradiol with ERa, where the binding 






This in silico study of isoflavones could be helpful in furtherly our understanding of the 
interactions between estrogens (include endogenous estrogens and xenoestrogens) and the 
LBC of ERb. This indicates that the structural features of ligands could determine the 
presence and strength of their noncovalent interactions (e.g., H-bonds) with the targeted 
receptor, resulting in different binding energies and different binding affinities, and 
bioactivities, which in turn differentiates the ERb-driven effects of individual isoflavones. 
5.4.2 Effects of isoflavones on the proliferation of Caco-2 cells  
Figure 5.4 shows that Caco-2 cell proliferation increased over 7 d of culture, and suggesting 
the log phase of the cell proliferation is from 3d to 4 d. However, the rate of proliferation is 










Figure 5.4: Caco-2 cell growth profile in culture; the values are mean ± SD (n=3) of the cell numbers 
are shown.  
As discussed before, the proliferative effects of E2 and GEN on the Caco-2 cell line is ERb 
mediated.52, 270, 271 The in silico research studied isoflavones with different substitution (i.e., 
hydroxyls) patterns were predicted to dock with ERb and gained similar DockingScore 
compared with GEN, this suggests that the seven selected isoflavones might interact with 
ERb and likely have similar ERb-driven bioactivity with GEN (i.e., increase the proliferation 
of Caco-2 cell). 
The results of experiment studying Caco-2 cell proliferation show isoflavones have a dose 
dependent stimulatory effects on proliferation of Caco-2 cells, but the effects of isoflavones 
were significantly weaker than E2 (Fig. 5.5). Also, the comparison between the group of 
isoflavones (either GEN or 3¢-OH-DAID) alone and an isoflavone (either GEN or 3¢-OH-
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DAID) combined with ICI 182,780 further supports that the effect of isoflavones on the 
proliferation of Caco-2 being ERβ-mediated (Fig. 5.6). 
 
Figure 5.5: The effects of different exposure concentrations of E2 and isoflavones on the Caco-2 cell 
proliferation. The values are mean ± SD (n=3) of the cell numbers at a given concentration of a test 




Figure 5.6: The effects of different exposure concentrations of 3¢-OH-DAID and GEN on the Caco-2 
cell proliferation. Caco-2 cells were grown in either 3¢-OH-DAID or GEN in presence or absence of 1 
µM ICI 182,780. The values are mean ± SD (n=3) of the cell numbers at a given concentration of a 
test isoflavone ratio to blank. 
In this study, the effects of selected isoflavones on the proliferation of Caco-2 cell were 
determined. Table 5.3 shows EC50 and RAAs of the selected isoflavones, where E2 equals 1. 
The stimulatory activity of studied isoflavones (EC50 ranges from 3.64 × 10−7 M to 1.70 × 
10−5 M) at least 10−3 times than E2 (EC50 = 3.911 × 10−11 M). The RAA values of the studied 
isoflavones showed a trend; hydroxylated metabolites have greater effects on the proliferation 
of Caco-2 cell than their parent compounds (i.e., GEN and DAID respectively). For example, 
6-OH-DAID (1.77 × 10−3) > DAID (6.12 × 10−5) and 3¢-OH-GEN (3.35× 10−3) > GEN (1.74 
× 10−3) (Table 5.3), this trend follows the predicated order of binding affinity between parent 
compounds and their hydroxylated metabolites in the in silico study shown in Table 5.1. 
However, 8-OH-GEN does not follow this tread is an exception; this compound was 
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predicted to have a greater binding energy than the parent compound GEN, but surprisedly 
showed a weaker activation on the proliferation of Caco-2 cell. Studied further in the in 
silico, the additional hydroxyl groups (Fig. 5.3) on 8-OH-GEN did not form H-bonds with 
amino acid residues at LBC, and is a unfavourable fitting to the hydrophobic region of the 
binding cleft; this might result in a low binding affinity and influence the receptor-driven 
bioactivity of 8-OH-GEN. 




E2 3.911 × 10-11 1 
3'-OH-GEN 1.168 × 10−8 3.35 × 10−3 
3'-OH-DAID 1.698 × 10−8 2.30 × 10−3 
8-OH-DAID 1.972 × 10−8 1.98 × 10−3 
6-OH-DAID 2.212 × 10−8 1.77 × 10−3 
GEN 2.246 × 10−8 1.74× 10−3 
DAID 6.386 × 10−7 6.12 × 10−5 
8-OH-GEN 2.411 × 10−7 1.62 × 10−4 
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Binding affinity is the strength of the binding interaction between a single biomolecule (e.g., 
ERa) and its ligand.246 Binding affinity is influenced by non-covalent intermolecular 
interactions (e.g., H-bonds, hydrophobic interactions) between the receptor and a ligand, 
which comprises free binding energy.184 Results of the in silico study (Table 5.1) show that 
all hydroxylated metabolites have higher theoretical binding energy—DockingScores than 
their corresponding parent compounds; this predicts that these hydroxylated compounds may 
have a greater binding affinity with ERb than their precursors. The additional hydroxyls 
might form extra H-bonds with specific adjacent amino acid residues in the LBC of ERb 
(e.g., His 475) (Fig. 5.3); thus, this might increases the binding energy and binding affinity 
with ERb (e.g., DockingScore of DAID = −11.03 kcal/mol, DockingScore of 3'-OH-DAID = 
−11.56 kcal/mol) (Table 5.1).  
The Caco-2 cell experiment showed that the hydroxylated isoflavone metabolites have a 
greater effect on the proliferation of Caco-2 cell than their less hydroxyl parent compounds. 
For example, the RAA of 3'-OH-DAID is 2.27 × 10−5 which is higher than DAID (its RRA 
equals 1.48 × 10−6. This indicates that the hydroxylation of isoflavone contributes to their 
ERb-mediated activities. In addition, based on the same ligand–receptor system, previous 
research showed biochanin A with an additional hydroxyl is more estrogenic than FOR (Fig. 
5.7).223 Again, previous research reports that in an inhibitor-enzyme system, which requires 
specific binding characteristics of substrates for interacting with the corresponding 
enzyme,276 kaempferol (a tetrahydroxy-flavonol) is a stronger inhibitor of XO than galangin 
(a trihydroxyl-flavonol) (Fig. 5.7).218 Interestingly, in the silico study, 8-OH-GEN was 
predicted to have higher binding affinity with ERb (Table 5.1) but resulted in less Caco-2 cell 
proliferation than GEN (Table 5.3); this anomaly might be explained by the two free 
hydroxyls of 8-OH-GEN (Fig. 5.3) which might not form H-bonds with any amino acid 
residues in the LBC because there are no free potential amino acid residues in the vicinity of 
the docked ligand (Fig. 5.3). These free hydroxyls are not favourable to the hydrophobic 
binding pocket of ERb and might resulting in a decrease in the ligand’s hydrophobicity, thus 
leading a reduction of the binding affinity of the ligand with ERb. Similarly, published result 
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shows kaempferol, which has one more hydroxyl (Fig. 5.7), has a weaker estrogenic potency 
than galangin.190  
 
Figure 5.7: Structures of FOR, biochanin A, kaempferol, and galanin. The extra hydroxyl of biochain 
A and kaempferol compared with FOR or galangin correspondingly are highlighted by a red circle. 
5.4.3 The influence of intestinal phase II metabolism on the ERb-driven activity 
of selected isoflavone in Caco-2 culture 
Isoflavones (e.g., GEN) have been reported to show higher binding affinity to ERb than 
ERa.52 For example, the RBA of GEN is 5 with ERa and 36 with ERb, where the binding 
affinity of E2 equals 100 with both ERa and ERb.52 Likewise, the results of YES assays 
show that the EC50 of GEN is 9.0 × 10−7 M with ERa and 4.2 × 10−9 M with ERb. 
Interestingly, the Caco-2 cell study does not show correspondingly strong effect of 
isoflavones on the ERb-mediated cell proliferation (e.g., the EC50 of GEN is 2.246 × 10−8 M). 


























heterogeneous human epithelial colorectal adenocarcinoma cells and is able to carry out 
phase II metabolism, during which, xenobiotics (e.g., isoflavones) might be conjugated with 
glucuronic acid and be converted into non-bioactive conjugates.269 The intestinal phase II 
metabolism might thus result in a reduction of the level of functional form of isoflavones, this 
could influence the interplay of such isoflavones with macromolecules (e.g., ERb), which, 
might in in turn, affect macromolecule-mediated bioactivities of isoflavones in different 
tissues.  
In this study, Caco-2 cells were pre-treated with 37.5 µM GA for 12 h to inhibit the UGDH 
activity, then incubated with either GEN or 8-OH-GEN (6.4 ×10–2 µM) for another 72 h. 
Previous research showed isoflavones (e.g., GEN) can be conjugated by 
glucuronosyltransferase with uridine diphosphate glucuronic acid (UDP-glucuronic acid), 
which is produced with UDP-glucose dehydrogenase (UGDH).269, 277 GA is a non-
competitive inhibitor of UGDH activity and it can reduce the production of UDP-glucuronic 
acid at post-translational level, which, in turn, would interfere with glucuronidation of 
isoflavones.278 Figure 5.8 shows that the Caco-2 incubation with the presence of GA did not 
show any significant reduction in cell proliferation compared with the blank. In addition, GA 
pre-treatment resulted in enhancement effects on both GEN and 8-OH-GEN induced 
proliferation of the Caco-2 cells (p < 0.05); this is likely due to the inference of GA with the 
conjugation of isoflavones increasing the amount of functional forms for interacting with 
ERb. This could explain that the why isoflavones showed higher binding affinity with ERb 
than with ERa,210 but did not exhibit a correspondingly greater ERb-driven proliferative 




Figure 5.8: Proliferation of Caco-2 cells following exposure to GEN or 8-OH-GEN in the presence or 
absence of GA. Caco-2 cells were grown in media containing GEN or 8-OH-GEN (6.4 ×10–2 µM) in 
the presence or absence of GA 37.5 µM. *Significant differences between cell number in isoflavone 
alone incubation compared with incubation containing isoflavone and GA were calculated by one-
way ANOVA (*: p < 0.05).  
In this study, the non-competitive inhibitor of UGDH—GA was used to inhibit the activity of 
UGDH; this would decrease the biosynthesis of UDP glucuronic acid which likely provides 
glucuronic acid for the conjugation of isoflavones.269 This bio-action will lead to the 
conversion of isoflavones to non-bioactive conjugates (Fig. 5.9). Thus, the GA pre-treatment 
of Caco-2 cells likely increases the amount of the functional form (i.e., bioactive aglycone) of 





Figure 5.9: The effects of UDP conjugation on isoflavones (e.g., DAID) estrogenic bioactivity in 
Caco-2 cells. Left of Schematic: UDP glucuronic acid is produced from UDP-glucose catalysed by 
UGDH, then UDP glucuronic acid conjugates with DAID to yield a non-bioactive conjugate of 
DAID. The conjugation decreased the amount of the functional form (i.e., aglycone) of DAID 
resulting in less DAID for interacting with ERb. An UGDH inhibitor—GA influences the production 
of UDP glucuronic acid, this results in accumulation more DAID which would interact with ERb or 




In this chapter, the Schrödinger platform was used to determine the theoretical binding 
energy represented by the DockingScore and to predict the order of ERb binding affinity of 
GEN, DAID and their hydroxylated metabolites. This in silico study indicated the hydroxyls 
patterns likely determines the H-bond interactions and hydrophobic interactions of 
isoflavones with amino acid residues in the LBC of ERb; this, in turn, might result in 
different binding energies and thus different estrogenicities. The in silico study indicates a 
trend: more hydroxyls form more H-bonds leading to higher receptor binding energy. For 
example, the DockingScore of 6-OH-DAID (−11.88 kcal/mol) is higher than DAID (−11.03 
kcal/mol). However, the extra hydroxyl, which cannot form H-bond with the amino acid 
residues in the LBC, in theory decreases the hydrophobicity of the ligand causing 
unfavourable interaction with the LBC, thus reducing the ligand’s binding energy; for 
example, the DockingScore of 8-OH-GEN (−11.64 kcal/mol) is lower than 3¢-OH-GEN 
(−11.72 kcal/mol). This theoretical approach to studying ligand/ ERb interaction gives 
important insight into the intimate biological chemistry, whether these in silico prediction 
translate to in vivo studies was studied of ERb-expressing Caco-2 cells. 
Results of Caco-2 cell proliferation experiments show that the proliferative effects of 
isoflavones on Caco-2 cell line were dose-dependent. Hydroxylated metabolites of GEN and 
DAID show greater proliferative effects on Caco-2 cells, compared with their less 
hydroxylated parent compounds. However, the exception to this trend is 8-OH-GEN, which 
has a significantly weaker proliferative effect than GEN. This might be due to the additional 
hydroxyl groups of 8-OH-GEN (Fig. 5.3); because there are no free potential hydrogen 
binding amino acid residues in the vicinity of docked ligand. In addition, the extra hydroxyl 
groups would decrease the hydrophobicity of the ligand. Interestingly, isoflavones have a 
higher binding affinity with ERb than with ERa,210 and a higher relative potency in the YES 
assay with ERb than with ERa.279 However, such isoflavones did not show correspondingly 
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greater effects in the Caco-2 cell line (which expresses predominantly ERb).  In this study, 
GA’s inhibition of UGDH might influence the conjugation of isoflavones and increase the 
amount of isoflavone aglycones in cells; this, in turn might promote the proliferative effects 
of isoflavones on Caco-2 cells. This finding might be significant in a health context because 
GA is present in many fruits (e.g., strawberry, banana) and in tea.278 This suggests that in a 
‘food combination’ situation, it is feasible that a complex interplay between GA inhibition, 
isoflavone deactivation in conjecture with metabolic (hydroxylation) activation of isoflavones 
could significantly increase and prolong their ER-mediated biological effects. This might 
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6 Chapter 6 – Structure bioavailability relationships of 
isoflavones and their effects on gut bacterial populations 
6.1 Introduction 
6.1.1 The metabolism of isoflavones  
As discussed before (Section 1.3.4 Chapter 1), soy isoflavones (i.e., GEN and DAID) are 
phytoestrogens, which can occupy and activate ERs, and might cause corresponding 
estrogenic bioactivity in vivo.280 281 70 Soy isoflavone is the main dietary phytoestrogen 
because of their high concentrations in soy and the huge consumption of soy-based foods.280 
281 The metabolism of isoflavones is complex.282 The two major isoflavones, GEN and 
DAID, are present in raw soy as their β-D-glycosides, namely genistin and daidzin (Table 
1.3). These glycosides are biologically inactive.122 Once ingested, isoflavone glycosides are 
hydrolysed by bacterial β-glucosidases in the intestine, resulting in conversion to their 
corresponding bioactive aglycones (i.e., GEN and DAID, respectively).282 Interestingly, the 
β-glucosidases gene is well present in Bacteriodetes and Firmicutes in the human intestine; 
this suggests the individual differences of these two type of bacteria may vary the hydrolysis 
of isoflavones glycosides and resulting different amount of aglycones.282 In addition, only the 
aglycones are absorbed in the intestine and are, therefore biologically active. Consequently, 
the individual different compositions of gut bacteria could affect the hydrolysis of glucosides 
isoflavones and influence the functionality of isoflavones.229 Moreover, aglycones might be 
further converted to different estrogenic metabolites. For example, DAID can be metabolised 
to more estrogenic S-equol (Fig. 3.3), and GEN would be converted into less estrogenic 
dihydrogenistein by intestinal bacteria (Fig. 3.3).283 All parent compounds and metabolites of 
isoflavones (e.g., GEN and DAID) have been detected in the blood and urine of humans and 
animals.284 The metabolic pathways of isoflavones have individual variations; 285 for 
example, only 30% of humans can metabolize DAID into S-equol, which has been associated 
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with individual difference in gut bacterial composition;229 this could individually differentiate 
the in vivo bioactivity (e.g., estrogenic regulation) of DAID. Recently, it has been reported 
that ‘equol producers’ have a lower prevalence of obesity than ‘non-equol producers;286 this 
might be linked to the estrogenic regulation of fatty acid distribution and energy 
homeostasis.287 
6.1.2 Gut bacteria and human health 
The human gut hosts billions of bacteria; the two major phyla, that make up 90% of the gut 
commensal microbiota are Bacteroidetes and Firmicutes, the most abundant genera of which 
are Bacteroides and Faecalibacterium.288 The phylum Actinobacteria is much less abundant, 
but it includes Bifidobacterium, which is a genus used in food supplements for delivering 
probiotic benefits to the host.289 The diversity of host-bacteria interactions, which could be 
influenced by diet or host health situations, plays a fundamental role in the well-being of the 
host via a wide range of pathways.288 For example, gut bacterial communities are suggested 
to contribute to the development of insulin resistance.53 Previous research indicates different 
diets affect the population of gut bacteria,290 the study using mice fed a high-fat diet shows an 
improvement in glucose insulin homeostasis and attenuation of weight gain when mice were 
given Lactobacillus and Bifidobacterium probiotics, compared to mice given a normal diet 
without probiotics.290 Another example is nonalcoholic fatty liver disease, the changing of 
gut microbiota has been observed in patients. Bacteroidetes (including Prevotllaceae) and 
Saccharibacteria were increased, but the main of phylum of Firmicutes including 
Lactobacillus were decreased.53 F. prausnitzii is one of the most abundant and important 
commensal bacteria.291, 292 In healthy adults, F. prausnitzii represents more than 5% of the 
bacteria in the intestine, and can produce butyrate and other short-chain fatty acids (SCFAs) 
through the fermentation of dietary fibre; these SCFAs might benefit colonocytes by 
increasing energy production and promoting cell proliferation, in turn, it has been suggested 
that they might protect against gut diseases (e.g., colon cancer).291 In addition, published data 
show lower than usual concentrations of F. prausnitzii in the intestines are associated with 
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Crohn's disease, obesity, asthma and major depressive disorders, while higher than usual 
concentrations have been associated with psoriasis.291 
Obesity is a physiological state that has emerged as a major health concern in populations, 
and this is closely linked to the gut bacteria.293 In animal model studies of obesity, the 
increased efficiency of energy harvest due to an increase in the ratio between  the 
concentration of Firmicutes/Bacteriodetes (F/B) has been implicated in the aetiology of 
obesity in mice.294 The same change of F/B was observed humans on weight-reduction diets; 
although another study showed that in obese individuals, a decrease in Bacteroidetes was 
accompanied by an increase in Actinobacterium rather than Firmicutes.294,295 These 
observations imply the important role of Bacterioidetes which has been linked to their 
sphingolipids production modulated lipid homeostasis.296 In addition, published data show 
the consumption of a high-fat diet in both animals and humans can result in both changes in 
the composition of gut bacteria and resulting an increase intestinal permeability;269 this might 
result in an increase in endotoxin concentrations (e.g., lipopolysaccharide). The 
lipopolysaccharide plays a central role in maintaining the integrity and functionality of the 
outer membrane of the Gram negative cell envelope,297 and thus, contribute to the low-grade 
inflammation, insulin resistance, adipocyte hyperplasia, and decreased β-cell function.298  
Section 1.5.2, Chapter 1 introduced two types of biotransformation products of DAID and 
GEN, namely OH-DAIDs and OH-GENs (Fig. 1.12), which have been detected in various 
fermented soybean foods (e.g. miso and soy sauce).157, 252 These metabolites inherit the same 
structural skeleton from their parent compounds, but with different hydroxyl patterns (Fig. 
1.12).157, 251, 252 The absorption and metabolism of xenobiotics (e.g., GEN) have been widely 
studied in Caco-2 cell monolayer system which mimic human intestinal mucosa.1, 277 
Previous research shows such xenobiotics can be transferred through the Caco-2 cell 
monolayer and conjugated in the cells by phase II metabolism; this determines the 




6.2 Research Objectives 
• Use an in vitro gut fermentation model to investigate the effects of isoflavones on 
human gut bacteria. 
• Use a Caco-2 monolayer transportation model gut system to study the absorption and 





These studies were carried out in collaboration with Dr. Shanthi Parkar, and the experiments 
were carried out in her laboratory (Plant and Food Research, Palmerston North). 
6.3.1 In vitro gut fermentation.  
The feces samples used as inoculates were obtained from 5 human volunteers with no a 
priori selection criteria beyond self-assessed good health and no intake of antibiotics for at 
least 3 months prior to the study (Central Health and Disabilities Ethics Committee Approval 
# 13/CEN/144). Pooling of the feces samples produced a standard with a diverse range of 
bacteria from different donors and avoided the inter-individual differences of bacterial 
compositions. These were processed under anaerobic conditions and stored as 20% v/v fecal 
slurries in 10% v/v glycerol buffered saline at −80 °C.300  
The preparation of WCA broth and experimental regents were described in the Chapter 2. 
The WCA broth (50 mL) containing each individual isoflavones (5 µM) or inulin (1 mg/mL) 
was incubated with human fecal slurry (1% v/v, final concentration). Inulin, which is a 
prebiotic fibre, is used as the positive control in this study. The media and buffers for the gut 
fermentations were left in an anaerobic chamber maintained at 5% CO2, 10% H2 and 85% N2 
for at least 24 h before the start of the isoflavones exposures. Fermentation was carried out in 
the anaerobic chamber at 37 ℃ rotating at 70 rpm. Aliquots (1 mL) of the fermented mixture 
were collected at 1, 2 and 20 h, and centrifuged at 13,000 ´ g at 4°C for 1 min. The pellets 
were separated and stored at −80°C prior to quantification of bacteria. The negative controls 
were WCA alone and WCA broth inoculated with the fecal microbiota. 
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6.3.2 Real-time PCR quantification of bacteria  
The total DNA was isolated from each fermentation aliquot using the ZR Faecal DNA kit 
following the manufacturer’s instructions. The extracted DNA then were ready for bacterial 
quantification by PCR. The concentrations of two phyla Bacteroidetes and Firmicutes, the 
concentrations of a specific species of Firmicutes—F. prausnitzii, and Bifidobacterium spp, 
in each sample were quantified using previously published real time PCR protocols.170, 301, 302 
Real-time PCR (RT-PCR) was performed with the Rotor-Gene 6000 machine, in a final 
volume of 10 µL containing 5 µL of LightCycler® 480 SYBR Green Ⅰ Master mix, 3.8 µL 
Milli-Q water, 0.1 µL of each primer (10 µM) and 1 µL of DNA (1 in 10 diluted sample). 
The reaction conditions were 95℃ for 5 min followed by 35 cycles at 94 ℃ for 15 s, and 
then annealing at conditions suitable for each primer set (see Table S2, Appendix C), an 
extension at 72°C for 60 s, followed by a melt cycle to determine the specificity of the 
amplification product. The reference bacterial strains and the primers used to construct the 
standard curves for and quantify the bacteria are given in Table S2 Appendix C. Bacterial 
quantitation was done using Rotor-gene 6000 series software 1.7, and expressed as log10 
colony forming unit/mL/fermenta (cfu/mL). 
6.3.3 Cell culture  
The Caco-2 transportation experiment of isoflavones was carried out in collaboration with 
Associate Professor Jacqui Keenan, and carried out in her laboratory (Christchurch School of 
Medicine, University of Otago). 
The preparations of cell culture media and experimental regents were described in Chapter 2. 
Cell culture methods were adapted from Budd GR et al.272 Caco-2 (ATCC HTB-37) cell line 
used in this study was derived from a human colon adenocarcinoma and is widely used to 
model differentiating gut enterocytes.272, 271 The cells were routinely cultured in the pre-
prepared MEM with Earle’s Salt and L-glutamine, supplemented with 10% (v/v) heat-
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inactivated FBS. Cell cultures were maintained at 37°C in a humidified atmosphere of 5% 
CO2 in air.272 
6.3.4 Isoflavone transport experiments in the Caco-2 gut model system 
Caco-2 cells were seeded into a 24-well transwell insert coated with type-I collagen at a 
density of 5 × 104 cells/well to form Caco-2 monolayers. The medium was replaced every 3 
d, and the monolayers were cultured to differentiate for 24 d post seeding. Before the 
experiment, the integrity of the cell layer and the development of the tight junctions between 
cells were monitored by measuring the transepithelial electrical resistance (TEER) of filter-
grown cell monolayers with Millicell Voltohmmeter. Only a monolayer with the TEER value 
>260 𝛀 hm cm2 was applied for the isoflavone transport experiments.303  
The cell monolayers were gently washed three times with PBS (pH 7.4, 37°C). Cell 
monolayers were then incubated at 37°C for 30 min in the PBS. To measure the apical-to-
basolateral (AP-BL) transport, 100 µL of PBS containing isoflavones (final concentration 5 
µM) were added to the AP side of the transwell inserts, and 600 µL of culture medium was 
added to the BL chamber. The plate was incubated at 37°C for 2 h.  
6.3.5 Samples collection 
The isoflavone extraction method was adapted from our previous research.199 Culture media 
from AP and BL media were directly collected for extraction. The Caco-2 cells were washed 
with PBS (37°C) three times, 200 µL RIPA buffer was added, then incubated on ice for 20 
min with occasional mixing to ensure cell detachment and lysis. Cell lysates were collected 
then centrifuged at 14000 × g for 30 min at 4°C to remove remaining cell debris. The 
supernatants (containing isoflavones) were collected for extraction and analysis by HPLC. 
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6.3.6 Extraction of samples of Caco-2 transportation experiment 
Samples (2 mL) prepared from previous section were extracted by vortex mixing with ethyl 
acetate (3 times volume of sample) in triplicate. The upper ethyl acetate layer of each sample 
transferred into a new test tube and evaporated under a stream of N2 gas (40 °C), this was 
designed Group I. The aqueous (bottom) layer from each extracted sample was treated with 
glucuronidase and sulfatase to realise aglycones of the isoflavones, then were shaken at 37 °C 
for 2 h,269, 277, 304 The incubate was extracted with ethyl acetate, the ethyl acetate layer was 
collected and evaporated as above.; this was designed Group II. Residues from Group I and II 
were dissolved in HPLC-grade acetonitrile (1 mL) containing 10 % (v/v) DMSO and filtered 
through a 0.45 µm non-sterile syringe filter into a 2 mL glass HPLC vial and then analysed 
by HPLC. 
6.3.7 HPLC analysis  
The HPLC method was same as from our previous research.199 The HPLC set-up comprised 
Dionex hardware (sample injector ASI-100, thermostatic column compartment TCC-100;) 
with a Phenomenex C18 Prodigy 5µm ODS3 100 A 250 mm × 4.6 mm column with a C18 
SecurityGuard column and an ultraviolet/visible detector; UV detection was at 254 nm. The 
HPLC mobile phases consisted of solvent A: Milli-Q water containing 0.05% (v/v) 
trifluoroacetic acid; solvent B: acetonitrile. A solvent gradient was run as follows: 0–25 min, 
solvent B linearly increased from 5% to 50%, remaining at 50% for 5 min; then solvent B 
decreased from 50% to 5% from 30 to 35 min. Correspondingly, solvent A linearly decreased 
from 95% to 50% over 0–25 min, remaining at 50% for 5 min; then solvent A increased from 
50% to 90% over the final 5 min of the run. The injection volume was 20 µL, the flow rate 
was 1 mL/min, and running time was 35 min.  
The calibration curves (Peak area vs concentration) for selected isoflavones (Table 5.1) all 
have good linear regression with R2 values in the range of 0.98–0.99 (see Fig. S2, Appendix 
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C). The linear nature of the calibration graphs allows for the reliable calculation of 
concentrations of selected isoflavones in the range of 0.02–4 µM. 
6.3.8 Caco-2 Isoflavone transport experiment: data analysis 
The rates of transport (Vt) of each isoflavone were obtained using the concentration of 
transported isoflavones (dC) (from AP to BL) divide 2 h (t) (Eq. 1). The apparent 
permeability coefficient (Papp)303 across a cellular membrane was calculated using the rate of 
transport divided by the surface area (A) (0.33 cm2) of the Caco-2 monolayer and the initial 
concentration, C0 (5 µM) of these compounds (Eq. 2).303 Calculation was carried out as 
follow.  
Vt = dC/t;                                                                                                                         (Eq. 1) 
dC = change in concentration of isoflavone 
Papp = Vt/AC0                                                                                                                                                                             (Eq. 2) 
Raw data from the Caco-2 monolayer transportations of isoflavones were analysed using 
Microsoft Excel®. Mean ± SD was calculated. Significant differences were calculated by one-
way ANOVA using GraphPad Prism (Version 7).  
 
170 
6.4  Results and Discussion 
6.4.1 Effects of isoflavones on different bacterial populations 
Previous research indicates that a bi-directional interaction exists between isoflavones and 
gut bacteria, this interaction is associated with host metabolic rate, body weight, and 
adiposity.66, 286 On the one hand, isoflavones can be metabolised by the gut bacteria; the 
glycoside forms of isoflavones (e.g., daidzin) are hydrolysed releasing their aglycones 
(functional forms). In addition, it is possible that aglycones are converted into more 
estrogenic compounds (e.g., DAID is converted to S-equol).229 However, the effects of 
isoflavones on the composition and population of human gut bacteria are not well 
understood. One limited example is GEN which has been reported to significantly alter the 
compositions of the fecal bacterial community in postmenopausal women by increasing the 
concentration of Bifidobacteriums spp, while decreasing Clostridiaceae.283  
In this chapter, two phyla Bacteroidetes and Firmicutes, a specific species of Firmicutes—F. 
prausnitzii, and Bifidobacterium spp, were quantified. Figure 6.1 shows the effects of the 
selected isoflavones on the concentration of Bifidobacterium spp in the in vitro fermentation 
system; the positive control group (incubated with inulin), continued increasing the 
concentration of Bifidobacterium spp. from 6.21 log10 cfu/mL to 7.48 log10 cfu/mL over 20 h. 
Over the 2 h incubation, except 6-OH-DAID, all other isoflavones have significantly greater 
(p < 0.03) proliferative activity on the concentration of Bifidobacterium ranging from 6.87 
log10 cfu/mL (8-OH-GEN) to 7.08 log10 cfu/mL (3¢-OH-DAID) compared with the inulin 
control (6.24 log10 cfu/mL), but GEN and DAID do not have any significant difference 
compared with their corresponding hydroxylated metabolites (Fig. 6.1). Following 2 h 
incubate, Bifidobacterium decreased in all of the isoflavone exposure groups. 
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Figure 6.1: Effects of isoflavones on the concentration of Bifidobacterium spp.. Mean ± SD are 
shown. # Significant difference in the concentration of Bifidobacterium spp. (##: p<0.03, ###: p<0.01, 
####: p<0.001), which was the comparison of each isoflavone with inulin control calculated by one-
way ANOVA. 
The in vitro gut fermentation experiment shows isoflavones (5 µM) affect the concentration 
of Firmicutes and Bacteriodetes over the 20 h incubation (Table S3, Appendix D), and the 
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F/B were calculated. Briefly, isoflavones decreased the concentration of Firmicutes and 
increased the concentration of Bacteriodetes, thus, decreasing F/B. The inulin control 
decreased the F/B over the 20 h incubation, while isoflavones resulted in a rapid decline in 
F/B over 2 h, and all of the studied isoflavones showed stronger effects on F/B (rang from 
1.36 to 1.54) than the inulin control (1.56) in 2 h (Table 6.1); 3¢-OH-DAID and 3¢-OH-GEN 















Table 6.1: The effects of isoflavones on the F/B ratio. 



































The effects of the studied isoflavones on the concentration of F. prausnitzii in the 20 h 
anaerobic fermentation are shown in Figure 6.2. Over 2 h incubation, isoflavones increased 
the concentration of F. prausnitzii; this ranged from 5.38 log10 cfu/mL (3¢-OH-DAID) to 5.82 
log10 cfu/mL (GEN). In addition, only 6-OH-GEN has significantly greater effect on the the 
concentration of F. prausnitzii compared with the inulin control (5.74 log10 cfu/mL), and 
DAID exhibits significant inhibition compared with its hydroxylated compound 8-OH-DAID. 
However, the hydroxylated GENs have a similar effect on the concentration of F. prausnitzii 
as the parent compound, GEN (Fig. 6.2).  
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Figure 6.2: Effects of isoflavones on the concentration of F. prausnitzii. Mean ± SD are shown. 
*Significant difference in the concentration of F. prausnitzii (*: p<0.05) which was comparison of 
each isoflavone with inulin control calculated by one-way ANOVA. #Significant difference in the 
concentration of F. prausnitzii (*: p<0.05) which was comparison of each OH-DAID with DAID 
calculated by one-way ANOVA. 
In a human health context, Bifidobacterium is one of the principal probiotic members in the 
gut, this genus of bacteria is used as a conventional treatment for ulcerative colitis and has 
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been associated with improved rates of remission and improved maintenance of remission.305 
Other beneficial gut commensal bacteria have been identified recently, such as the butyrate-
producer-F. prausnitzii, which decreases in inflammatory bowel disease and is particularly 
associated with the pathophysiology of Crohn’s disease.306 The F/B has been shown to have 
some health implications and suggested as a potential parameter for the assessment of gut 
health.307 For example, the F/B changes with age, for infants (0.4), adult (10.9) and elderly 
individuals (0.6), respectively. In addition, a higher F/B has been associated with obesity and 
type 2 diabetes, which might due to their important role in energy regulation via modulating 
the recirculation of estrogens.308 In this study, isoflavones show different effects on the 
bacteria studied. Notably, over the 2 h incubation, isoflavones exhibited increased effect on 
the concentration of Bifidobacterium, F. prausnitzii, and Bacteriodetes; however, they 
decreased the concentration of Firmicutes. This might be significant in the in vivo 
fermentation process that occurs in the human intestine. The temporary exposure of bacteria 
in a gut region (e.g., ileum) to isoflavones is short (2–3 h), and a certain gut region has a 
specific gut bacterial compositions because of the different oxygen tensions at different 
places in the GI tract.309, 310 However, in others in vitro experiments, a longer exposure time 
(12–48 h)311 with such xenobiotics (e.g., isoflavones); this might result in an exaggerated 
effect of test chemicals on some specific groups of gut bacteria.  
Chemically, flavonoids are further divided into subclasses (e.g., flavones, isoflavones, and 
flavanols), and they are regarded as prebiotics present in the diet.312 Flavanols (e.g., 
quercetin) have been shown anti-proliferative activity on Gram-negative bacteria (most 
pathogenic bacteria are Gram-negative); this is likely due to the ring fragmentation of 
flavanols during their intestinal metabolism to produce the corresponding phenolic acids.170, 
187 For example, quercetin can be broken down into hydrocattetic acid and 4-
hydroxyphenylpropionic acid (Fig. 6.3).170 However, with a different molecular skeleton (i.e., 
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different relative positions between A ring and B ring, Table 1.2), isoflavones are rarely 
found to be fragmented into their corresponding phenolic acids.229, 285  
Figure 6.3: The metabolism of quercetin (A) by gut bacteria to form 4-hydroxyphenylpropionic acid 
(B) and hydrocattetic acid (C). 
6.4.2 Transport study of isoflavones in Caco-2 cell monolayer system 
There were seven isoflavones with different hydroxyl patterns studied in the Caco-2 cell 
monolayer model system. These isoflavones were rapidly transported and metabolised in the 
transportation experiment. The apparent transport rates (TRs) of the individual isoflavones 
are different and range from 13.59 to 25.2 pmol/min/cm2 (Fig 6.5). The transport rate (TR) of 
GEN is fastest, followed by DAID (17.87 pmol/min/cm2), 3´-OH-GEN (17.58 
pmol/min/cm2) and 8-OH-GEN (17.73 pmol/min/cm2) which are similar. 6-OH-DAID (14.04 
pmol/min/cm2), 3´-OH-DAID (13.39 pmol/min/cm2) and 8-OH-DAID (14.0 pmol/min/cm2) 
(Fig. 6.5). In addition, the Papp of the studied isoflavones (Fig. 6.4) follows the same trend as 
their transport rates, ranging from 24.5 to 37.2 ×10−6 cm/s (Fig. 6.4). In summary, the 
transport across the Caco-2 monolayer of GEN and DAID are faster than their corresponding 




















Figure 6.4: Papp and total TR of isoflavones (mean ± SD, n = 3). Papp and total TR were measured in 
Caco-2 cell monolayer system. *Significant difference in the Papp value (**: p<0.03; ***: p<0.01), # 
significant difference in the TR (###: p<0.01), both of which were comparisons of each compound 
with GEN calculated by one-way ANOVA. 
Intestinal phase II metabolism (e.g., sulfation and glucuronidation) is important metabolic 
pathways of xenobiotics (e.g., flavonoids); the conjugation of xenobiotics has the potential to 
facilitate their excretion to the lumen of the intestine.313 Figure 6.6 shows the transport rates 
of conjugates and aglycones of the studied isoflavones. All the aglycones of the studied 
isoflavones were absorbed by Caco-2 cells. GEN has the fastest TR (18.67 pmol/min/cm2), 
followed by DAID (13.58 pmol/min/cm2), and the slowest compound was 3´-OH-DAID 
(7.07 pmol/min/cm2). Interestingly, there is no significant difference in the conjugate 
transport rates between individual studied isoflavones; this might be due to their structural 
features, namely—same molecular skeleton and common substitution arrangements (Fig. 
1.12). This finding is also supported by previous research of regioselective sulfation and 
glucuronidation of phenolic,313 this research shows structural basis for the conjugation of 
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isoflavones is the 7-hydroxy group is the major site for glucuronidation whereas the 4¢-
hydroxyl group is the only possible site for sulfation. Indeed, both the 7-hydroxyl and 4¢-
hydroxyl are common structural features of all isoflavones (Table 1.10).  
Figure 6.5: TR of conjugates and aglycone (mean ± SD, n = 3). *Significant difference in the TR of 
aglycone (****: p<0.001), which was the comparison of each compound with GEN calculated by 
one-way ANOVA. 
In addition, the plotted line in Figure 6.5 shows the ratio between the absorbed aglycones and 
their corresponding conjugates in the Caco-2 cell monolayer system, which ranges from 1.11 
to 2.9.; this follows the trend of the TR of the aglycones of the isoflavones studied. This 
finding suggests the structural features of isoflavones could influence the absorbed of their 
corresponding aglycones (functional forms), and, thus, an effect their bioactivity in vivo. 
Furthermore, the amount of absorbed hydroxylated isoflavones in the Caco-2 monolayer 
system was less than the amount of their corresponding parent compounds absorbed (Fig. 
6.5); for example, the aglycone TR of 8-OH-GEN is 11.42 pmol/min/cm2, while the aglycone 
TR of its parent compound—is 18.67 pmol/min/cm2. This means the hydroxylated isoflavone 
metabolites may have less functional forms than their corresponding parent compounds, 
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which imply the hydroxylated biotransformation in food fermentation may results a reduction 
of bioavailability of isoflavones. This trend could be important in a cellular bioactivity or 
human health setting. This is exemplified by recent evidence suggested that interaction exists 
between estrogens (including endogenous estrogens and xenoestrogens) and gut health (e.g. 
colon carcinogenesis).270, 314 Isoflavones in the diet are the main source of phytoestrogen 
exposure, which is shown to stimulate the proliferation of human colon cells at low exposure 
concentrations in this thesis (Section 5.4.2, Chapter 5), but to inhibit cellular proliferation at 
high exposure concentrations in previous research271. Importantly, isoflavones have a higher 
binding affinity with ERb, which is the predominant ER form in the GI tract. Bringing all 
these facts together suggests the structural features of isoflavones might determine the 
absorption and metabolism of isoflavones, the absorbed aglycones of isoflavones might affect 
gut health via ERb mediated bioactivity. This is exemplified by the ERb-mediated 
proliferation of gut cell, which influences the integrity of the GI tract, and, thus, affect the 




6.5 Conclusions  
Soy isoflavones are phytoestrogens which can occupy and activate ERs due to their structural 
mimicry of E2. In this chapter, seven isoflavones including GEN, DAID, and their 
hydroxylated metabolite, have been studied. 
Firstly, the in vitro fecal fermentation experiment showed that the studied isoflavones have 
different effects on populations of target groups of gut bacteria (i.e., Bacteroidetes and 
Firmicutes), one species of Firmicutes—F. prausnitzii, and a species of principal beneficial 
commensal bacteria—Bifidobacterium spp., and respectively). Briefly, over 2 h of the 
fermentation, isoflavones increased the concentration of Bifidobacterium spp, F. prausnitzii, 
and declined the F/B rapidly. The inulin control group continued increasing the concentration 
of Bifidobacterium spp, F. prausnitzii, and declined the F/B. Over the 2 h incubation, except 
6-OH-DAID, all isoflavones have significant greater (p < 0.03) proliferative activity on the 
concentration of Bifidobacterium ranging from 6.87 log10 cfu/mL (8-OH-GEN) to 7.08 log10 
cfu/mL (3¢-OH-DAID) compared with the inulin control (6.24 log10 cfu/mL), but GEN and 
DAID do not show any significant difference compared with their corresponding 
hydroxylated metabolites (Fig. 6.1). In addition, all studied isoflavones show stronger 
inhibitory effects on F/B (ranging from 1.36 to 1.54) than inulin control (1.56) in 2 h (Table 
6.1); 3¢-OH-DAID and 3¢-OH-GEN have the highest potency of reduction on F/B (Table 6.1). 
Interestingly, DAID and GEN do not show any significant differences in the effect on the 
concentration of F. prausnitzii compared with their corresponding hydroxylated metabolites. 
The exception of this finding is 8-OH-DAID, which exhibits significant greater effect on the 
concentration of F. prausnitzii compared with DAID. In addition, Only 6-OH-DAID (6.60 
log10 cfu/mL, p < 0.03) shows significant greater effect on the concentration of F. prausnitzii 
compared with the inulin control (5.74 log10 cfu/mL) (Fig. 6.2).  
The transport experiment shows that all studied isoflavones can be absorbed across the Caco-
2 monolayer system and conjugated by phase II metabolism in the cells. The apparent 
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transport rates indicate that the transportation of GEN and DAID are faster than their 
corresponding hydroxylated compounds, respectively; the OH-GENs are transported faster 
than OH-DAIDs. Interestingly, there is no significant difference between these isoflavones in 
terms of their conjugate transport rates. This is likely due to the regioselective sulfation and 
glucuronidation on the characteristic structural features of isoflavones (i.e., 7-hydroxy and 4¢-
hydroxy). The Caco-2 cell line mimics the differentiating gut enterocytes and models the 
function for absorbing xenobiotics (e.g., isoflavones).277 The amount of aglycones 
(transported by Caco-2 cell monolayer from AP to BL) of hydroxylated isoflavones are less 
than their corresponding parent compounds. This could be important in a cellular bioactivity 
or even human health setting. Food fermentation would convert GEN and DAID in their 
hydroxylated metabolites, and influence the gut cell transportation of aglycones which are the 
functional forms. Aglycones might interact with macromolecules in cells (e.g., ERs) thus 
having biological effects (e.g., estrogenic regulation), and thus; the amount of absorbed 
aglycone might determine the functionality of dietary isoflavones. 
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Chapter 7: Overall Discussion and 






7 Chapter 7 – Overall Discussion and Concluding Remarks 
7.1 Communication between the LBC of ERs and their AF-2 site is 
triggered by the docked ligands 
ERs have functions beyond traditional ideas of estrogen activity.20 Not only do they initiate 
and guide sexual development, they also have key roles in stimulating cell division; for 
example, early neurological development.14, 316 All of this is achieved by a specialised region 
of the receptor—LBC, which interacts with estrogens to cause conformational changes in the 
receptor and in turn leads to receptor/ligand complex dimerization followed by occupancy of 
a DNA region (ERE) which controls gene expression of transactivation genes (Fig. 3.1).19, 23 
Chapter 3 reports that, LBC and AF-2 are two connected binding sites in the LBD of ERs. A 
ligand docks at the LBC and induce conformational change, which rearrange the 
conformation of the LBD; this results in ripple effects on the structural components of AF-2 
via its sharing loop or helices with the LBC (e.g., H11 or H12). The “triangular relationship” 
involving two binding sites (i.e., the LBC and AF-2) and the bound ligand24 could explain the 
communication between the LBC and AF-2 which facilitates fine tuning of the estrogenic 
response. 
7.2 Individual ligands docked at the LBC can cause different knock-on 
effects on AF-2 
Chapter 3 indicates that individual ligands with different structural features (e.g., substituent 
bulkiness) can initiate various conformational changes in the LBC. Aligning X-ray 
crystallographic data of different complexes of ligand/ERα reveals that LBD has intimately 
interactive components (i.e., LBC and AF-2), the LBC is open to abuse by non-natural 
ligands of ERα that can also interact with AF-2. For example, GEN docked at the LBC and 
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slightly shifted the orientation of His 524 compared with the complex of E2/ERα (Fig. 3.6). 
In addition, the protein alignment study in Chapter 3 shows docked ligands with bulky side 
substituents have much greater effects on the conformation of the LBC with a consequently 
greater communication effect to AF-2. A breast cancer drug—raloxifene is a good example 
as an antagonist ligand of ERα.20 In the complex of ERα/Raloxifene, the H12 is pushed away 
by the ethylpyridine side group of Raloxifene (Fig. 3.13); this destroys the harbour (i.e., AF-
2) for accommodating regulatory proteins. The alignment of the complex of ERα/E2 (PDB 
entry code: 1ERE) and ERα/ Raloxifene (PDB entry code: 1ERR) might differentiate agonist 
and antagonist in terms of ERα’s conformation. However, the comparison between two 
complexes of ERα with different agonist compounds (e.g., E2 (PDB entry code: 1ERE) and 
OBHS (PDB entry code: 5U2D) indicates significant insight into the intimate interplay of the 
receptor: the knock-on effects of these two ligands on AF-2 are different and resulting in 
different amino acid residue arrangements in the AF-2 (e.g., the orientation and distribution 
of Glu-380) (Fig. 3.11). This means the binding environment of AF-2 for regulatory proteins 
depends on LBC docked ligands. Interestingly, a closer look at the spatial arrangement of 
amino acid residues at AF-2 when GEN or ETP is docked shows subtle, but important 
differences; for example, Glu-542 on H12 is re-orientated when ETP is in situ compared to 
GEN (Fig. 3.13). The different orientations of Glu-542 influence the distance or angle 
between the donor (i.e., Glu-542) and the acceptor (Leu-2004) on a H-bond thus determine 
the presence of H-bonds between the AF-2 and the GRIP-peptide (a fragment of a regulatory 
protein) (Fig. 3.14). Occupancy of AF-2 by a regulatory protein is important in modulating 
ERα’s biological activity.16 Regulatory proteins are histone acetyltransferaes-acetylation 
rearranging the chromatin structure, exposing the target genes to the transcriptional 
machinery.16 Recruitment of regulatory proteins influences this process, leading to gene 
transcriptional changes, which might underlie different estrogenicities.16 Furthermore, 
regulatory protein recruitment controls ERα degradation via phosphorylation of Tyr537.179 
This phosphorylation signals initiation of the proteasome ubiquitination pathway, leading to 
polyubiquitinated ERα which is transported to the proteasome for degradation.180 The 
regulatory protein recruitment influences the ubiquitination process, leading to differential 
downstream bioactivity effects; for example, cell proliferation and cell migration.179 In 
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summary, the conformational differences resulting from ligands’ (e.g., GEN or ETP) docking 
at the LBC likely alter ERα’s biological response—this might explain the molecular interplay 
between LBC and AF-2 determining ERs’ activities. For example, previous research 
indicates that ERα expressed in the hypothalamus mediates antiobesity effects of estrogens in 
females, and the interaction between ERα and a coactivator protein (steroid receptor 
coactivator-1) has been shown to mediate the antiobesity effects of E2-ERα signals.317 
Bringing the thoughts in this section suggests that different ligands (e.g., GEN) when docked 
at the LBC lead to a conformational change which result in different amino acid residue 
arrangements in the AF-2, thus differentiating the interaction of coactivators (e.g., steroid 
receptor coactivator-1) with ERα; in turn, this influences the functionality of ERα per se 
(e.g., antiobesity). 
7.3 The interactions of studied isoflavones with ERa and ERb are 
different 
The comparison of the LBD of ERα and ERb can be illustrated by the alignment of 
ERα/GEN crystal (PDB entry code: 1ERE) and ERb/ GEN crystal (PDB entry code: 1ERR) 
(Fig. 1.2); Chapter 1 indicates the two isoforms of ER have similar helices architecture (Fig. 
1.2), which means the interrelationships between each helix in ERα and ERb are similar. 
However, the overall homology between ERα and ERb is surprisely less than 55%.52 
Intriguingly, the amino acid residues comprising the LBC of ERs are highly 
homologeneous.52 Figures 1.7 & 1.8 show that ERα and ERb provide a similar compact 
hydrophobic pocket for hosting ligands, but have subtle differences in amino acid residue 
orientations; for example, the relative position of histidine (His 524 in ERα; His 475 in ERb) 
and threonine (Thr 347 in ERα; Thr 299 in ERb) in the LBC. This suggests a ligand may 
facilitate different noncovalent interactions docked in ERα and ERb, resulting in different 
binding energies. The in silico studies of isoflavones in Chapters 4 & 5 predict that the ligand 
candidates (i.e., isoflavones) can dock in both ERa and ERb, but with different theoretical 
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binding energies represented by their DockingScores. Interestingly, an isoflavone (e.g., GEN) 
can form the same number of H-bonds with ERa and ERb but having different H-bond 
values (i.e., H-bond energy) (Table 7.1). This is likely due to the different orientations of 
amino acid residues in the LBC between ERa and ERb, which determines the angle and 
distance between the donor and acceptor atoms in an H-bond, and, thus results in different H-
bond values.217 Results of Chapters 4 & 5 indicate that, since H-bond values may influence 
the binding affinity and corresponding receptor-driven activity, a ligand interact with 
different receptors (i.e., in this thesis, ERa and ERb) having different H-bond values, thus 
may result in different estrogenicities. In addition, the subtle differences of arrangements of 
amino acid residue affect the hydrophobic interactions between the docked isoflavones with 
the LBC and result in different HER values (Table 7.1). This shows a trend that isoflavone’s 
HER docked with ERb are greater than docked with ERa, but their corresponding 
DockingScores do not follow the same trend. For example, DAID has a higher DockingScore 
with ERb (−11.03 kcal/mol) than with ERa (−10.49 kcal/mol); but 6-OH-DAID has a lower 
DockingScore with ERb (−11.88 kcal/mol) than with ERa (−11.99 kcal/mol) (Table 7.1). 
This finding indicates that isoflavones might facilitate greater hydrophobic interaction with 
ERb compared with ERa. Importantly, the predicted binding energies of isoflavones with 
ERa and ERb suggest isoflavones have binding selectivity with different ERs; this indicates 
isoflavones’ bioactivities may differ in different tissues because of the varying ER tissue 
distributions (e.g., ERa is predominantly in breast, ERb is predominantly in the GI tract), and 
thus, the functionality of isoflavone-containing foods may be tissues-selective in humans 
because of their ER isoform preferences in tissues.  
From a food functionality perspective, it is important to integrate both dose-related biological 
effects of isoflavones and the difference in tissue distributions of ERs. The complex interplay 
between these factors will determine specific tissue-isoflavone related effects. For example, 
GEN has breast cancer inhibitory effects at high doses and promotes the proliferation of 
MCF-7 cell in culture at low doses.93 The balance between dietary phytoestrogen and 
endogenous estrogen levels should also be considered; for example, isoflavone supplements 
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are sometimes used to alleviate symptoms of menopause318 because they enhance total 
plasma estrogenicity, thus ameliorating the biochemical and physiological effects of 
declining natural estrogens as the menopause progresses. On the other hand, women with 
high circulating estrogen levels (e.g., child-bearing age women) would be unlikely to benefit 
from isoflavone dietary supplementation because they would increase the total circulating 
estrogenicity. A similar argument applies to the implications of dietary phytoestrogen to 
breast cancer risk where high isoflavone (e.g., GEN) doses appear to prevent breast cancer 
cell proliferation, whereas low doses promote proliferation.122 Importantly, GEN can interfere 
with the action of ERa-based treatments for breast cancer (e.g., tamoxifen) because they 
might compete with tamoxifen for occupancy of the LBC; 319 this suggests isoflavone 
metabolites (e.g., 6-OH-DAID), which have been shown greater predicted binding affinity 
with ERa than GEN in Chapter 4, may have a greater impact on ERa-based treatments for 
breast cancer.319 In addition, the greater interaction of some isoflavones (e.g., DAID, GEN) 
with ERb should draw attention to their ERb-driven activity in predominately ERb 




Table 7.1: Comparison of docking studies of isoflavones bound to ERa and ERb.  
 
Compounds 














DAID −10.49 −1.26 −4.90 −11.03 −1.21 −5.68 
GEN −10.79 −1.7 −4.8 −11.45 −1.67 −5.52 
6-OH-DAID −11.99 −2.42 −4.99 −11.88 −2.18 −5.57 
8-OH-DAID −11.62 −2.27 −4.97 −11.56 −1.72 −5.64 
3¢-OH-DAID −11.5 −2.13 −5.01 −11.85 −1.92 −5.64 
8-OH-GEN −11.68 −2.5 −4.6 −11.72 −2.18 −5.47 
3¢-OH-GEN −11.8 −2.59 −4.71 −11.64 −1.66 −5.38 
7.4 The structures of isoflavones determine their ER-driven activities 
Chapters 4 & 5 indicate that the induvial structural features of ligands determine their 
theoretical binding energy and binding affinity and might affect their ER-driven activities. In 
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this thesis, the in silico study of isoflavones with different hydroxyl arrangements indicates 
the structure binding energy/affinity relationships of ligands with ERα and ERb; the 
hydroxylated metabolites (e.g., 6-OH-DAID and 3¢-OH-GEN) of DAID and GEN have 
higher binding energies and greater affinities with either ERa or ERb, thereby resulting in 
greater bioactivities in both the MELN assay and Caco-2 cell proliferation studies compared 
with the corresponding parent compound (i.e., DAID or GEN) (Tables 4.5 & 5.3). Bringing 
these results together, the increased bioactivity of these hydroxylated metabolites is likely 
due to their additional hydroxyls, which might form extra H-bonds with amino acid residues 
at the LBC (Figs 4.3 & 5.3). The exception to this trend is 8-OH-GEN; this compound is 
predicted to have higher binding energy and greater binding affinity than the parent 
compound GEN (Tables 4.6 & 5.1); however the additional hydroxyl groups on 8-OH-GEN 
decreases the hydrophobicity of the ligand resulting in lower HER compared with the less 
hydroxyl parent compound (Tables 4.3 & 5.1), and do not contribute any polar interaction 
(i.e., H-bond interaction) at the LBC (Fig. 7.1); this might result in weaker ER-driven 
activities (Tables 4.5 & 5.6). So, contrary to expectations the extra hydroxyl group resulting 
the molecular hydrophobicity in a key region of the ligand results in less favourable 
interaction with the LBC and likely lowers bioactivity. 
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Figure 7.1: Interaction between 8-OH-GEN and the LBC of ERa from in silico study showing the 
free hydroxyls decrease the molecular hydrophobicity of the ligand and are not favour for the 
hydrophobic region of the LBC. Purple arrows represent H-bonds; the direction of arrow denotes 
electron donor to electron acceptor in the H-bond. Different coloured residues represent amino acid 
properties: blue = positive charge; red = negative, cyan = polar, green = nonpolar. (NB: Schrödinger 
uses a non-standard amino acid abbreviation system: HIE = Histidine). 
Caco-2 cells comprise a continuous cell line of heterogeneous human epithelial colorectal 
adenocarcinoma cells and with phase II metabolising capacity.321, 322 The intestinal Phase II 
metabolism is important in isoflavone deactivation—isoflavones are glucuronic acid 
conjugates via their hydroxyl group.277,269, 323 In this thesis, Chapter 6 also proves that Phase 
II conjugation of isoflavones occurred in the Caco-2 monolayer transportation experiments in 
this thesis. The pre-treatment with GA, an inhibitor of UGDH, enhanced GEN or 8-OH-GEN 
mediated Caco-2 cell proliferation. This suggests that GA treatment interferes with the phase 
II conjugation of isoflavones resulting in an increase of amount of functional aglycones in the 
Caco-2 cells. Interestingly, Chapter 5 indicates that a “food cocktail” effect involving fruits 
containing GA and soybeans containing isoflavones may lead a complex food functionality. 
GA from fruit or tea might inhibit the activity UGDH and decrease the biosynthesis of UDP 
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glucuronic acid, which would provide glucuronic acid for the conjugation of soy isoflavones 
(Fig. 7.2).269 This would interfere with the conversion of isoflavones to non-bioactive 
conjugates and result in an increase in the aglycone concentration leading to this modulation 
ER-driven bioactivities (e.g., in gut) (Fig. 7.2). The fact that ERβ is the predominant ER 
isoform in gut draws more attention to the potential importance of ERβ in gut health.64, 259, 263 
On the positive side, ERβ mediates gut cell proliferation, and the cell proliferation plays an 
important role in the maintenance of the integrity of GI tract, which has linked to the 
immunity, digestion of GI tract.324, 325 Collectively results from Chapter 5 indicate isoflavone 
intake may benefit gut health via its proliferative effect on gut cell, and in combination with  
GA may increase the positive effect of isoflavone on gut health. On the negative side, for 
example, gut transit is associated with ERβ, the delayed gut transit time during pregnancy has 
been associated with high circulating estrogenicity because of the high level of E2.266 During 
this period, isoflavone intake may worsen gut transit; the food combination including 








Figure 7.2: Schematic to show the complex dietary cocktail effects involving DAID and GA from 
different foods, and leading different proliferative effects of isoflavones on gut cells.  
This finding is also important and might be helpful in reducing foo-related risks; for example, 
a breast cancer patient would want to avoid the additive ER-driven bioactivities caused by the 
complex dietary intake of GA and isoflavones, because isoflavones may interfere with the 
tamoxifen treatment, and therefore, it might result in ERa positive breast cancer cell 
proliferation; On the other hand, the additive ER-driven bioactivities may be beneficial for 





7.5 The interrelationships between food isoflavones, gut bacteria, 
and gut cells, and potential health consequences 
7.5.1 The interaction between gut bacteria and isoflavones 
Isoflavones can be metabolised by gut bacteria in the human intestine.282, 285, 326 The 
glycoside form of isoflavones (e.g., daidzin), which normally exist in raw soy, are hydrolysed 
to release the functional form (i.e., aglycone) of the isoflavone (e.g., DAID).285 In addition, 
the gut bacterial metabolism produce different estrogenic metabolites compared with the 
corresponding parent compound; DAID is metabolised to the more estrogenic S-equol (Fig. 
3.3);190 and GEN is converted to the less estrogenic dihydrogenistein (Fig. 3.10).223 Chapter 
6 reports a in vitro gut fermentation study of isoflavones and showing the effects of 
isoflavones on the concentrations of two phyla, Bacteroidetes and Firmicutes, the 
concentrations of a specific species of Firmicutes—F. prausnitzii, and Bifidobacterium spp. 
This indicates the bi-directional interaction between gut bacteria and isoflavones. This means 
that gut bacteria can metabolise isoflavones so changing their potential bioactivity while also 
changing the bacterial population in response to the isoflavone. So, in a dynamic context, the 
bacteria metabolise isoflavones which change their effect on the bacterial carrying out the 
metabolism.  
7.5.2 The interaction between isoflavones and gut cell 
Results in Chapter 6 show that all isoflavones studied (i.e., aglycones) were taken up by the 
Caco-2 cell monolayer system, since this mimics the human intestinal mucosa, this likely that 
these isoflavones are also taken up by human gut cells in vivo (Chapter 6). Following uptake, 
the aglycones (functional form) can be conjugated by phase II metabolism (e.g., sulfation and 
glucuronidation). It has been suggested that, in the gut cell, the aglycones might interact with 
macromolecules (e.g., ERs) or be transported to other tissues;277 this indicates that the phase 
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II metabolism of isoflavones determines the functionality of isoflavones and influences 
macromolecules-driven activities (e.g., via ER interactions). As discussed before, ERβ is the 
predominant ER isoform in the GI tract, and Chapter 6 shows isoflavones have been shown 
to be absorbed by the Caco-2 monolayer system;64 this suggests the potential interactions 
between soy isoflavones and ERβ could be significant in a cellular context. The Caco-2 
proliferation experiments in Chapter 5 showed isoflavones have a stimulatory activity on the 
proliferation of the cells. This ERb-driven activity of isoflavones in Caco-2 cell might have 
more significance in a human health level. For example, the higher incidence of Crohn’s 
disease in women327, 328 and more frequent acute episodes of disease activity in women329 
points to a possible E2 link. The dominant role of ERβ in small bowel mucosal cells, 
particularly in the terminal ileum, could be significant given that exposure to E2 would occur 
via its excretion in bile. In addition, in Chapters 4 & 5 , selected isoflavones have been 
shown to be estrogen mimics in both in silico and in in vitro studies, and shown to increase 
the concentration of F. prausnitzii, which has been associated with Crohn’s disease. This 
suggests the combination of ERb-driven activity and the effect on bacteria of isoflavones 
may be important in the aetiology of Crohn’s disease, and this dietary manipulation might 
play a role in the treatment of Crohn’s disease. Thus, isoflavone may become a potential 
treatment or specific functional food for Crohn’s disease. 
7.5.3 Gut health might determine the expression of ERb 
The potential role of ERb in the GI tract is attracting considerable attention, since the 
presence ERb and its mRNA has been identified in rat, monkey and human colon tissues;51, 
183, 270, 330 but the influence of gut health on the expression of ERb is rarely studied. A limited 
example is the colonic tumorigenesis, which results in decreased ERβ mRNA steady-state 
levels compared with normal colon mucosa cells;51 this might influence the expression of 
ERb, and thus affect ERβ bioactivity in the gut. This might indicate that gut disease could 
affect ERb expression and affect the impact of dietary isoflavones on gut cell proliferation. 
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7.5.4 Isoflavones might interfere with the metabolism of endogenous 
estrogens and affect health 
Estrogens undergo hepatic recirculation (Fig. 1.6).The aglycone forms of endogenous 
estrogens (e.g., E2) could undergo first-pass hepatic metabolism.48 Hepatically conjugated 
estrogens excreted in the bile can be deconjugated by bacterial (e.g., Bacteroidetes and 
Firmicutes) b-glucuronidase activity in the gut, leading to the reabsorption into the 
circulation.48 Interestingly, in Chapter 6 , the in vitro gut fermentation experiment showed 
that isoflavones influence the concentration of Bacteroidetes and Firmicutes in the mixed 
culture and  suggesting that the dietary isoflavones might influence the reabsorption of 
endogenous estrogens. This suggests that the isoflavones influence the total circulating 
estrogenicity in two ways. Firstly, isoflavones are estrogen mimics, a part of aglycone of 
isoflavones would be taken up by gut cell and circulated in bloodstream. Secondly, 
isoflavone may affect the estrogen reabsorption via modulating gut bacterial populations. 
This is significant as isoflavones have been shown to alleviate the symptoms caused by the 
loss of E2 (e.g., menopausal symptoms).  
7.6 Future work 
The complexity of gut microbial ecology, inter-individual host variability in both bacterial 
species and their distribution, and difficulties replicating human systems in animal models 
means that significant effort is needed to address and understand these issues.  This could be 
achieved by: 
• Studying microbial ecology in human normal gut sampled during cancer excision 
surgery using rRNA Gene Sequence technology. 
• Maintaining the human gut samples in culture to allow isoflavone metabolism/uptake 
experiments to be conducted. 
• Studying the effect of varying gut bacteria on isoflavone metabolism. 
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• Studying the effects of isoflavones in culture media on microbial replication and 
biochemistry. 
• Studying the effects of isoflavone microbial metabolites on human cell systems (e.g., 
Caco-2). 
• Extrapolating the findings to human gut-based diseases (e.g., Crohn’s disease, 
gastrointestinal tract cancer). 
At the other end of the spectrum, it is necessary to understand better the interaction of 
isoflavones and their metabolites with ERs to enable prediction of biological activity.  This 
could be achieved using dynamic modelling systems such as DESMOND which facilitate 




7.7 A integrated approach to gut health, the microbiome and 
functional food components  
 
Figure 7.3: The interrelationships between food science and technology, functional food components, 
gut microbiome, human health and wellbeing. Morden food science and technology enables 
manipulation of food to modify their components and functionality (1). This functionality might 
modulate the population of gut microbiota (2) and influence human health and wellbeing (3). The 
human health outcomes might lead the development of functional foods by food science and 
technologists (4). 
Food science technology influences the compositions of food’s functional compounds.331 A 
good example is the changes in the composition of isoflavones during tofu, a soy-based 
food’s production.11 The production of tofu includes soaking, grinding, filtering, boiling, and 
coagulating. The different ratios between water and soybeans during grinding leads to 
variation in tofu isoflavone compositions;152 and heat treatment in the boiling process has 
been reported to convert some malonyl isoflavones into their corresponding acetyl forms.332 
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In addition, calcium sulfate has been reported as the best coagulant for tofu manufacture 
because in maintains the natural isoflavone compositions.154 What’s more, during food 
fermentation, DAID and GEN are converted into to two types of biotransformation products: 
OH-DAID and OH-GEN;157, 251, 252 this biotransformation is a regiospecific hydroxylation 
which depends on the specific of CYP450 in microorganism used in food fermentation 
process (Table 7.2).253, 254 This suggests that, in food fermentation, using specific 
microorganism could yield different isoflavone hydroxylated metabolites with different 
bioactivities of, and thus, modulate food functionality. This varying the bacteria species used 
in fermentation-based food manufacturing processor could affect the functionality of the 
resulting food products. For example, to enhance the alleviation of isoflavones on 
menopausal symptoms, specific microorganism can be used in food fermentation to produce 












Table 7.2: Hydroxylated metabolites of DAID and GEN, food sources, and microorganism used in 
food manufacture.253, 254  
Fermented soy food Microorganism used Metabolites of DAID and 
GEN 
Tempeh Rhizopus and other bacteria 6-OH-DAID, 8-OH-DAID, 3¢-
OH-GEN 
Soybean koji Aspergillus saitoi 8-OH-DAID, 8-OH-GEN, 6-
OH-DAID 
Miso Aspergillus oryzae 8-OH-DAID, 8-OH-GEN. 6-
OH-DAID, 3¢-OH-DAID 
Douchi Aspergillus oryzae 6-OH-DAID, 8-OH-DAID, 3¢-
OH-DAID, 8-OH-GEN 
Doenjang Diverse fungi and bacteria 6-OH-DAID, 8-OH-DAID, 3¢-
OH-DAID 
The gut microbiome comprises tens of trillions of bacterial cells.189 A major function of these 
bacteria is to digest food ingredients (including food functional compounds) so that the 
products of the intestinal biotransformation can be utilized in beneficial ways to support 
myriad aspects of human biology.170 Some non-digestible food functional compounds are 
described as “prebiotics” which beneficially affect the host by selectively “stimulating” the 
growth and /or activity of one or a limited number of bacteria in the GI tract and thus might 
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improve host health.189 Some well-known examples of prebiotics include the dietary 
polysaccharides which can produce SCFAs by bacterial metabolism;333 the plant flavonoids 
which have been reported to have pharmacological properties including anti-proliferative 
effect on Gram-negative bacteria (most pathogenic bacteria are Gram-negative).334 A good 
example of prebiotics in Chapter 6 is that isoflavones can increase the amount of F. 
prausnitzii, these bacteria have been associated with the pathophysiology of Crohn’s 
disease.306 Interestingly, GEN and DAID from raw soy or soy milk have a greater effect on 
the growth of F. prausnitzii compared with their hydroxylated metabolites from fermented 
soy foods (e.g., soy sauce, miso). This suggests fermented vs non-fermented food 
manufacturing processes might alter the compositions of food functional compounds and 
varying their effects on the populations of specific gut bacteria, which, in turn, might 
influence health.335, 336 A great deal of evidence indicates the connections between gut 
bacteria and human health. For example, gut bacterial communities have been suggested to 
contribute to the development of insulin resistance,53 and the dynamic of gut bacteria has 
been associated with immune function due to their effect of intestinal permeability.297, 298 In 
addition, gut-brain axis seems to be bidirectional-the brain acts on GI and immune functions 
that help to modulate the gut's microbial makeup, and gut bacteria make neuroactive 
compounds, including neurotransmitters and metabolites that also act on the brain.337 The 
ongoing exploration of gut bacteria promises to bring the “gut-brain axis” into a clearer 
focus.338, 339 Research is clearly pointing that bacteria being a key component of health, it 
might be the right time to include the dynamic of bacterial populations and the effects of the 
dietary component (e.g., prebiotics) on gut bacteria as part of health and wellbeing 
strategies.340, 341 
In future, it might be possible to develop food functionality for a specific purpose with foods 
“designed” to contain specific functional components for a desired positive health outcome. 
In a functional food context, the ingredient list of food functional compounds would reflect 
the fact that the food contains components designed to deliberately manipulate gut bacteria in 
a selective manner so as to benefit one or more facets of in vivo biology, with resulting 
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improvements in health status. The development of synergism between physiological and 
technical should be given more attention. Food technology will be able to manipulate and 
exploit the synergistic effect of tailored food components, which enhance functionality of a 
or a few targeted food components, on physiological functionality leading to positive health 
effects; advanced analytical techniques should be employed to tract and quantify food 
functional components before processing the manufacture of foods. For example, the 
circulating estrogen levels differ between gender and age. It is feasible to quantify the 
concentration of isoflavones in soy-based foods, this would cater to different gender-basis or 
age-basis requirements of total circulating estrogen levels via modulating the populations of 
gut bacteria. This leads to the modification of food process aiming to manipulate the 
compositions of food functional components. In short, these designer functional foods would 
be fashioned based on considerations of the food functional components’ characteristics, 
availability and affordability, how the ingredients might be processed in ways that do not 
deleteriously affect the integrity and/or bioactivity of key nutrients and whether the 
manufactured food products will have acceptable organoleptic properties.  
Getting back to isoflavones in food and their role in functionality and health. Isoflavone can 
modulate gut bacterial populations, this may influence reabsorption of estrogens. During the 
interaction between isoflavone and gut bacteria, the parent isoflavone might be converted to 
different and possible more estrogenic metabolites, these metabolites may have different 
ERb-driven effects on the proliferation biochemistry of gut cell, this may in turn influence 
gut health. Then the gut health status might change the expression of ERb. This is an 
incredibly complex cyclical interplay that moderates biological activity—this is a Pandora’s 
Box of complexity with potentially profound health implications. 
As Hippocrates (c. 460 BC– c. 370 BC) famously said: “let food be thy medicine and 
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Appendix A: Supporting information for Chapter 3 
Table S 1: Missing amino acid residues of the complexes of ERa with different ligands. 
PDB code Missing amino acid residues 
1ERE SER 301, LYS 302, LYS 303, ASN 304, TYR 
331, ASP 332, PRO 333, THR 334, ARG 335, 
PRO 336, LEU 462, SER 463, SER 464, LEU 
549, HIS 550, ALA 551, PRO 552, THR 553 
1ERR SER 301, LYS 302, LYS 303, ASN 304, SER 
305, LEU 306, THR 460, PHE 461, LEU 462, 
SER 463, SER 464, THR 465, LEU 466, LYS 
467, SER 468, LEU 469, LYS 529, CYS 530, 
LYS 531, ASN 532, VAL 533, VAL 534, ARG 
548, LEU 549, HIS 550, ALA 551, PRO 552, 
THR 553 
1X7R SER 305, TYR 331, ASP 332, PRO 333, THR 
334, ARG 335, PRO 336, PHE 337, ARG 548, 
LEU 549, LYS 686 
4TV1 LYS 302, LYS 303, ASN 304, LEU 462, SER 
463, SER 464, THR 465, LEU 466, LYS 467, 
SER 468, LEU 469, LEU 549, HIS 550, ALA 
551, PRO 552 
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5T1Z LEU 462, SER 463, SER 464, THR 465, LEU 
466, HIS 550, ALA 551, PRO 552, THR 553, 
SER 554 
5U2D ILE 298, LYS 299, ARG 300, SER 301, LYS 
302, LYS 303, ASN 304, LEU 462, SER 463, 




Appendix B: Supporting information for Chapter 4 
Figure S 1: Calibration graph of the protein content in MELN cells (exposure to isoflavones) in the 
fluorescence assay (n = 3). 
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Appendix C: Supporting information for Chapter 6 
Table S 2: The bacterial standards, primers and the annealing conditions used for real time PCR 
quantification of bacteria 
Target bacteria Bacterial 
standard 
Primer sequence (5´ → 3´) Temperature 












63 °C, 20 s 342 
Firmicutes Lactobacillus 
rhamnosus 
ATCC 7469  
Fwd: 
G AGYA GT TTTAATTCGAAGCA  
Rev:  
AGCTGACGACAACCATGCAC 






G AG A AGGT T CGG 
Rev:  
AATTCCGCCTACCTCTGCACT 







GGG GGTAATG GGATG 
Rev: 
CCACCGTTACACCGGGAA 




Figure S 2: Calibration graphs for all selected isoflavones authentic standards. All show good linear 












Table S 3: The effects of selected isoflavones on the growth of Firmicutes, Bacteriodetes and thus the 
F/B ratio 
Compound Time (h) Firmicutes (F) Bacteriodetes (B) 
Control                    
(no isoflavones) 
0 10.1709 ± 0.0143 6.4069 ± 0.0074 
2 9.9241±0.0056 5.6606 ± 0.0107 
20 9.541± 0.0178 4.5374 ± 0.0210 
Inulin 
2 10.1889±0.0202 6.5280 ± 0.0078 
20 10.2535±0.0217 6.84306 ± 0.0049 
DAID 
2 9.91185±0.0097 6.9446 ± 0.0087 
20 8.9749±0.0110 6.0260 ± 0.0108 
6-OH-DAID 
2 9.5322±0.1770 6.6530 ± 0.0167 
20 9.3306 ± 0.1801 6.082592476 ± 0.0043 
3¢-OH-DAID 
2 9.8320 ± 0.0455 7.177476922 ± 0.0059 
20 9.4818 ± 0.0698 6.528309519 ± 0.0113 
8-OH-DAID 2 9.7851 ± 0.1015 6.371815434 ± 0.0077 
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20 8.7884 ± 0.1980 5.561316933 ± 0.0108 
GEN 
2 10.1157 ± 0.0076 7.22246626 ± 0.0033 
20 9.1790 ± 0.1006 5.91983807 ± 0.0201 
3¢-OH-GEN 
2 9.0846 ± 0.0945 6.639486 ± 0.0191 
20 9.7550 ± 0.07876 6.322553162 ± 0.0452 
8-OH-GEN 
2 9.8386 ± 0.1015 6.37963775 ± 0.0390 
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